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ABSTRACT 
Despite the success of antiretroviral therapy, a cure for HIV-1 infection remains 
elusive. The persistence of cellular reservoirs harboring transcriptionally silent (latent) HIV 
provirus is responsible for the viremia rebound observed following treatment withdrawal. 
Stimulation of latent viral expression is considered critical to target HIV reservoirs for 
elimination through a “shock and kill” approach. Pharmacological drugs have systematically 
proven ineffective to drastically reduce the reservoir size and may cause severe side effects 
owing to their indiscriminate mode of action. In the present thesis, gene-targeted strategies were 
explored to stimulate and eliminate HIV latent cells. To stimulate latent virus expression, we 
designed synthetic activators based on transcription activator-like effector (TALE) proteins that 
recognize conserved regions on HIV 5’LTR promoter. Four TALE activators strongly induced 
HIV transcription, acting in cooperation to specifically enhance viral expression from cell line 
models of HIV-1 latency. Moreover, we show that histone deacetylase inhibitors can further 
enhance the effect of TALE-mediated activation in highly repressed latent cells. To further 
potentiate the elimination of stimulated latent cells, we conjugated an HIV-responsive suicide 
lentivector to our TALE activator technology. For this purpose, we incorporated a modified 
5’LTR promoter into the suicidal lentivector as a safety mechanism to dissociate TALE-driven 
activation, restricting the responsiveness of this plasmid to the HIV regulatory proteins. The 
therapeutic plasmid was capable of specifically eliminate latently infected cells stimulated by 
TALE activators through a Tat/Rev-dependent expression of the diphtheria toxin. Finally, we 
presented a “gene-free” approach to specifically activate latent HIV expression through protein 
delivery of cell-penetrating zinc-finger activators (CPP-ZFA). A single activator based on 
Cys2His2 zinc-finger domains proved effective at inducing viral expression from the primer 
binding site downstream of 5’LTR promoter. When conjugated with positively charged nuclear 
localization signal repeats, this synthetic activator efficiently translocated across cell membrane 
without the need of carriers. Short-term presence of CPP-ZFA following protein delivery was 
sufficient to stimulate gene expression in HIV-1 latent cells, offering a safer alternative to avoid 
off-target effects from prolonged exposure to these synthetic activators. In resume, this work 
provides proof-of-concept that synthetic activators and suicide lentivectors constitute promising 
candidates for the eradication of HIV-1 reservoirs through gene-targeted strategies. 
Key-Words: Human Immunodeficiency Virus type 1 (HIV-1); Latency; Gene therapy; 
Synthetic activators; Suicide lentivectors. 
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RESUMO 
A Síndrome de Imunodeficiência Adquirida (SIDA) constitui uma das principais 
preocupações de saúde pública a nível mundial, sendo detetados anualmente mais de 2 milhões 
de novos casos. Esta doença é caracterizada por uma deterioração progressiva do sistema 
imunitário do hospedeiro que culmina na ocorrência de infeções oportunistas fatais. Desde a 
sua descoberta em 1983, o agente etiológico da SIDA, o Vírus da Imunodeficiência Humana 
(VIH), tem sido um dos patógenos mais investigados no desenvolvimento de estratégias 
terapêuticas. O VIH é um lentivírus pertencente à família Retroviridae, tendo sido até agora 
identificados dois tipos: VIH-1 e VIH-2. O VIH-1 é mais patogénico do que o seu homólogo 
do tipo 2, sendo caracterizado por uma taxa de transmissão elevada e maioritariamente 
responsável pela pandemia global de SIDA. Como tal, a infeção pelo VIH-1 tem sido o foco no 
desenvolvimento de estratégias antirretrovirais.  
Apesar dos constantes avanços no desenvolvimento de fármacos antirretrovirais, estes 
não são capazes de eliminar completamente o vírus do organismo. O maior obstáculo a esta 
erradicação é a existência de reservatórios virais persistentes. Estes reservatórios são 
constituídos por células infetadas que não são eliminadas do hospedeiro, principalmente devido 
à capacidade do VIH-1 de estabelecer um estado não-replicativo (latente). Esta latência viral é 
caracterizada como um estado de infeção não expressivo que permite a evasão do vírus à 
resposta do sistema imunitário e à atividade farmacológica do tratamento antirretroviral. Como 
tal, estes reservatórios contribuem para uma viremia residual, e asseguram o restabelecimento 
da infeção ao ocorrer uma interrupção na terapêutica. Por outro lado, os principais reservatórios 
de VIH-1, os linfócitos T CD4+ de memória, persistem nos pacientes devido ao seu tempo de 
meia-vida prolongado, evidenciando a importância da eliminação destes reservatórios virais. 
Devido à sua natureza silenciosa, que permite a evasão dos reservatórios virais, é 
considerado essencial a estimulação do VIH latente de modo a expor estes reservatórios ao 
efeito tóxico da replicação viral ou à resposta do sistema imunitário do hospedeiro. Entre as 
diversas estratégias propostas para eliminar estes reservatórios, os fármacos que causam uma 
estimulação de vias de sinalização celular ou alteração de marcadores epigenéticos têm sido 
dos mais testados como ativadores da expressão do VIH latente. No entanto, estas abordagens 
não foram capazes de reduzir significativamente os reservatórios virais em pacientes. Por outro 
lado, a ação generalizada destes fármacos tem sido associada a efeitos colaterais geralmente 
causados pela desregulação do sistema imunitário. Um tratamento eficaz contra os reservatórios 
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de VIH-1 deve ter como base o desenvolvimento de uma terapia que seja capaz de eliminar 
especificamente as células infetadas, sem causar danos a células saudáveis. Deste modo o 
desenvolvimento de terapias alternativas, tal como a terapia génica, mostra especial interesse. 
A terapia génica consiste na transferência de material genético exógeno para células-
alvo, promovendo a alteração do seu fenótipo. Até ao momento vários tipos de abordagens 
antirretrovirais tendo como base esta terapia foram testadas principalmente com o objetivo de 
potenciar o sistema imunitário, mediar a morte de células infetadas ou tornar as células do 
hospedeiro resistentes à infeção. O objetivo proposto na presente dissertação é focado no 
desenvolvimento de estratégias terapêutica que permitam eliminar especificamente células 
infetadas com VIH-1 latente através de engenharia de ativadores sintéticos e vetores lentivirais 
suicidas. Uma área da terapia génica com particular relevância é a engenharia do genoma 
através de plataformas de ligação ao ADN. Estas proteínas podem ser manipuladas para 
reconhecer sequências específicas de ADN genómico e causar modificações na sua sequência 
ou alterar o nível de expressão génica, dependendo da função que lhes é atribuída através da 
ligação a um domínio funcional. Nesse sentido, a engenharia de ativadores sintéticos poderá 
ser uma abordagem importante no contexto de latência do VIH. Estes fatores de transcrição 
artificiais são formados por um domínio de ligação ao ADN que reconhece uma sequência 
predeterminada e um domínio de ativação que recruta a maquinaria celular para promover a 
transcrição do gene-alvo. 
No Capítulo II descrevemos o desenvolvimento de ativadores sintéticos com base em 
proteínas TALE (do inglês Transcription activator-like effector) com o objetivo de induzir a 
expressão de VIH em células latentes. Estas plataformas de ligação ao ADN com origem nas 
bactérias Xanthomonas sp são maioritariamente constituídas por módulos de 34 resíduos 
conservados, cuja composição determina a afinidade para o tipo de ácido nucleico. Como tal, a 
junção contígua destes domínios numa ordem específica determina a sequência-alvo de ADN. 
Ativadores TALE foram desenhados em fusão com o domínio ativador VP64 para reconhecer 
sequências conservadas na região promotora do VIH, denominada 5’LTR. Quatro ativadores 
TALE foram selecionados como potentes estimuladores da expressão viral num modelo celular 
de latência. Determinados contextos de elevada repressão viral estão frequentemente associados 
com marcadores epigenéticos tais como a desacetilação de histonas que podem limitar o acesso 
de fatores de transcrição à região promotora do VIH. Como tal, demonstrámos que inibidores 
de desacetilases de histonas podem atuar em sinergia com os ativadores TALE aumentando 
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drasticamente a capacidade destes para reativar a expressão viral em contextos adversos. Deste 
modo, os ativadores TALE apresentam-se como uma abordagem promissora e segura para a 
estimulação de reservatórios virais. 
Neste capítulo, explorámos ainda o uso de vetores lentivirais suicidas com o objetivo 
de promover especificamente a eliminação das células latentes estimuladas pelos ativadores 
TALE. Esta abordagem é baseada na construção de um plasmídeo lentiviral que codifica uma 
toxina letal, cuja expressão é dependente da presença das proteínas virais Tat e Rev. Como base 
para as construções, utilizámos um vetor lentiviral cuja transcrição é controlada pelo promotor 
5’LTR ativado pelo transativador Tat e que possui ainda 2 locais de splicing do VIH entre os 
quais foram clonados os genes das toxinas e um local de ligação da proteína Rev (RRE). Este 
vetor tem a particularidade que, ao iniciar a sua transcrição intensificada pela presença de Tat, 
o RNA mensageiro incorporando a toxina só é transportado para o citoplasma para tradução na 
presença de Rev, impedindo a sua expressão células em não infetadas. Uma vez que 
pretendemos atacar células latentes, na qual a expressão de Tat e Rev é inexistente, este 
plasmídeo tem de atuar em conjunto com os ativadores TALE gerados. Estes ativarão a 
expressão viral, forçando a saída de latência e expondo a célula latente à ação da toxina e 
consequente morte celular. 
De modo a conjugar este plasmídeo com ativadores TALE, modificámos o seu 
promotor 5’LTR – idêntico ao promotor nativo do VIH-1 – de modo a evitar ligação das 
proteínas TALE e ativação inespecífica em células não infetadas.  A incorporação do promotor 
modificado reduziu drasticamente a expressão do vetor lentiviral na presença dos ativadores 
TALE, conferindo maior especificidade à ação mediada pelas proteínas virais Tat e Rev. Por 
outro lado, esta modificação no vetor não alterou a capacidade infeciosa dos lentivírus, que 
demonstraram elevada expressão apenas em células infetadas. Este efeito manteve-se mesmo 
quando testados como lentivírus não-integrativos que são frequentemente implementados em 
abordagens de terapia génica, onde se pretende evitar efeitos adversos da integração no genoma 
da célula. Para a morte específica de células VIH latentes, recorremos à elevada potência da 
toxina da difteria que promove diretamente a morte celular através da inibição da síntese 
proteica. Ao testarmos o vetor lentiviral suicida em conjunto com ativadores TALE, 
verificámos elevada morte de células infetadas com VIH latente em comparação com células 
não infetadas. Face à incapacidade do sistema imunitário para combater células infetadas, esta 
abordagem poderá potenciar a eliminação de reservatórios virais após a sua estimulação e como 
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tal, apresenta-se como uma nova estratégia de terapia genética para combater os reservatórios 
de VIH-1 latente. 
No capítulo III testámos uma estratégia alternativa de ativação da expressão de VIH 
latente sem recorrer à introdução de material genético ao explorar a capacidade intrínseca de 
proteínas de dedos-de-zinco para penetrar na membrana celular. Estas proteínas humanas 
podem ser manipuladas para reconhecer sequências específicas de ADN de acordo com a 
composição de aminoácidos presente na sua hélice-alfa, que determina a afinidade para três 
ácidos nucleicos ou tripletos. A elevada frequência de resíduos de aminoácidos com carga 
positiva na sua estrutura promove a interação e internalização destas proteínas através da 
membrana lipídica aniónica, conjugando a função de reconhecimento de ADN e translocação 
celular na mesma molécula. Entre diversos ativadores dedos-de-zinco desenvolvidos para 
reconhecer o promotor 5’LTR em fusão com o domínio ativador VP64, apenas um foi capaz de 
induzir expressão viral em células latentes, ligando-se a uma região altamente conservada a 
jusante do promotor do VIH-1. Ao aumentar a sua carga positiva através da conjugação com 
péptidos sinalizadores catiónicos, este ativador consegue penetrar diretamente nas células VIH 
latentes e estimular a expressão viral, demonstrando a sua versatilidade como molécula de 
transporte celular e manipulação da expressão génica. Observámos que esta proteína persiste 
na célula durante apenas 48 horas, o que, no entanto, é suficiente para estimular a expressão de 
VIH latente. Esta abordagem é particularmente relevante na redução de potenciais efeitos 
adversos noutros genes derivados da exposição prolongada à ação dos ativadores sintéticos no 
ambiente intracelular.  
Em resumo, os resultados obtidos nesta dissertação de doutoramento demonstram o 
potencial terapêutico de ativadores sintéticos e vetores lentivirais para combater os 
reservatórios de VIH latente, abrindo caminho para uma nova geração de moléculas 
terapêuticas para o tratamento da infeção pelo VIH.  
 
Palavras-chave: Vírus da imunodeficiência humana (VIH-1); Latência; Terapia génica; 
ativadores sintéticos; vetores lentivirais suicidas. 
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ABBREVIATIONS 
AAV Adeno-associated virus  LTR Long-terminal repeat 
ABTS 
2,2'-azino-bis(3-ethylbenzothiazoline-6-
sulphonic acid) 
LV Lentiviral vector 
ADA-SCID Adenosine deaminase-deficiency SCID MA Matrix 
ADN Ácido desoxirribonucleíco MFI Mean fluorescence intensity 
AdV Adenoviral vector miRNA microRNA 
AIDS Acquired immunodeficiency syndrome mLTR mutant LTR 
ART  Antiretroviral therapy  mRNA Messenger RNA 
AS Acceptor splicing site NC Nucleocapsid 
aza-CdR 5-aza-2’deoxycytidine  Nef HIV negative factor 
Brec1 Broad HIV-recombinase 1 NELF Negative elongation factor 
C/EBP CCAAT-enhancer-binding protein NES Nuclear export sequence  
CA Capsid NFAT Nuclear factor of activated T-cells 
CAR Chimeric antigen receptor NF-κB Nuclear factor kappa B 
Cas9 CRISPR associated protein 9 NHEJ Non-homologous end joining 
CCR5 CC Chemokine Receptor 5  NLS Nuclear localization sequence  
CD3 Cluster differentiation 3 NNRTI Non-nucleoside reverse transcriptase inhibitor 
CD34 Cluster differentiation 34 NRTI Nucleoside reverse transcriptase inhibitor 
CD4 Cluster differentiation 4 PAM Protospacer adjacent motif  
CDK9 Cyclin-dependent kinase 9 PBMC Peripheral blood mononuclear cells 
cDNA Complementary DNA PBS Primer-binding site 
CMR-1 Chromosome region maintenance 1 PHA Phytohemagglutinin 
CMV Cytomegalovirus promoter PKC Protein kinase C 
CNS Central nervous system PMA Phorbolmyristate acetate  
CPP Cell-penetrating peptide Pol Polymerase 
CPP-ZFA Cell-penetrating zinc-finger activators PolII RNA Polymerase II 
Cre Cyclization recombinase PR Protease 
CRISPR 
Clustered Regularly Interspaced Short 
Palindromic Repeats 
P-TEFb Positive transcription elongation factors b 
CRM-1  Chromosome region maintenance 1 rAAV Recombinant adeno-associated virus  
CTD C-terminal domain  Ran Ras-related nuclear protein 
CTL Cytotoxic T lymphocyte  Rev Regulator of Virion Protein 
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1.1. Human immunodeficiency virus  
The Human Immunodeficiency Virus (HIV) was discovered in 1983 as the causative 
agent of the acquired immunodeficiency syndrome (AIDS) [1]. HIV infection remains as one 
of the most predominant epidemics worldwide, with approximately 37 million people currently 
living with HIV, leading to over 1 million deaths per year caused by AIDS (Fig. 1.1; World 
Health Organization Database, 2016). AIDS is characterized by the suppression of the immune 
system in otherwise healthy individuals, leading to the emergence of opportunistic diseases 
that eventually leads to the death of the HIV infected patients [2–4]. Two types of HIV were 
identified so far: HIV-1 and HIV-2. Main concerns have been focused on HIV-1 as its 
transmission is responsible for AIDS global pandemic, being highly pathogenic. Due to its 
lower capacity of transmission, HIV-2 has been mainly restricted to the region of West Africa 
[5,6].  
 
Figure 1.1- Global HIV adult prevalence (15-49 years) by 2016. 36.7 million [34.0–39.8 million] people were 
living with HIV at the end of 2015. An estimated 0.8% [0.7-0.9%] of adults aged 15–49 years worldwide are 
living with HIV, although the burden of the epidemic continues to vary considerably between countries and 
regions. Sub-Saharan Africa remains most severely affected, with nearly 1 in every 25 adults (4.4%) living with 
HIV and accounting for nearly 70% of the people living with HIV worldwide. Source: World Health Organization, 
2016. 
The main targets of HIV are CD4+ T lymphocytes and macrophages [7–9]. Briefly, when 
it enters the host, HIV directly infects these cells in the blood or mucosa. Spread of infection 
in lymphoid tissues leads to the viremia observed during acute phase of infection. The viremia 
Chapter I – General Introduction 
 
4 
 
is controlled by the host immune response that mostly contains viral spread and the patient 
enters a phase of clinical latency. However, HIV continues to replicate leading to a gradual 
decline in CD4+ T cells and sequentially the patient develops clinical symptoms of AIDS [10]. 
The central nervous system (CNS) is also affected by HIV-1 invasion, particularly through 
infected macrophages that cross the blood-brain barrier and migrate to the brain. Infection of 
resident macrophages and microgial cells in the CNS can lead to neurodegenerative symptoms 
derived from inflammatory response to infection [11]. 
HIV tropism is mostly determined by the presence of cell surface receptor Cluster 
Designation 4 (CD4) and co-receptor CC Chemokine Receptor 5 (CCR5) or CXC Chemokine 
Receptor 4 (CXCR4) that mediates binding and entrance of the virus into target cells (Figure 
2) [12]. HIV viruses that bind CCR5 (R5-tropic) co-receptors are the most commonly 
transmitted viral strains, being predominant during early stage of infection. CXCR4 targeted 
(X4-tropic) HIV strains tend to emerge later during disease progression to AIDS [13,14]. Dual-
tropic strains (X4R5-tropic) capable of targeting both co-receptors emerge during transition 
from CCR5 to CXCR4 tropism. 
1.1.1.  HIV-1 genome and structure 
The Human Immunodeficiency Virus belongs to the Retroviridae family as a member 
of the Lentivirus group. The HIV virus particle packages two copies of the viral RNA genome. 
Retroviruses are characterized by the presence of a Reverse Transcriptase (RT) and an 
Integrase (IN) that are essential to the viral replication cycle. The RT enzyme reverse-
transcribes their positive genomic RNA into a proviral DNA, while the Integrase promotes the 
integration of the viral DNA into the host cell genome [15]. HIV-1 genome consists in a 9.8 
Kb single-stranded positive RNA molecule, flanked by terminal repeats that are converted to 
5’ and 3’ long-terminal repeats (LTRs) after RNA is reversely transcribed into cDNA and 
integrated in the host cell genome. This integrated form of HIV is denominated a provirus. The 
HIV-1 promoter controlling virus transcription and expression is comprised within the 5’ LTR 
region. HIV-1 genome encodes for 9 open reading frames (Fig. 1.2). The gag, pol and env 
genes encode for polyproteins which are then lysed by the viral Protease (PR) into individual 
proteins: the gag (group-specific antigen) region codes for structural proteins – MA (matrix), 
CA (capsid), NC (nucleocapsid), and p6; pol (polymerase) region encodes for essential 
enzymes participating in the HIV replication cycle – Protease (PR), Reverse Transcriptase (RT) 
and Integrase (IN); and env (envelope) region encode glycoproteins present in the outer 
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membrane of the virion that mediate binding and entrance into host cells – SU surface/gp120 
(SU) and transmembranar/gp41 (TM) [16]. 
 
Figure 1.2- Organization of the HIV-1 genome. Source: Frankel and Young 1998 [16]. 
Accessory genes (vpr, vif and nef) and 
regulatory genes (tat, rev, vpu) are also encoded 
by HIV-1 genome, presenting a particular role 
in HIV-1 entry and replication. Regulatory Tat, 
Rev and Vpu proteins are not incorporated in 
the HIV-1 mature virion (Fig. 1.3).  
Figure 1.3- Structure of mature HIV-1. HIV-1 virion 
consists in a capsid particle, incorporating 2 RNA 
genome copies, along with reverse-transcriptase, 
integrase and protease enzymes. Accessory proteins Vif, 
Nef and Vpr are also packaged in viral particles. Matrix proteins stabilize capsid, interacting with viral envelope, 
a bilayer lipid membrane containing surface glycoproteins gp120 anchored to the capsid by the transmembranar 
protein gp41 Source: Kumar et al. 2010 [17]. 
1.1.2.  HIV-1 replication 
HIV-1 replication cycle can be divided into 2 distinct stages: early (infection) and late 
(expression) phase (Fig. 1.4). Early phase of HIV-1 replication consists in the binding and entry 
steps of the mature virion into the cell. Binding occurs by specific interactions between the 
viral glycoprotein gp120 and the amino-terminal immunoglobulin domain of the cellular CD4 
molecule, exposing the CCR5 or CXCR4 co-receptors [18,19]. As mentioned above, these co-
receptors determine HIV-1 tropism [20]. The interaction of gp120 with these co-receptors 
causes conformational changes in the transmembrane protein gp41 that, in turn, exposes an N-
terminal hydrophobic region (“fusion peptide”). Exposure of this region mediates fusion of 
viral and cellular membranes, and the subsequent entry of the virion core into the cell cytosol 
[18,19,21].  
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Once inside the cell, capsid proteins are dissociated from the viral core, which is 
converted to a reverse-transcription complex by a process called “uncoating”. In this complex, 
the RNA genome remains associated with the nucleocapsid, matrix, reverse-transcriptase, 
integrase and the accessory protein Vpr. Following uncoating, the single-stranded RNA(+) 
genome is converted in the cytosol to a double-stranded linear DNA molecule by the reverse-
transcriptase. Reverse-transcription of the RNA genome is initiated after the binding of a 
cellular tRNALys primer [15,18,19]. The newly formed cDNA molecule is transported to the 
nucleus as part of the pre-integrative complex containing the RT, IN, MA and Vpr proteins. 
This nuclear import is assisted by Vpr, which connects the complex to the nuclear import 
machinery [22]. The viral cDNA is then integrated into the host cell chromosome by the viral 
integrase, thus concluding the early phase of infection [18,19]. 
 
Figure 1.4- HIV-1 replication cycle. HIV-1 particles bind to target cell through interaction between viral 
envelope (Env) gp120 and cell CD4 receptor and a chemokine co-receptor. Viral and cellular membranes are 
fused and the virion core is released into the cell cytosol. In the cytosol, single-stranded RNA genome is converted 
to a double-stranded cDNA molecule by Reverse-transcriptase. Viral cDNA is imported into the nucleus as part 
of a pre-integration complex and integrated into host cell chromosome by viral Integrase. Host RNA polymerase 
II (RNAPII) promotes transcription of integrated proviral genome. Regulatory Tat assists transcription of 
elongated transcripts while Rev mediates exportation of single-spliced and unspliced transcripts to the cytoplasm. 
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HIV-1 full-transcripts are assembled with Gag and Pol polyproteins near the cell membrane and incorporated into 
immature virions. Viral particles are released from the cell by budding with cellular membrane. Viral protease 
cleaves GagPol polyprotein into individual functional proteins, triggering the maturation of virions by promoting 
the reorganization of their core and enabling them to infect new cells. Source: Peterlin et al. 2003 [23]. 
The late phase of infection begins with the transcription of the provirus by the host 
RNA Polymerase II. At first, only Tat, Rev and Nef are initially expressed by means of 
alternative multiple splicing of the HIV-1 transcript. Tat has an essential role in this stage, 
activating the 5’ LTR promoter and thereby enhancing the rate of HIV-1 transcription and 
elongation. Rev regulates transcription exportation by promoting export of single-spliced and 
unspliced RNA to the cell cytosol. Once Rev is expressed, single-spliced RNAs (env, vif, vpu 
and vpr) and unspliced RNAs (gag and gagpol) are translated in the cytoplasm [18]. More 
details on the Tat and Rev function are described below in section 1.1.2.1. 
Gag and GagPol polyproteins are transported to the cell membrane where assembly 
of new viral particles occurs. Envelope proteins gp120 and gp41 are directed to the membrane 
through the ER-Golgi pathway. HIV-1 full-transcript RNA is encapsulated and immature 
virions are released from the cell. The viral protease triggers subsequently the maturation of 
virions, promoting the reorganization of their core and enabling them to infect new cells [18].  
1.1.2.1. Tat and Rev regulatory function in HIV-1 replication 
Several accessory proteins contribute to the efficiency of HIV-1 infection, replication 
and spread. After provirus genome integration into host chromatin, expression of Tat and Rev 
is a critical step in HIV-1 replication. In the absence of these viral proteins, the replication 
cycle is stalled, preventing efficient production of viral particles [18].  
Host RNA polymerase II is capable of successfully initiate provirus transcription from 
5’ LTR HIV-1 promoter which contains binding sites for several transcription factors, such as 
NF-κB, Sp1 and TBP and contributes to the basal transcriptional activity of the viral promoter. 
However, RNA pol.II-mediated transcription fails to perform elongation of the RNA chains. 
The transcriptional transactivator Tat is the actual responsible for the bulk of viral transcription 
in more than two orders of magnitude above basal transcription [16,18]. Tat binds the trans-
activating response element (TAR) stem-loop located at 5’ end of the nascent RNA chain and 
recruits host positive transcription elongation factors b (P-TEFb), including CyclinT1 and 
CDK9. These proteins form a complex and phosphorylate the C-terminal domain (CTD) of the 
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largest subunit of RNA polymerase II, stimulating its elongation activity and allowing the 
production of full-length HIV-1 transcripts (Fig. 1.5A) [24,25]. 
Additionally, Rev also has an essential role in HIV-1 replication, regulating the RNA 
export of single-spliced and unspliced transcripts from the nucleus to the cytoplasm. Rev binds 
to a loop structure named Rev-responsive element (RRE) located at the 3’ of RNA transcripts 
and interacts with nucleoporin-like proteins at the nuclear pores to initiate a Rev-mediated 
RNA export cycle (Fig. 1.5B). These interactions allow Rev to export the RNA transcripts to 
the cytosol without being spliced, enabling production of viral components necessary for 
particle assembly [26]. 
 
Figure 1.5- Tat and Rev regulatory function on HIV-1 replication. (A) Tat-mediated elongation of HIV-1 
transcripts. Following activation of the LTR promoter through binding of NFAT, NF-kB and Sp1 transcription 
factors, Tat recruits the CycT1/CDK9 complex and other P-TEFb interacting proteins and binds to the nascent 
RNA chain TAR element. This complex phosphorylates RNA polymerase II CTD, along with negative elongation 
factors DSIF and NELF, leading to the activation of transcription elongation of HIV-1 transcripts. Source: Ruelas 
and Greene 2013 [27]. (B) Rev-mediated RNA export cycle. Rev binds to RRE element at viral transcripts and 
forms a nuclear export complex, by interacting with CRM-1 through the nuclear export sequence (NES) and Ran-
GTP. This complex is then exported to the cytoplasm through interactions with nuclear pore proteins. Once in the 
cytoplasm, Ran-GTP is converted to Ran-GDP, releasing Rev and CRM-1. Rev is imported back to the nucleus 
by interacting with Importin-β through the nuclear localization sequence (NLS) and Ran-GDP. In the nucleus, 
Ran-GDP is phosphorylated to Ran-GTP, releasing Rev to begin a new cycle of Rev/RNA export. Source: Karn 
and Stoltzfus 2012 [26]. 
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1.1.3.  Current treatment to HIV-1 infection 
Over the past 30 years, numerous advances in the development of therapies against 
HIV-1 improved significantly life quality and span of infected patients. Highly active anti-
retroviral therapy (HAART) is currently the most successful therapy against HIV-1 infection. 
HAART consists in a selected combination of three or more antiretroviral drugs that inhibit 
HIV-1 infection by targeting key steps of the HIV replication cycle (Fig. 1.6). These include 
nucleoside reverse transcriptase inhibitors (NRTIs) or non-nucleoside reverse transcriptase 
inhibitors (NNRTIs), protease inhibitors, entry inhibitors and more recently, integrase 
inhibitors [28,29]. This antiretroviral cocktail causes a striking decrease in plasma virus levels 
to below the limit of detection of clinical assays (50 RNA copies/mL) (Figure 8) [30–32].  
 
Figure 1.6- HIV-1 replication target points by antiretroviral therapy. Schematic representation of the HIV-1 
replication cycle and the key steps targeted by the antiretroviral drugs. NRTIs, Nucleside Reverse Transcriptase 
Inhibitors. NNRTIs, Non-nucleoseide Reverse Transcriptase Inhibitors. Source: Kalapila and Marrazzo 2014  
[33].   
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HAART became the standard clinical practice for treatment of HIV-1 infection, 
allowing a sustained antiviral effect and improving life expectancy of infected patients while 
considerably reducing the risk of HIV transmission. However, there are adverse effects 
associated with antiretroviral drugs. Most common issues include hepatic and nephrotoxicity, 
gastrointestinal symptoms (nausea, vomits, diarrhea), neuropsychiatric problems, myopathy, 
or decreased bone mineral density. Emergence of resistant virus to some of the antiretroviral 
drugs is also a potential risk. Patient monitoring for treatment selection is critical to minimize 
toxicity and optimize adherence [29,33]. 
In addition, antiretroviral treatment must be maintained throughout the life course while 
patients have to be constantly monitored for HIV viral load and CD4 cell count from 2-8 weeks 
to every 3-6 months after HAART initiation [33]. Although no viremia is detected, treatment 
interruption results in the recovery of viral replication and consequently disease progression 
(Fig. 1.7). HAART does not cure the patient from HIV-1 infection due to the existence of 
residual HIV-1 viremia hidden in persistent cellular reservoirs, an infected anatomical site or 
cell type in which a replication competent form of HIV persists due to low drug penetration or 
latency [34,35]. 
 
Figure 1.7- HIV-1 kinetics under antiretroviral therapy (ART). The administration of ART leads to a dramatic 
decay in the plasma HIV-1 viremia. In the first phase, plasma viremia is decreased reflecting the death of the 
productively infected CD4+ T lymphocytes. The second phase is characterized by persistent replication bellow 
the detection limit of commercial assays (50 copies/ml) associated with residual infection of long-lived cells, such 
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as tissue macrophages. Existence of latently infected resting CD4+ T cells which are spontaneously reactivated 
help maintain the low-level viremia during ART. The contribution of non-T cell reservoirs including chronically 
infected tissue macrophages to residual viremia remains uncertain. Treatment interruption (in case studies 
stopping ART with close monitoring) leads to viral rebound and detectable plasma viremia. Source: Spivak and 
Planelles 2016 [36]. 
1.1.4.  HIV-1 Latency 
One of the primary focus for novel antiretroviral developments, HIV latency is widely 
considered the main obstacle to achieve a cure for HIV infection. Existence of latent HIV-1 
hidden in persistent cellular reservoirs enables them to escape from antiretroviral therapy or 
host immune response. Even though latent HIV-1 does not replicate in normal conditions, 
cellular reservoirs can serve as a source of new replicating virus that emerge once its stimulated 
by specific antigens or cytokines (Fig. 1.7) [27,37]. HIV reservoirs are disseminated into the 
host and can be found in the blood or bone marrow, and in anatomical sites including the brain, 
genital tract and gut-associated lymphoid tissues [38]. 
Latent HIV-1 reservoirs are mainly resting memory CD4+ T-cells established early 
during acute phase of infection [39]. Residual viremia can be found in other cell lineages such 
as monocytes-macrophages, astrocytes, follicular dendritic cells and hematopoietic progenitor 
cells, however their role in the latent HIV-1 reservoir maintenance is not completely 
understood [34]. The HIV-1 latency can be characterized by two states: pre-integration or post-
integration latency (Fig. 1.8). Pre-integration latency is the presence of full-length viral dsDNA 
that is reverse-transcribed but fails to integrate the host genome, being the most predominant 
form in untreated patients [40]. The non-permissive environment found in resting memory T 
cells often blocks HIV-1 replication at this stage, leading to accumulation of linear or circular 
unintegrated cDNA [41,42]. Stimulatory signals can promote integration of viral cDNA into 
host genome leading to production of infectious particles, thus this extrachromosomal form of 
HIV is considered latent [43–45]. However, unintegrated HIV has a very short half-life of 24 
hours to few days, limiting the impact of these cells for maintenance of stable reservoirs of 
HIV [46,47]. 
Post-integration latency is considered the most relevant form of HIV persistence, 
established when the viral transcription of a stably integrated provirus is abolished, impairing 
virus production [40,48]. This is the general case in infected CD4+ lymphoblasts that revert 
back to a resting memory state and HIV-1 expression is extinguished [27,41]. Their frequency 
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is rare, in the order of 1 in 106 resting CD4+ T cells [49–51].  Resting memory T cells harboring 
latent integrated proviral DNA are highly persistent in the patient (approximately 44 months), 
being able to maintain the HIV reservoir for long periods [27]. Once latent cells are stimulated, 
silenced provirus is reactivated and novel particles emerge to spread infection to new cells [52]. 
The half-life of HIV latent reservoir is longer than the average life span of the patients, 
estimated to take approximately 73 years of therapy to eradicate the reservoir [53]. 
Consequently, HIV-1 latency is considered as the main barrier for complete eradication of the 
virus from the infected host. Therefore, understanding the mechanisms behind HIV-1 latency 
is crucial for the development of new drugs or therapies capable of target latent HIV and its 
cellular reservoirs. 
 
Figure 1.8- Establishment of HIV-1 latency in resting memory CD4+ T cells. Prior to stimulation with specific 
antigens, naïve CD4+ T cells can be infected and carry unintegrated viral double-stranded HIV provirus which is 
partially transcribed (Pre-integration latency). Once these cells are stimulated by their cognate antigen, they begin 
clonal proliferation and promote viral integration into host cell genome and fully activate HIV-1 replication. Over 
the course of infection, most of these highly HIV-replicating infected cells die through apoptosis. However, some 
of the effector T cells revert to resting memory T cells, and integrated provirus can be silenced (Post-integration 
latency). Once the cell is stimulated again with the same antigen, virus replication is reactivated. Alternatively, a 
resting memory CD4+ T cell can be directly infected and carry unintegrated partially transcribed HIV as it occurs 
with naïve T cells. Under suboptimal activation, these cells integrate HIV provirus into their genome, inducing a 
post-integration latent state, which can also promote low-level replication even in the absence of antigen 
stimulation. Source: Coiras et al. 2009 [42]. 
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Establishment of HIV-1 latency is mainly determined by the cell transcriptional 
environment. Several mechanisms involved in the establishment of latency have been 
identified (Fig. 1.9) [27,37]. Integration in less favorable chromatin environments lead to 
suppression of HIV-1 transcription by impairing access of key host transcriptional factors to 
proviral genome [54,55]. Nevertheless, these events occur with low frequency since HIV-1 
integrates mostly in actively transcribed regions [56], highlighting the potential role of 
transcriptional interference on HIV latency. In fact, integration of proviral genome close to 
highly expressed genes leads to silencing of HIV-1 transcription either through viral promoter 
occlusion caused by an upstream host gene transcription that displaces critical transcription 
factors [57,58]; or by collision of RNA Pol II complexes from HIV-1 provirus and a host gene 
in opposite directions [59–61]. Epigenetic changes caused by DNA methylation [62,63] and 
histone deacetylation [64] have also a role play in HIV-1 shutdown. Sequestration of host 
transcription factors in resting CD4+ T cells critical to initiation of HIV-1 transcription, such 
as NF-kB or NFAT [65,66], or low levels of cyclin T1, part of the P-TEFb complex that assists 
Tat in the enhancement of HIV transcription elongation [67,68], impairs the completion of the 
HIV-1 replication cycle. Posttranscriptional mechanisms, including impairment of HIV mRNA 
nuclear export [69] or innate host miRNA control [70,71] were also identified. 
 
Figure 1.9- Cell transcriptional environment promotes establishment of HIV-1 latency. Schematic 
representation of the mechanisms associated with HIV latency. Sequestration of NFAT or NF-kB transcription 
factors essential to HIV transcription initiation leads to silencing of viral gene expression. Transcriptional 
interference may lead to silencing of viral transcription, either by promoter occlusion when integrated provirus is 
silenced by an active upstream host promoter and the RNA pol II reads through the HIV-1 LTR; or by convergent 
transcription, when opposite transcription from host and viral promoter leads to collision of initiating polymerases, 
inhibiting expression of one or both genes. Low levels of cyclin T1, part of the P-TEFb complex that cooperates 
with Tat for enhancement of HIV transcription also leads to HIV silencing. Epigenetic mechanisms such as DNA 
Chapter I – General Introduction 
 
14 
 
methylation or histone deacetylation also lead to shutdown of HIV transcription. Integration of HIV provirus into 
condensed chromatin regions could block access of key transcriptional factors to LTR promoter required to initiate 
viral transcription. Source: Ruelas and Greene 2013 [27]. 
1.1.4.1. Pharmacological approaches to treat latent HIV-1 
reservoirs 
Because the presence of latent HIV-1 represents an enormous barrier toward its 
eradication, numerous strategies have been developed to purge it from its cellular reservoirs. 
In theory, mechanisms associated with HIV latency could be manipulated pharmacologically 
to reactivate latent HIV-1 and expose these reservoirs to the immune response or cytopathic 
effects that would clear the infected cells. This strategy is commonly known as “shock and 
kill” (Fig. 1.10). 
Figure 1.10- “Shock and kill” 
approach to target HIV-1 
reservoirs. HIV latent cells 
harbor an integrated silent 
provirus, persisting through 
antiretroviral treatment or host 
immune response. However, as 
simulating memory T cell 
stimulation, latent reservoirs 
can be reactivated using a broad 
panel of stimulating drugs 
causing cells to actively 
produce virus. Combinations of 
these drugs (such as PKC 
activators and HDAC 
inhibitors) can synergistically 
enhance latency reactivation. 
The production of viral 
particles can ultimately lead to 
cell death from the infection or alternatively through immune effector mechanisms or novel approaches targeted 
to infected cells (such as antibody-drug conjugations). The continued present of HAART will prevent HIV spread 
to new cells. HDAC, Histone deacetylase. HMT, Histone methyltransferase. PKC, protein kinase C. IL, 
interleukin. HAART, highly active antiretroviral treatment. Source: Marsden and Zack 2013 [72]. 
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Considering the mechanisms responsible for the development of latency, methods to 
force HIV reservoirs to produce viral particles tested so far were mostly based in 
pharmacological approaches to stimulate T-cells through receptor engagement or downstream 
activation of signaling pathways [52]; or epigenetic remodeling through inhibition of histone-
modifying [73] or DNA methylation [62,63] enzymes. 
Strategies that simulate the natural activation of T-cells through antigen and cytokine 
stimulation should reactivate latent expression similarly as occurs in the patient. Treatment 
with anti-CD3 chain of T-cell receptor and IL-2 triggers cell activation along with expression 
of latent HIV [74], nonetheless it reveals toxic effects resulting in long-lasting depletion of 
CD4+ T cells in peripheral blood and lymph nodes [75]. IL-7 cytokine causes a milder 
activation of T-cell but sufficient to trigger HIV expression [76,77] yet homeostatic 
proliferation caused by this cytokine proved responsible for maintenance of HIV reservoir [78]. 
Protein kinase C (PKC) signaling pathway is connected to activation of transcription factors 
necessary to induce HIV transcription. PKC agonists such as prostatin [79,80] or bryostatin 
[81] reactivate HIV transcription in latent T cells through induction of NF-kB. Although these 
agents cause a striking increase in HIV transcription, they also trigger undesired global 
activation of immune response with a toxic inflammatory response [42,52]. 
Histone deacetylases (HDACs) promote hypoacetylation of nucleosomes with 
compaction of chromatin, contributing to HIV reservoirs by restricting access to transcription 
factors [37]. HDAC inhibitors, such as valproic acid [82] and vorinostat [83,84] are promising 
agents capable of inducing viral gene expression without global T cell activation by disrupting 
recruitment of HDAC proteins to the HIV long terminal repeat (LTR) promoter. Both HDAC 
inhibitors are able to increase HIV transcription from resting T cells of aviremic infected 
patients, however no significant reduction of the reservoir size was observed [85–88]. DNA 
methylation of CpG dinucleotides at HIV 5’LTR is another relevant epigenetic mark 
responsible for HIV silencing by impairing binding of critical transcription factors like NF-kB 
[89]. Treatment with 5-aza-2’deoxycytidine (aza-CdR), an inhibitor of DNA 
methyltransferases, increases viral gene expression of latent cells [62,63]. Nevertheless, this 
treatment is limited by the low level of 5’LTR methylated events that actually contribute to the 
HIV reservoir  [90]. In conclusion, despite the evidence that these drugs can induce latent viral 
expression, none of the strategies mentioned above could eradicate latent HIV from cellular 
reservoirs, and some of them were associated with undesirable and toxic generalized immune 
activation. 
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In addition to these limitations, the immune system of infected patients lacks a robust 
cytotoxic T lymphocyte (CTL) response essential to clear the reactivated cells, suggesting that 
reactivating HIV reservoirs alone is not sufficient to promote their elimination. Stimulation of 
CTLs with HIV-specific antigens prior to reactivation of latent infected cells seem critical for 
efficient eradication of these reservoirs [91]. Another major concern is the high frequency of 
CTL escape mutations detected in resting CD4+ T cells from patients receiving antiretroviral 
treatment during the chronic phase of infection in a study by Deng et al. 2015 [92]. Emergence 
of HIV reservoirs harboring escape mutations seem to be driven by the selection pressure 
caused by CTL response during the acute phase of infection leading to selected growth of CTL 
escape variants, posing a major challenge to the reservoir eradication [92,93]. These limitations 
highlight the need for the development of alternative and more targeted strategies against latent 
HIV-1 and its cellular reservoirs. 
1.2. Gene Therapy 
Emerging in the late 1980s, gene therapy has promised to innovate the field of 
molecular medicine, providing novel ways to correct a wide range of genetic or acquired 
diseases. Gene therapy can be described as the transfer of nucleic acids (DNA or RNA) to treat, 
cure or prevent human disorders. Most gene therapeutic applications aim to correct a cell 
harboring a defective gene responsible for the syndrome by introducing a functional copy of 
the gene, or reduce levels of a harmful gene product by targeting its transcription using 
sophisticated tools [94]. 
Initially focused on primary immune-deficiencies, for which there was lack of 
alternative treatments, gene therapy quickly spread out to target other disorders related to 
cancer, heart failure, neurodegenerative or metabolic disorders, so far with approval of over 
2300 clinical trials for gene therapeutic applications (Fig. 1.11; The Journal of Gene Medicine 
Clinical Trial site). 
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Figure 1.11- Indications addressed by gene therapy clinical trials. Global representation of worldwide gene 
therapy clinical trials distributed by targeted diseases. Source: The Journal of Gene Medicine Clinical Trial site 
(www.wiley.co.uk/genmed/clinical). 
Gene therapeutic applications can be implemented in vivo, by direct introduction of the 
therapeutic gene into the patient, or ex vivo, by correcting the defective cells outside the patient 
(Fig. 1.12). 
 
Figure 1.12- Gene therapy in vivo vs. ex vivo. For in vivo applications, correction of the patient defective cells 
is promoted by direct introduction of the therapeutic gene into the body (e.g. muscle, liver) through a delivery 
vector (viral or non-viral). For ex vivo applications, cells (e.g. hematopoietic stem cells from the bone marrow) 
are collected from the patient, genetically modified outside the body and reintroduced into the patient as an 
autologous transplant. BM, bone marrow. Source: Kaufmann et al. 2013 [94]. 
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Gene transfer to target cells is mediated through vectors that can surpass the complex 
cell and tissue barriers and deliver the new genetic material into the target cell without 
disrupting essential regulatory mechanisms (Fig. 1.13). These vectors are classified as viral or 
non-viral. Ideally, vectors for gene delivery should possess some of these critical attributes: 
ease production on a commercial scale with low costs associated; sustain long-term gene 
expression; present low immunogenicity; programmable to be retargeted to certain cell types 
or tissues; package large genetic material; replicate or segregate during cell division for long-
term effects; and transfect either dividing or non-diving cells [95]. Although non-viral methods 
(e.g. naked DNA, liposomes or cationic polymers) present some advantages such as lower cost 
and immunogenicity as well as higher packaging capacity [96], viral vectors continue to be the 
most exploited vehicles, dominating gene therapy clinical trials due to their superior efficiency 
in gene delivery [95,97]. 
 
Figure 1.13- Gene-transfer vectors typically used for therapeutic applications. Therapeutic gene is 
incorporated into an expression cassette, flanked at 5’ by a promoter and at 3’ by a polyadenylation site. This 
expression cassette is packaged into a viral or non-viral vector. Viral vectors implemented are mostly composed 
by adenovirus, adeno-associated virus (AAV), retrovirus or lentivirus. Non-viral vectors deliver plasmid DNA or 
mRNA either naked or incorporated into liposome or cationic based particles. The limit of expression cassette 
size is indicated for each vector. ITR, inverted-terminal repeats.  Ψ, packaging signal. E1-E4, early genes. L1-L5, 
late genes. LTR, long-terminal repeats. cPPT, central polypurine tract. CTS, central termination sequence. Ori, 
bacterial origin or replicarion signal. Source: Sheridan 2011 [98]. 
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Viral vectors are derived from natural viruses by splitting their genetic components 
and replacing the pathogenic elements for a therapeutic gene. These components are introduced 
in trans to a packaging cell line to produce viral particles that will deliver the therapeutic gene 
to the target cell but lacks the components necessary for further propagation to other cells [95]. 
Viral vectors derived from adenovirus, adeno-associated virus, retrovirus or lentivirus family 
(Figure 14) are so far, the most relevant vehicles implemented for gene therapy applications. 
Replication-defective adenoviral vectors (AdVs) are derived from the Adenoviridae 
family of double-stranded DNA non-enveloped viruses able to transduce both dividing or non-
dividing cells, remaining in the nucleus as non-integrated episome [95]. More than 50 types of 
adenovirus have been identified that interact with a broad range of cell receptors and are 
associated with asymptomatic infections specially in the respiratory tract, intestine, eyes or 
liver, possibly lethal in immunocompromised individuals [99]. AdVs can be produced at high 
titers and their large dimension enables packaging of large or multiple transgenes – up to 37 
Kb if most viral components are removed from the vector - into viral particles that sustain high-
level expression in target cells without risk of insertional mutagenesis [100]. These key abilities 
made these viruses the most used vector for gene therapeutic applications, with over 500 
clinical trials involving adenovirus delivery. In addition to gene delivery, AdVs are also 
exploited as prophylactic vaccines or oncolytic viruses. Human trials using AdVs were carried 
for treatment of cardiovascular disorders, cystic fibrosis, hemophilia A or viral infections [101]. 
However, most AdV applications focus on cancer treatment, opening up the door for the first 
world-wide gene therapy approved in China for treatment of head and neck carcinoma 
(Gendicine) [99]. The main hurdle with AdVs is the in vivo cellular and humoral 
immunological response to viral particle components or transgenes which can trigger fatal 
adverse effects [102], but also cause loss of long-term transgene expression [103,104]. This 
adverse effect limits adenoviral gene transfer applicability in vivo particularly for cases that 
only require sustained gene transfer or multiple doses of vector injection. 
Similar to adenovirus, adeno-associated virus (AAV) efficiently transduce both 
dividing and non-dividing cells but present far less immunogenicity, being widely explored for 
in vivo applications [105]. These single-stranded DNA particles from the Parvoviridae family 
are small and non-enveloped, persisting in the target cell mostly in the episomal form, able to 
replicate only in the presence of helper virus (adenovirus or herpes simplex virus) [106]. Viral 
tropism is determined by the capsid composition that mediate binding to cell surface-receptors, 
promoting endocytic uptake [107]. The discovery and engineering of several naturally 
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occurring AAV serotypes with distinct viral tropism greatly expanded available options for 
targeting a broad range of tissues, including the brain, liver, eye or muscle [108]. Recombinant 
AAV (rAAV) vectors have shown tremendous clinical efficacy for treatment of numerous 
genetic diseases such as haemophilia B, Leber’s congenital amaurosis type II, chloroideremia 
and lipoprotein lipase deficiency [109], the latter culminating in the first gene therapy product 
approved in the European Union by 2012 (Glybera) [110]. Challenges faced with AAV come 
from their reduced size which limits the packaging of large transgenes [111]. Additionally, 
although it can integrate genome at low frequencies through NHEJ-repair [112], AAV do not 
possess an integration machinery, therefore unable to sustain gene transfer in proliferating 
populations relevant for gene therapeutic applications, such as malignant or hematopoietic 
cells.  
Retroviral vectors (RVs) were among the first to be implemented in gene therapy 
clinical trials, particularly due to its unique machinery that promote stable gene transfer into 
dividing populations. Retrovirus are RNA-virus that retrotranscribe its genome and integrate it 
into the target cell chromosome, therefore propagating long-term expression to its progeny 
[95]. Gene therapy through murine leukemia-derived gamma-retroviral vectors (γ-RVs) took 
significant importance for translation of ex vivo cell therapies, in particular for hematopoietic 
stem cell (HSC) transplantation. CD34+ HSCs can be collected from the patient and genetically 
modified with a transgene to correct the defective cell, emerging as an alternative therapeutic 
option for treatment of several blood and immune, or lysosomal storage related disorders [113]. 
Once reinfused in the patient, these genetically modified pluripotent cells allow long term 
repopulation and differentiation, which could represent a long-life treatment for the patient. 
Opposed to using HSC from healthy donors, reinfusing autologous (self) HSC from the patient 
has the advantage of preventing immune incompatibilities which could lead to rejection of 
engraftment or graft-versus-host disease. γ-RVs were naturally adopted for HSC therapy due 
to the requirement for transgene integration and long-term expression that is propagated to the 
reconstituted hematopoietic lineage [113]. Early clinical trials used HSCs genetically modified 
with γ-RVs to treat two types of severe combined immunodeficiency (SCID), X-linked (SCID-
X1) [114] and adenosine deaminase-deficiency (ADA-SCID) [115] with outstanding results, 
clearly showing the potential benefit of autologous HSC gene therapy to correct these inherited 
genetic diseases. In 2016, the first ex vivo HSC gene therapy was approved by the European 
Union for treatment of ADA-SCID (Strimvelis), after 18 infants showed clear marks or long 
term benefits and survival from this treatment [116].  
Chapter I – General Introduction 
 
21 
 
Despite their tremendous success in early gene therapy clinical trials, cases of children 
developed leukemia were reported from this vector transfer [117]. The abnormal condition 
derived from retrovirus-mediated insertional mutagenesis that caused activation of a particular 
oncogene [118,119]. In addition, retrovirus are unable to transduce non-dividing cells, which 
difficult gene transfer into primitive progenitor cells [113]. These hurdles clearly marked the 
need for continuous development of more efficient but also importantly safer vectors for gene 
transfer. 
1.2.1. Lentiviral gene therapy 
Early gene therapeutic applications derived in a large portion from murine leukemia-
derived γ-RVs gene delivery which were particularly used for their ability to integrate the cell 
genome, allowing life-long treatment for the patient [113]. However, reports of several cases 
of hematological malignancies were associated with insertional activation of oncogenes by 
these vectors [117,118,120]. In addition, this class of retroviruses is limited by its inability to 
infect non-dividing cells, impairing their application in a wide variety of target cells and tissues 
[121–123]. 
HIV-derived lentiviral vectors (LVs) overcame these limitations as these viruses do 
not require cell division to transduce and integrate the target cell genome [124], resulting in 
more efficient gene transfer and robust gene expression as compared to γ-RVs. LVs have also 
been associated with less risk of insertional genotoxicity and potential to trigger oncogenesis 
due to differences in integration profile [125–128]. Introduction of self-inactivating (SIN) LTR 
that removes transcriptional elements from both LTRs during retro-transcription further 
enhanced safety of lentivirus transduction [127]. Furthermore, LVs present reduced 
immunogenicity upon in vivo injection [129,130] compared to other frequently used virus 
family for gene therapy such as adenovirus [131] or adeno-associated virus (AAV) [132]. 
Substitution of the virus natural envelope for vesicular stomatitis virus G protein (VSV-G) 
releases lentivirus of their dependence of CD4 receptor to target a wide range of host cells 
[124]. VSV-G pseudotyped lentivirus bind LDL receptors ubiquitous expressed across most 
cell types [133] and also confer high stability to viral particles that enable its concentration to 
higher titers for efficient gene transfer [134], commonly used as the standard envelope used for 
ex vivo lentiviral gene therapy. 
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Preclinical research has improved vector safety and reduced possibility of generation 
of replication-competent by removing viral genes and regions important for HIV pathogenesis 
but unnecessary for gene transduction [135,136]. These modifications to the lentivirus genome 
led to the development of second-generation and third-generation of lentiviral systems which 
are now broadly used to deliver transgenes (Fig. 1.14). 
Lentivirus has tremendous potential in clinical applications, nevertheless potential 
side effects derived from insertional mutagenesis might still occur with these vectors [61,137]. 
In certain cases, correction the defective cell only requires transient transgene expression. To 
avoid genotoxicity, LVs can be modified to abrogate integration of the provirus into the cell 
chromosome, generating integration-deficient lentiviral vectors (IDLV). Gene expression from 
IDLVs is driven from unintegrated retroviral episomes that can remain in the nucleus for long 
periods as a linear or circular form [138]. IDLVs are generated by incorporating class I 
mutations in the pol region of the packaging construct that disable viral Integrase activity (Fig. 
1.14). 
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Figure 1.14- HIV-1 based lentivirus production system. Schematic representation of the second and third-
generation lentiviral production system. HIV-derived lentiviruses are assembled by co-transfecting producer cells, 
generally HEK293T cells, with transfer, packaging (gag-pol) and envelope constructs. Transfer construct harbors 
the therapeutic transgene flanked by 5’ and 3’ long terminal repeats (LTR). Gene expression can be regulated by 
the 5’LTR or a heterologous promoter incorporated upstream of transgene. Third-generation transfer plasmid 
contain a hybrid 5’LTR composed of partial HIV sequence necessary for integration preceded by heterologous 
transcriptional elements (generally from cytomegalovirus) that confer Tat independence to vector genome 
expression. Self-inactivating (SIN) vectors have their LTR enhancer region deleted (ΔU3) to reduce potential 
recombination events that generate replication-competent virus. Transfer construct also contains packaging signal 
(Ψ) for genome encapsidation, the Rev-responsive element (RRE) that mediates nuclear export of unspliced and 
single-spliced transcripts, and the central polypurine tract (cPPT) for transduction enhancement. To increase 
biosafety of lentivirus production, packaging construct of third-generation system is disposed of tat and rev coding 
sequences, driving expression of particles components Gag and Pol alone. In the third-generation system, tat is 
not necessary to drive expression of the transfer plasmid, while rev encoding plasmid is delivered in trans to drive 
efficient translation of RRE-containing transfer and packaging constructs. The envelope plasmid generally 
encodes the vesicular stomatitis G protein (VSV-G) that confer pantropic host range to viral particles. Integration-
deficient lentiviral vectors (IDLV) can be produced by delivering packaging constructs that incorporate class I 
amino acid substitutions (D64, D116 and E152) of the Pol polyprotein that are located at the catalytic core of viral 
Integrase and disable its function. Source: Chen and Gonçalves 2016 [139]. 
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Remarkable efficiency and safety of engineered lentivirus led to the implementation 
of these vectors for clinical applications in human disorders [140]. The first clinical trial in 
humans involving lentiviral delivery used genetically modified autologous CD4+ T cells 
(VRX496-T) transduced with an LV encoding an antisense RNA targeting the HIV envelope. 
Multiple engraftment of vector-modified T cells in HIV aviremic patients reduced viral load in 
6 out of 8 subjects without any signs of clonal transformation or integration near oncogenes 
[141], demonstrating the potential of lentivirus for gene therapy. The stable expression and 
safety profile of lentiviral transduction in T cells played a key role in the progress of cancer 
immunotherapy by engineering T lymphocytes to express a transgenic T-cell receptor (TCR) 
or chimeric antigen receptor (CAR) that target and eliminate malignant cells [142]. 
More importantly, LV mediated gene transfer dramatically improved efficiency of 
HSC therapy due to their superior and safe gene delivery in more primitive progenitor cells as 
compared to early generation γ-RVs [140]. Lentivirus succeed in obtaining robust levels of 
gene transfer in HSCs, having so far achieved tremendous efficacy in clinical trials that treated 
patients from fatal disorders such as X-linked adrenoleukodystrophy [143], metachromatic 
leukodystrophy [144], or Wiskott-Aldrich syndrome [145]. Other ongoing trials for X-linked 
severe combined immunodeficiency (SCID-X1) [146] or hemoglobinopathies [147] also 
promise to follow the same level of success, raising expectations about a wave of market 
approval of novel gene therapies through lentiviral ex vivo correction of HSC. 
In addition to correct stem cells for gene therapeutics, lentivirus have also been 
exploited to generate in vitro this scarce and hardly accessible source. Lentiviral delivery of 
reprogramming factors, also known as “Yamanaka factors” [148], can reprogram somatic cells 
back into pluripotent state, generating induced pluripotent stem cells (iPSC) [149]. This method 
promises to revolutionize regenerative medicine by producing healthy stem cells from a nearly 
unlimited source that could in principle be programmed to correct and generate any cell type 
or tissue [150]. However, reprogramming factors must be expressed during a short window 
period (20-30 days) just enough to induce pluripotency but maintain their ability to 
differentiate. This requirement led to development of a next-generation inducible lentivirus for 
specific control over expression of reprogramming factors, incorporating Cre-recombinase 
excisable cassettes with a doxycycline-inducible promoter for transient transgene expression 
[151]. Nevertheless, concerns about the unpredictable effect of genomic scars remaining after 
lentiviral integration appeal to investigate non-integrative vectors as an alternative and safer 
method to reprogram iPSC [152]. 
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It was mentioned that lentivirus can be engineered to avoid genotoxicity associated 
with integration into cell chromosome, while maintaining episomal transgene expression. 
IDLVs provide transient expression in proliferating cells at lower levels compared to its 
integrative counterpart. Nevertheless, these non-integrative vectors have shown tremendous 
persistent expression  both in vitro and in vivo – up to several months in some cases – after 
transduction of non-dividing tissues, including the eye, brain, spinal cord, muscle and to a less 
extent the liver [138]. 
Transient gene transfer by IDLV have proven useful for several clinical applications, 
particularly in cases for which sustained expression is detrimental to the target cells. 
Overexpression of a truncated form of CXCR4 receptor by IDLV transduction promotes 
mobilization of peripheral blood stem cells after interaction with its correspondent SDF1 
ligand, enhancing HSC engraftment in mouse models of SCID [153]. Vaccination through 
IDLV mediated intracellular expression is able to stimulate antigen-specific cellular or humoral 
immune responses against HIV [154] or hepatitis B [155]. Efficient knockdown of target genes 
by IDLV delivery of short hairpin RNAs demonstrate the potential of this technology for 
modulating gene expression through RNA interference [138]. One major application of IDLV 
transduction is their potential to correct defective genes in situ through genome engineering 
methods, acting not only for transient expression of targeted endonucleases but also encoding 
healthy gene templates for homologous recombination [156] (further discussed in chapter 
1.2.3.3.). In the future, methods that promote IDLV episomal replication to sustain gene 
expression in proliferating populations, such as inclusion of viral SV40 origin of replication 
[157] or eukaryotic scaffold/matrix attachment regions (S/MAR) [158], will surely broaden the 
range of IDLV gene therapeutic applications while maintaining the non-integrative vector 
biosafety. 
Most successful lentiviral applications focus on ex vivo correction of defective cells 
due to their limitation to target specific cell types in vivo. Efficient gene delivery to the target 
cell population is of major importance to avoid wasting vector particles to irrelevant cells, 
potentially triggering side effects if delivering a toxic gene or possibly targeting harmful cells 
such as antigen-presenting cells. For this purpose, strategies have been developed to generate 
receptor-targeted lentivirus by engineering viral surface to adapt targeting ligands that mediate 
transduction to specific cell population. Proof-of-principle of targeted LV transduction was 
demonstrated in tumor or endothelial tissue, nervous or hematopoietic system, as well as 
distinct lymphocyte cell subtypes [159]. This method holds great potential for the direct 
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application of lentivirus in vivo for treatment of relevant human diseases, including HIV 
infection. 
1.2.2. Gene-therapy against HIV-1 
Over recent years, gene-based therapies have gained increased relevance as a 
promising alternative to treat HIV-1 infection. Although antiretroviral drugs have significantly 
improved quality of life of treated patients, these have failed to eradicate HIV infection. Gene 
therapy offers alternative methods to eliminate HIV infection in a targeted and more efficient 
manner by using a wide panel of sophisticated tools that can target key aspects of HIV beyond 
the scope of antiretroviral drugs. 
The concept of gene therapy against HIV-1 consists in delivering therapeutic genes to 
inhibit HIV replication or promote elimination of HIV infected cells. Strategies developed so 
far aimed to turn cells resistant HIV-1 replication, promote apoptosis of HIV-1 infected cells 
or immunize against HIV-1 antigens to engineer anti-HIV cytotoxic cells (Fig. 1.15) 
[72,160,161]. Most of these gene therapeutic applications are divided into protein-based 
therapies (e.g. transdominant negative mutants, toxins, and targeted endonucleases) and RNA-
based strategies (e.g. antisense, ribozyme, RNA aptamers, RNA decoys, short-hairpin RNA 
and small-interfering RNA) [72,160,162].  
Figure 1.15- Gene therapy 
approaches targeting HIV-1 
infection. Schematic representation 
of relevant HIV-1 gene therapeutic 
applications developed against 
HIV-1 infections. Source: Marsden 
and Zack 2013 [72]. 
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1.2.2.1. Engineering HIV immunity 
During chronic infection, the host immune response mediated by CD8+ cytotoxic T 
lymphocytes (CTL) is not able to clear the HIV infected cells. Supplementary stimulation of 
anti-HIV immune response could enforce more efficient responses when battling HIV infection 
[91]. Initial efforts aimed to enhance antiviral humoral immune response through passive 
administration of HIV neutralizing monoclonal antibodies [163,164],  or enhance the existing 
cellular immunity by collecting and expanding anti-HIV CTL ex vivo followed by reinfusion 
into the patient [165–167]. Although these approaches were proven safe and successfully 
stimulated host immunity against HIV infection, they failed to significantly reduce the patient 
viral load [168]. Immune-based gene therapy has provided novel methods for this goal, by 
genetically manipulating the natural immune system to enhance the anti-HIV cellular immune 
response [168]. Gene therapy approaches to engineer HIV immunity consist in redirecting the 
peripheral blood CTLs cells to target HIV more effectively. Peripheral CTLs cells have been 
genetically modified to express a transgenic full T-cell receptor or a modified chimeric receptor 
at the surface to target them to HIV-antigen expressing cells [169]. 
Incorporation of transgenic T-cell receptor (TCR) selective for HIV-antigens 
presented by human leukocyte antigen (HLA) has proven to enhance redirection of peripheral 
T cells to suppress HIV infection [170]. In this approach, HLA-restricted peptide-specific TCR 
are collected from reactive T cells of infected individuals that show robust CTL-mediated 
immune response against HIV. These TCR are then molecularly cloned, modified and selected 
for higher affinity towards HIV peptide-HLA [170–173] and transferred by retroviral or 
lentiviral gene delivery into patient’s peripheral T cells ex vivo to enhance the anti-HIV 
immune response [168]. 
Opposed to transgenic TCR engineering, chimeric antigen receptor (CAR) uses an 
exogenous antigen-binding domain fused to the zeta chain signaling domain of the T-cell 
receptor that triggers cell immune activation once the antigen is recognized. CAR-T cells have 
gained awareness in the treatment of hematological malignancies, achieving outstanding 
results in remission of B-cell acute lymphoblastic leukemia for several patients, consequently 
considered one of the breakthroughs of 21st century [174]. The use of chimeric receptors should 
enable a broader recognition of HIV-antigen expressing cells by avoiding the obstacles 
associated with human leukocyte antigen (HLA) restriction observed with full-length TCR 
[168]. Early studies using CARs based on CD4 epitope directed to gp120 have presented 
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increases in the CD4 T cells and moderate decreases of viral reservoirs in HIV infected patients 
infused with these ex vivo modified CAR-T cells [175]. Following the development of broadly 
neutralizing antibodies and design of new-generation of CARs, recent data have demonstrated 
improved efficacy towards elimination of HIV-Env expressing cells and demonstrating the 
potential of CAR T cells for treatment of chronic HIV infection [176–179]. 
Limitations with these approaches arise mainly from the ex vivo manipulation of these 
cells which could interfere with their normal function or life span once reinfused in the patient 
[180].  The presence of natural TCR in these modified cells could also generate auto-immunity 
by self-reactive T cells as a result from cross-pairing between endogenous and the transgenic 
TCRs [181,182]. 
1.2.2.2. HIV suicide gene therapy 
Besides engineering peripheral T cells to selectively eliminate HIV infected cells, 
gene therapy can also provide tools to cause the infected cell to kill itself, an approach known 
as “suicidal gene therapy”. This approach is frequently used to target cancer cells [183] and 
consists in delivering toxins or suicidal genes that induce cell apoptosis once its expressed. To 
target HIV infected cells and avoid harming heathy uninfected cells, expression of these 
suicides genes is conditioned to elements responsive to virus infection.  
Selective killing of HIV-1 infected cells is generally achieved by delivering lentiviral 
vectors encoding suicidal genes responsive to Tat/Rev proteins. These lentiviral vectors were 
initially developed as sensors for HIV infection by encoding a gene reporter which expression 
was conditioned to the Tat-mediated enhancement of gene expression from the LTR promoter 
[184–187]. However, leaking of expression from Tat-independent basal transcription lead to 
development of new-generation of reporter vectors that also conditioned gene expression to the 
Rev-mediated exportation of unspliced transcripts for translation in the cytoplasm [188] 
(Figure 1.16).  
Chapter I – General Introduction 
 
29 
 
Figure 1.16- Rev-dependent 
lentivirus reporter for HIV-1 
infection. HIV-reporter vector was 
constructed based on HIV-1 
genome elements. Lentiviral 
construct contains both LTRs, 5’ 
end of gag gene, virus splice 
donors (D1, D4) and acceptor (A5, 
A7) sites, and a segment of env 
gene containing the Rev-response 
element (RRE). Green fluorescent 
protein (GFP) is present in this 
vector as gene reporter for HIV 
infection. In the absence of HIV 
infection, transcripts generated by 
Tat-independent basal transcription are immediately spliced, removing the region encoding the GFP open reading 
frame. Once the cell is infected by HIV, Rev expression promotes export of single and non-spliced transcripts 
from the nucleus to the cytosol, thus leading to gene reporter expression. Source: Wu et al. 2007 [188].  
Rev-dependent lentiviral vector appeared to be absent of HIV-independent 
background activity, and consequently strategies for selective killing of HIV infected cells were 
developed by introducing suicidal genes in these HIV-reporter constructs [189,190]. Although 
these reports have proven that it is possible to achieve specific elimination of HIV-infected 
cells using a Rev-dependent lentiviral vector, cell death is completely dependent of the 
presence of an active replicating virus. HIV-1 cellular reservoirs are not targeted, due to lack 
of Tat/Rev expression. Prior reactivation of latent transcription is required to induce viral gene 
expression, activating the Tat/Rev-dependent circuit that leads to elimination of the infected 
cell. 
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1.2.2.3. HIV intracellular immunization 
In general, most gene therapeutic approaches that reached clinical trials aimed to turn 
cells resistant to HIV infection. Development of innovative tools that target key points of HIV 
replication cycle can be genetically transferred into the patient cells and generate intracellular 
immunization (Fig. 1.17).  
Figure 1.17- Gene therapeutic 
strategies to engineered HIV 
resistant cells. Schematic 
representation of relevant antiviral 
gene therapy approaches that target 
viral replication cycle. Source: Rossi 
et al. 2007 [191]. 
 
 
 
 
 
HIV proteins Tat and Rev have a critical role in the transition from early to late stage 
of replication cycle by respectively transactivating viral transcription and mediating 
exportation of single-spliced and unspliced transcripts (see chapter 1.1.2.1. for more details). 
Several gene therapy approaches have focused on these regulatory proteins by targeting both 
protein expression and function. Delivery of syntethic small-interfering RNA (siRNA) 
targeting both Tat and Rev mRNA to degradation were able to block their protein expression 
and inhibit viral replication in human T-cell lines and primary lymphocytes [192]. Similar 
approaches using lentiviral delivery of multiple short-harpin RNA (shRNA) targeting not only 
Tat and Rev transcripts, but also accessory Nef, and major coding regions of Gag, Pol and Env 
observed the same effect [193]. 
Earlier studies using TAR RNA “decoy” sequences as competitive inhibitors for Tat 
recognition could reduce viral replication in vitro [194,195]. A phase I clinical trial in four 
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HIV-1 infected children assessed retrovirus-mediated transduction of a Rev-binding RRE 
decoy in CD34+ cells isolated from the bone marrow but the treatment was unable to establish 
multilineage hematopoiesis of cell expressing the Rev inhibitor [196] . Further phase I clinical 
studies were carried out in HIV-1 infected patients using a Rev-transdominant negative (Rev 
M10) mutant incorporating two point mutations in highly conserved regions shown that would 
interfere with Rev function [197]. Autologous CD4+ T cells from HIV-1 infected patients 
transduced with γ-RVs expressing Rev M10 presented a selective survival advantage, however 
engraftment efficiency was still limited [198,199].  
Besides Tat and Rev, HIV-1 accessory protein Vpr, which also contributes for viral 
gene expression by arresting cell cycle in G2 to enhance HIV transcription and translation, was 
also targeted by gene therapy [160]. Two phase I studies were conducted using CD34+ HSC 
gammaretroviral delivery of an anti-tat/vpr rybozyme (OZ1), a catalytic RNA that specifically 
cleaves its target RNA. Long-term survival of CD4+ T-lymphocytes expressing anti tat/rev 
ribozyme was observed [200], managing to reduce the mean plasma viral load at later time 
points when it advanced to phase II trial involving 74 patients [201]. This study was the first 
randomized, double-blind study placebo controlled phase II trial in autologous CD34+ HSCs 
from HIV patients, proving gene transfer to autologous stem cells is safe and feasible for HIV 
treatment, but once again the life span and engraftment of modified cells was very limited. 
One of the drawbacks of targeting viral pathway is the emergence of resistant strains 
to gene therapy [202,203]. Combinatorial approach of multiple anti-HIV genes that target 
distinct steps in the viral replication cycle increase the broad inhibitory potential of these 
resilient virus [204,205]. An alternative to this approach is targeting endogenous human 
factors. HIV-1 replication is highly dependent of cell machinery and helper factors [206], thus 
gene therapy approaches were also designed to target these host proteins essential to viral 
expression, such as P-TEFb [207] or NF-kB [208,209]. Such approaches demonstrated 
inhibition of HIV-1 infection in vitro but failed to move towards clinical trials. Large-scale 
screening of helper factors through RNA interference knockdown methods identified over 800 
potential host proteins required for viral infection [210–213], still there was very little overlap 
between these studies and lack of validation of identified targets. Nevertheless, a recent 
genome-wide screening using a potent gene knockout tool identified and validated three novel 
targets (TPST2, SLC35B2 and ALCAM) that provided robust resistance to HIV infection 
consistently in cell lines and primary CD4 T cells across different contexts [214]. 
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Interestingly, non-human factors can also interfere with HIV infection in human cells. 
Rhesus macaque TRIM5α and owl monkey TRIMCyp were identified as strong HIV 
xenogeneic restriction factors by targeting and directing viral capsid towards proteasome 
degradation [215]. Lentiviral delivery of humanized engineered TRIMCyp could potently 
inhibit HIV viral loads in vitro and in vivo [216,217], nevertheless potential in treatment of 
HIV patients still remains elusive. Overall, gene-based therapies to suppress HIV-1 gene 
expression are promising but still immature at this point. Strategies attempted so far have failed 
to confer efficient inhibition of HIV-1 replication for a sustained period of time, due to various 
efficacy and safety issues but also to the emergence of resistant mutants [218]. 
Ex vivo modification of CD34+ HSCs to render them resistance against HIV-1 entry 
have been one of the focus of antiviral gene therapy specially since the remarkable case of an 
unprecedented result achieved in the struggle against HIV-1. In 2009 it was announced the first 
cure of HIV-1 from an infected patient, which became known as the “Berlin patient”. Suffering 
from acute myelogenous leukemia derived from the HIV-1 infection, this patient was treated 
with chemotherapy, total body irradiation, and then transplanted with hematopoietic stem cells 
from a donor homozygous for the CCR5Δ32 mutation [219]. This 32-bp deletion in HIV-1 
major cell co-receptor CCR5 gene was found as a natural form of HIV-1 resistance in 
individuals that were homozygous for this mutation, characterized by the absence of this co-
receptor on the cell surface [220,221]. HAART treatment was interrupted one day prior to the 
transplant, and there is still no sign of any residual HIV-1 viremia up to this date [219,222] 
However, besides the high risk associated with this action, there is still no evidence if the 
myeloablative treatment or graft-versus-host effects contributed for the eradication of HIV-1 
in this particularly case [219]. In addition, using allogenic (non-self) cells implies locating a 
bone marrow donor match homozygous to CCR5Δ32 to avoid immune incompatibilities. This 
is not possible for most individuals, especially considering that the homozygous CCR5Δ32 
deletion is only present in 1% of the Caucasian population and even more rare in other ethnic 
populations [223], making this approach impracticable for standard treatment of HIV-1 
infection. In fact, six other patients have received allogenic donor transplant of homozygous 
CCR5Δ32/Δ32 HSC but none survived for longer than one year [224], and in one case it was 
detected a shift in HIV tropism from CCR5 to CXCR4 [225]. Nevertheless, this notable case 
proved that it was possible to eliminate HIV infection by infusing the patient with resistant 
cells that lacked the virus co-receptor.  
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Even prior to this achievement, researchers had already attempted to produce the 
CCR5 deletion on autologous (self) cells before reinfused back into the patient, avoiding issues 
with immunological incompatibility observed with allogenic cell transfer [168]. Developed 
gene therapeutic strategies to delete CCR5 surface expression used lentivirus-delivery of 
shRNA [226–228] or ribozymes [229,230] that targeted CCR5 transcription, or CCR5-specific 
single-chain intrabodies that retained the co-receptor in the endoplasmic reticulum preventing 
the co-receptor emergence to cell surface [231,232]. Overall, CCR5 inhibition generated HIV 
resistant CD4+ T cells protected from CCR5-tropic virus infection in vitro and in vivo. 
Furthermore, human CD34+ HSCs transduced ex vivo with a lentivirus incorporating a CCR5 
ribozyme along with an anti-tat/rev shRNA and a TAR decoy also generated HIV resistant 
monocytes and thymocytes [233,234]. This combinatorial approach led to a phase II clinical 
trial in AIDS lymphoma patients transplanted with autologous transduced HSCs [235]. Follow 
up indicated that less than 0.2% of modified cells were detected in peripheral blood after one 
year and no immediate clinical benefit was observed. 
In consonance with gene therapy targeting HIV replication, these approaches were 
often unable to sustain CCR5 knockdown. Strong expression of the anti-CCR5 genes must be 
maintained for long-term often resulting in cytotoxicity, especially with anti-HIV shRNA that 
can interfere with the endogenous microRNA pathway [204,236,237]. Genome engineering 
through site-directed nucleases have emerged as a prominent alternative to knockout CCR5 in 
an irreversible and more efficient manner. 
1.2.3. Genome engineering 
Traditionally, gene therapy counters genetic-associated diseases by inserting a 
functional copy of the symptom-associated gene. Although promising, this concept is not free 
of challenges towards implementation. In general, long-term stable expression of therapeutic 
genes require genome integration into replicating cells, which can have unpredictable effects 
on gene expression and also cause toxicity derived from random integration [238]. Moreover, 
much of these integrated genes are regulated by constitutive exogenous promoters that do not 
always reflect the normal gene regulation in physiologic context-dependent. In addition, some 
of these therapeutic genes are too large to be packaged into available delivery vectors. Finally, 
addition of exogenous genes is unable to address the presence of toxic or unwanted gene 
products that directly or indirectly promote the pathogenic disease, such as viral genomes or 
receptors [239]. 
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The prospect of directly target and correct the defective or unwanted gene instead of 
just adding an exogenous copy paved the way for the rise of genome engineering. Over the 
quest of correcting defective genes associated with severe pathologies, genome engineering is 
the ultimate revolution in biomedical research and regenerative medicine. Development of 
cutting-edge technologies have enabled the generation of “surgical scalpels” that can target and 
make precise modifications in a small DNA region among billions of base pairs that constitute 
the human genome. These tools are based on DNA-binding domains that naturally exist in life 
forms but were found to be programmable and repurposed to target any DNA sequence in 
human cells through synthetic biology. 
Three major DNA-binding domains (DBD) have been widely adopted for genome 
engineering applications: zinc-fingers (ZF), transcription activator-like effectors (TALEs) and 
CRISPR-Cas9 system (Fig. 1.18). Each of these targeted domains have a particular DNA 
recognition mode that is engineered for targeting the desired sequence and additionally, their 
DNA-binding domain is completely separated from the natural catalytic domain [240]. Their 
versatility allows researchers to assemble a wide panel of genome modification effector 
domains to attain distinct outputs [239–241]. 
Zinc-Finger [242,243] and TALE [244,245] proteins are programmable DNA-binding 
domains derived from the assembly of modules that mediate interaction between amino acid 
side chains of the DBD and the nucleotides of the target sequence. However, the recent 
discovery that the bacterial adaptive immunity CRISPR-Cas9 system [246] could be redirected 
to perform human genome engineering have revolutionized this field. Opposed to zinc-finger 
and TALE proteins, Cas9 protein is directed to the target sequence by a small guide RNA 
(gRNA) that mediates binding to the complementary DNA strand via Watson-Crick base-
pairing.  The small size of the gRNA targeting domain (20 nucleotides) permit the quick 
synthesis of these oligonucleotides to direct the Cas9 to a unique or multiple DNA sites without 
the need of protein engineering [246]. This unique feature has greatly simplified DNA targeting 
[247–250] and led to the general adoption of this system for a wide range of genome 
engineering applications [251]. 
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Figure 1.18- Programmable DNA-binding domains for genome engineering applications. Schematic 
representation of DNA targeted platforms (left) and corresponding crystal structure (right). a) Zinc-finger 
proteins are assembled by modules that each recognize 3-4 nucleotides. b) Transcription activator-like effectors 
(TALEs) DNA-targeting domain is located at the central region with a composition of array of modules, each 
recognizing a single nucleotide. c) CRISPR-Cas9 is directed to the DNA target by a guide RNA (gRNA) consisted 
of a 20-nucleotide sequence (protospacer) complementary to the genomic sequence via Watson-Crick base-paring 
and a constant region that interacts with the Cas9 protein. The DNA-target sequence is located next to a 
protospacer adjacent motif (PAM), required to promote Cas9 binding (5’-NGG-3’ for Cas9 derived from S. 
pyogenes). Source: Thakore et al. 2016 [241]. 
DNA-targeting of Cas9 by the gRNA complimentary sequence (protospacer) is 
restricted however to the presence of a protospacer adjacent motif (PAM) at the 3’ end of the 
target sequence. The PAM motif varies according to the Cas9 strain used (5’-NGG-3’ for the 
most common Cas9 strain derived from S. pyogenes) [252]. The requirement for PAM limits 
the targeting range of Cas9. 
In the next chapter, we will focus on structural and functional aspects of genome 
engineering tools implemented in this dissertation: Zinc-fingers and TALE binding domains. 
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1.2.3.1. Cys2His2 Zinc-finger proteins 
Zinc-finger proteins were the first engineered platforms adopted for gene targeting 
in human cells, due to their modularity and their capability to bind DNA in a specific and 
efficient manner [242]. The Cys2His2 motif is the best characterized zinc-finger domain, 
standing among the most frequent DNA-binding domains in eukaryotic cells. Structural studies 
have demonstrated that an individual zinc-finger domain consists of approximately 30 amino 
acids arranged in a conserved ββα arrange. This conformation is folded by a zinc ion 
coordinated by two cysteine and two histidine residues [253]. The α-helix typically contacts 3 
base-pairs (bp) or triplets with DNA-binding residues located at the position -1, 3 and 6, critical 
to determine specificity towards the major groove of the DNA sequence (Fig. 1.19; Top). 
Nevertheless, residues at positions 2, 4 and 5 are also important to enforce target specificity 
and minimize off-target towards other triplets [243]. The zinc-finger domain is positioned 
backwards relatively to the DNA strand, meaning the N-terminal finger contacts the 3’-terminal 
DNA triplet, and so on. Through phage display technology, Barbas and colleagues screened 
for zinc-finger domains that bound most of the possible 64 triplets through randomization of 
the α-helix residues. In these studies, synthetic zinc-finger domains were identified that bound 
all possible 16 5’-GNN-3’ [254,255], 5’-ANN-3’ [256], and 5’-CNN-3’ triplets as well as some 
5’-TNN-3’ targets [257]. The work established by Carlos Barbas was crucial for the 
understanding of zinc-fingers interaction with target DNA and the establishment of 
predetermined codes between the sequence targeted and the corresponding zinc-finger optimal 
α-helix domain [243] (Fig. 1.19; Bottom). 
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Figure 1.19- Structure of zinc-finger domains. (Top) Representation of the Cys2His2 zinc-finger motif bound 
to target DNA (grey). Each zinc-finger domain consists of approximately 30 amino acids in a ββα arrangement. 
The α-helix and antiparallel β-sheet are folded by a zinc ion (purple) coordinated by two cysteine and two histidine 
residues, depicted as sticks. The α-helix surface residues (-1, 2, 3 and 6) that promote DNA contact are illustrated 
as sticks. Source: Gaj et al. 2013 [240]. (Bottom) Summary of the zinc-finger domains used for each target, 
represented by the α-helical amino acids selected. The α-helix residues (-1, 3 and 6) that contact the major groove 
of the DNA strand are underlined. Source: Gersbach et al. 2014 [243]. 
The modular structure of zinc-fingers have opened many opportunities for drug 
discovery and gene therapy based approaches [258]. Design of zinc-finger proteins binding 18 
bp can confer unique specificity within more than 3 billion bp of the human genome [259], 
allowing for the first time targeting specific sequences for genome engineering applications in 
human cells [254,260].  
Having deciphered the code for zinc-finger domains to target specific DNA sequences 
and the means to assemble them to achieve genome-wide specificity, a vast number of genome 
engineering applications have arisen from zinc-finger technology. Due to their versatility, zinc-
fingers were assembled to effector domains and repurposed for a variety of applications, 
ranging from generation of artificial transcription factors or chromatin modulators to targeted 
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nucleases and recombinases that would target genes associated with human disorders (Fig. 
1.20) [243] or even create zinc-finger libraries to find potential genes that control tumor 
progression [261] or generate drug resistance [262].  
 
Figure 1.20- Modular assembly of DNA-binding zinc-fingers with effector domains for precise 
modifications in the human genome. Source: Gersbach et al. 2014  [243]. 
Standard zinc-finger delivery methods present limitations such as toxicity derived 
from plasmid transfection or electroporation, viral vectors immunogenicity, and potential for 
mutagenic effects derived from vector integration into the genome. Due to the net positive 
charge involving zinc-finger proteins, these were found to possess the innate ability to cross 
the anionic cellular membrane [263]. Purified zinc-finger nuclease (ZFN) proteins are able to 
penetrate a wide variety of mammalian cells, including primary CD4+ T cells or CD34+ HSCs, 
and perform targeted gene editing ex vivo without the need for additional protein engineering 
[263,264]. This remarkable property confers an advantage to ZFN-mediated gene editing since 
delivered protein is shortly degraded resulting in less off-target activity while avoiding DNA 
insertional mutagenesis [263,264].  
Overall, zinc-finger technology has pioneered the application of genome engineering 
for human diseases and the progress obtained with these proteins contributed to thrive 
researchers to pursuit novel DNA-binding and expand the genome engineering toolbox. 
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1.2.3.2. Transcription activator-like effectors 
In 2009, the decipher of DNA targeting mode of transcription activator-like effector 
(TALE) proteins from the plant pathogenic bacteria Xanthomonas sp., has enthused researchers 
about the prospect of a novel genome engineering tool with a more straightforward modular 
recognition of DNA. Opposed to the zinc-finger proteins, transcription activator-like effectors 
(TALE) possess a simpler DNA recognition code [244,245]. TALEs central region is 
composed of an array of DNA recognition domains of ~34 amino acid repeats that each 
recognizes a single DNA bp. The TALE specificity for each bp is mediated by two variable 
residues at position 12 and 13 named repeat-variable diresidues (RVD) (Fig. 1.21). 
Conjugations of several RVD domains targeting single bp generate site-directed TALEs able 
to recognize contiguous DNA sequences of 15-40 bp without the need of linker adjustment 
[265]. The TALE N-terminal domain recognizes the 5’ terminal nucleotide (N0) at the binding 
start site. General guidelines suggest that its activity is optimized when the binding site starts 
with a T base [266,267]. Nevertheless, direct evolution of N-terminal domain generated TALEs 
with optimal recognition of all 5’ base-pairs [267]. 
 
Figure 1.21- Structure of transcription activator-like effectors. Representation of the TALE protein bound to 
target DNA (grey). Individual TALE repeats consist in 33-35 conserved amino acids except at positions 12 and 
13. These two hypervariable residues (shown as sticks) mediate recognition of a single base-pair and are known 
as repeat-variable diresidues (RVD). Sequence of TALE repeat is indicated below its structure with RVD position 
underlined. Specificity towards different base-pairs varies according to the RVD compositions indicated. Adapted 
from Gaj et al. 2013 [240].  
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Based on the RVD-bp one-to-one simplicity of TALE assembly to target any DNA 
sequence in the human genome, numerous TALE effectors have been designed for genome 
engineering applications such as transcription activators [268,269] or repressors [270], site-
directed nucleases [268,271,272], recombinases [273] and epigenetic effectors [274–276]. The 
ease by which TALE arrays can be assembled using the Golden Gate method enabled the 
construction of libraries targeting a large range of human genes [277] that facilitated genome-
wide screening studies for identification of novel targets to counter human disorders. As a 
result, TALEs have achieved widespread use throughout biotechnology, with the potential to 
impact future developments in human gene therapy. 
1.2.3.3. Genome engineering applications for gene therapy 
In general, genome engineering applications focus on gene editing of the human 
genome [239,251]. Gene editing is performed when targeted nucleases based on the DNA-
binding domains promote double-strand breaks (DSB). When repaired, DSB can generate 
random insertions or deletions introduced by the non-homologous end joining (NHEJ) pathway 
that knockout (or eventually restore) target genes by frameshifting, or alternatively cause large 
gene deletions or chromosome translocations after promoting DSB at two distal sites. In the 
presence of a donor template with homologous sequences to the target site, DSB can be 
resolved by homology-directed repair (HDR) that can directly correct the defective gene or 
promote gene integration into a specific locus (Fig. 1.22; Left). Another side of the genome 
engineering is modulation of gene transcription, either through genesis of artificial 
transcription factors that directly activate or repress target genes, or by modulating chromatin 
marks such as histone acetylation or DNA methylation through epigenome editing [241] (Fig. 
1.22; Right). 
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Figure 1.22- Precise modifications in the human genome by genome engineering. (Left) Gene editing of 
genomic sequence. DNA-binding domains when fused to nuclease catalytic domains can promote targeted double-
strand breaks (DSB) in the human genome. DSB can be repaired by non-homologous end joining (NHEJ) through 
random nucleotide insertion or deletion leading to frameshifts that disrupt the gene ORF. In addition, large 
deletions can also be performed and repaired by NHEJ when two targeted nucleases cut at distal sites. 
Alternatively, DSB can be repaired by homology-directed repair (HDR) in the presence of a donor template that 
share homologous sequences with the adjacent regions of the DSB. HDR can be used for site-specific gene 
correction or single base pair repair or alternatively, targeted integration of a full-length therapeutic gene. (Right) 
Epigenome editing and transcriptional regulation. Targeted DNA-binding domains can be fused with effector 
domains that modify and regulate gene expression. These artificial transcription factors can either activate or 
shutdown a gene of interest (GOI) directly by fusing to activators or repressors of gene transcription or by 
modulating chromatin epigenetic marks such as DNA methylation or histone acetylation. Source: Hilton and 
Gersbach 2015 [278]. 
Opposed to traditional gene therapy, genome engineering does not require sustained 
gene expression to achieve clinical benefit. Transient expression of site-directed DBD is 
sufficient to modify the defective genomic trait through “hit and run” strategies that enable 
genome modification but minimizes exposure to DBD off-target activity [239,279]. The most 
used method for delivery of genome engineering proteins is through plasmid DNA 
electroporation, an easy and fast method to promote high levels of gene expression but reveals 
a number of issues such as DNA-related toxicity, low efficiency in primary cells or other types, 
and potential for recombination of plasmid within the cell genome [280,281]. Instead, mRNA 
electroporation overcame some of these advantages while retaining high efficient gene 
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expression, becoming a preferred method for ex vivo gene editing of HSCs [248,282]. Direct 
protein delivery through electroporation [283,284] or engineering of cell-penetrating nucleases 
[263,285–287] have surprisingly achieved high gene editing levels ex vivo with minimal 
toxicity.  
Viral vectors are highly desirable due to efficient and wide range of cell transduction 
and are optimal vehicles to deliver exogenous templates for HDR gene correction or integration 
[139]. Non-integrative lentivirus can efficiently transduce primary T cells and HSCs without 
causing undesired vector integration [138] and therefore have been widely used for transient 
nuclease delivery or as HDR substrates for ex vivo gene editing [156,288]. Adenovirus have 
likewise been successful in providing transient nuclease expression for ex vivo gene editing 
[289], also benefiting from high efficiency transduction in a variety of cell types and large 
packaging capacity to deliver sizable cassettes, being generally preferred over lentiviral 
methods for TALE nuclease editing [290,291]. Recombinant adeno-associated virus or rAAVs 
are highly promising for genome engineering in vivo due to their broad gene delivery potential, 
low immunogenicity and innate ability to promote homologous recombination [109], achieving 
exciting results when targeted to mouse liver [292,293], brain [294–296] or muscle [297–299]. 
Nevertheless, their limited packaging capacity limits their ability to carry large TALE or Cas9 
nucleases or HDR substrates. 
In addition to biomedical application, genome engineering benefits can extend to other 
broad applications from basic research to biotechnology, including but not limited to: facilitate 
the generation of cellular or animal models; provide useful synthetic materials or sustained 
biofuels derived from engineered microorganisms; improve agriculture crops resistance to 
severe environment or pathogenic infection; or enhance bacterial production of therapeutic 
drugs to reduce cost and accessibilty to such pharmaceuticals [300]. 
1.2.3.3.1. Transcriptional modulation and epigenome editing 
In several pathologies, therapeutic benefit can be achieved by silencing or activating 
the target gene rather than modifying its sequence. Transcriptional modulation or epigenome 
editing through artificial transcription factors that targets a gene promoter or regulatory element 
has offered an alternative solution to silence or restore target gene expression without causing 
disruptive breaks in the double-helix DNA strand. Zinc-fingers [301] and TALE [302] modular 
proteins can be assembled to effector domains that regulates gene transcription (Figure 24; 
right). CRISPR-Cas9 is a natural endonuclease, however inactivating mutations in the catalytic 
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domains RuvC and HNH generates a deactivated Cas9 (dCas9) that is unable to cut DNA but 
retains its DNA recognition ability [303], allowing this system to be repurposed for modulation 
of gene transcription in a similar way to ZF and TALEs. 
Earliest reports of programmable transcription activators fused zinc-fingers to VP16, 
a Herpes viral activation domain that recruits PolII transcriptional machinery to induce gene 
activation [259,304]. The generation of VP64 [301], a synthetic tetramer of VP16, substantially 
increased activation potency and has been widely adopted for generation of transcription 
activators [241]. Previous reports demonstrated that recruitment of multiple TALE or dCas9 
activators to a single locus synergistically enhanced gene activation [302,305–310]. In 
addition, natural transcription activation is characterized by multiple recruitment of distinct 
transcription factors and chromatin remodelling complexes [311]. This concept led to the 
exploitation of strategies to provide robust gene expression with a single activator that recruit 
multiple activation domains, ultimately culminating in the development of next-generation 
activators such as VPR (a tripartite fusion of VP64, RTA and p65 activation domains) [312], 
SunTag (antibody-mediated tagging of multiple VP64) [313] or synergistic activaton mediator 
(SAM;  dCas9-VP64 fusion with gRNA-recruitment of p65 and HSF1 co-activators) [314]. 
These methods outperformed by far the standard VP64 activator in multiple context and 
organisms [315], being able to promote sustained gene expression and potentiating genome-
wide gene activation screens [314]. 
Targeted gene reppression through site-directed DBDs emerged as an alternative to 
RNA interference, which presents limitation towards sustained gene silecing, off-target effects 
and toxicity associated with oversaturation of endogenous microRNA pathways [316,317]. 
Furthermore, programmable DBD can target and silence regulatory elements and non-coding 
regions that RNAi cannot. The most common reppressor domain used for site-directed gene 
silencing is Krüppel-associated box (KRAB) which silence transcription by recruiting multiple 
histone methyltransferases and deacetylases [318–321], being able to shut down a wide range 
of target genes when fused to DNA-binding domains [254,270,322]. 
Instead of directly modulating gene expression by recruiting transcription factors, it is 
possible to do so by remodelling the chromatin epigenetic marks sorrounding to the target gene, 
a strategy known as epigenome editing. Epigenome edting is particularly desired due to the 
long-term and inheritable gene modulation which can persist through cell replication [241]. 
Epigenetic effectors located to a specific locus can catalyze modifications to DNA methylation 
or histone acetylation/methylation status to activate or silence a target gene [241,323,324]. TET 
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and TGD epigenetic effectors can promote transcriptional activation through CpGs 
demethylation at endogenous promoters when directed by ZF or TALE proteins [274,325,326]. 
Alternatively, DBDs can be fused to catalytic core of p300 histone acetyltransferase that 
remodel chromatin compactation to activate promoter regions unresponsive to transcription 
factors or even distal enhancers [276]. Reversal of these modifications by targeted reppressive 
DNA methyltransferases (e.g. DNMT3a) or histone deacetylases (e.g. LSD1) have shown to 
reppress transcription from endogenous promoters or active enhancers when tethered by ZF, 
TALE or CRISPR-dCas9 domains [327–330]. Transient expression of targeted DNA 
methyltransferases have shown to permanently induce gene silecing that can only be reversed 
by targeted demethylation effectors [331,332]. 
Methods to treat human disease through transcription regulation or epigenome editing 
are generally applied in cases where abnormal gene regulation is the causative factor of the 
disorder [333]. Site-directed transcription factors or epigenetic modulators provide the 
opportunity to restore normal gene regulation, up-regulate genes that counter the symptomatic 
effect or silence genes/pathways that are reponsible for the disease progression. 
Hematological disorders such as sickle cell anemia or β-thalassemia, caused by 
disruption of β-globin expression can be countered by activation of γ-globin through  ZF or 
dCas9 engineered activators [308,334,335]. TALE-VP64 activators have demonstrated 
potential to treat Friedreich’s ataxia, a neurodegenerative and cardiac disroder caused by loss 
of frataxin gene expression [336,337]. Activation of endogenous vascular endothelial growth 
factor (VEGF) is pursued to enhance wound healing or generate neovasculature in patients with 
diabetic neuropathy and peripheral arterial disease. Engineered ZF activators targeting VEGF 
promoter were able to activate all isoforms of this growth factor and stimulate angiogenesis 
expression and neovascular formation in vivo [338,339]. On the other hand, silencing VEGF 
expression through ZF targeted reppression [340] or methylation [328] is able to reduce tumour 
angiogenesis. Other ZF reppressors were developed to target oncogenes and inhibit cancer 
progression [341,342]. Other disorders targeted by ZF reppressors include neutodegenerative 
Huntington’s disease [296] or HIV infection (detailed in chapter 1.2.2.3) [343–346]. 
In addition to treat human disorders, targeted transcription modification or epigenome 
editing is an important asset to interrogate gene function and correlation with chromatin state 
and cell phenotye for a wide range of applications (Fig. 1.23) [241]. 
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Figure 1.23- Diversity of epigenome editing applications. Source: Thakore et al. 2016 [241]. 
Considering that a vast number of diseases is caused by complex genetic variations, 
knowledge obtained from gene or chromatin interrogation could provide novel approaches to 
treat human disease. Study of gene regulation is challenged by the existence of multiple 
putative elements that often regulate gene expression at a distance. Epigenetic modulators can 
target distal enhancers to reveal their role in the human genome context, enabling modulation 
of multiple genes with a single epigenetic editing protein [276,347]. Design or modulation of 
complex gene networks can elucidate mechanisms controlling cellular programs such as cell 
migration, tissue development or inflammatory response [241].  For this purpose, targeted 
orthogonal systems that can promote different epigenetic outputs at distinct loci have 
tremendous potential. The CRISPR-Cas9 system versatility enables simultaneous gene 
activation and reppression [348] or even knockout [349,350] at different target genes using the 
same Cas9 protein in a programmable manner by engineering the gRNA to recruit different 
effector domains according to the target site. 
Development of site-directed transcription factors [314,351–353] libraries that target 
and control expression of all potential human genes brought great impact for screening and 
identification of genes responsible for induction of signaling pathways, disease progression or 
resistance and cell programming. Finally, targeted epigenetic modulators could represent an 
effective tool to guide cell differentiation or reprogramming back to pluripotency, a proeminent 
method of cell-based therapy for regenerative medicine. Site-directed TALE or dCas9 gene 
modulators that control expression of key transcription factors critical to determine cell fate 
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were able to reprogram and generate relevant cell types from induced pluripotent stem cells to 
neurons or skeletal myocites [312,354,355]. In conclusion, modulation of transcripional or 
epigenome marks in a tunable and reversible manner by these evolved programmable enzymes 
promises to bring new insights on the complex mechanisms involving gene regulation and cell 
programming for the development of improved gene and cell-based therapies. 
1.2.3.3.2. Targeting HIV-1 infection through genome engineering 
Genome engineering applications were specially focused at correcting hereditary gene 
defective pathologies. Nevertheless, it didn’t take long before researchers expanded their 
attention to develop strategies to counter acquired diseases such as antiviral, with HIV naturally 
being at the center of these approaches. The reported case of the “Berlin patient”, cleared of 
HIV for almost 10 years after transplantation with HIV-resistant HSC homozygous for 
CCR5Δ32 mutation (see chapter 1.2.1.3) [219], had motivated researchers to keep pursuing 
therapeutic approaches that replicate this effect. Efforts to reproduce the CCR5 deletion were 
mostly based on gene therapy that either shut down CCR5 transcription using RNA interference 
methods [226–230] or prevent CCR5 emergence to the cell surface [231,232]. However, none 
of these reports have shown reduction in patient viremia, being associated with ineffective 
long-term CCR5 inhibition and toxicity derived from requirement of sustained high levels of 
transgene expression [192]. These limitations showed that these methods were still far from 
being evolved to the point of providing clinical benefit.   
The development of targeted nucleases for gene editing may have provided the solution 
to efficiently eliminate CCR5 co-receptor permanently and turn cells resistant to HIV-1 entry 
with a single treatment [356] (Fig. 1.24). Disruption of CCR5 gene through zinc-finger 
nucleases has proven to reduce HIV-1 viremia in CD4+ T cells [289] and HSCs [357] in vitro 
and in vivo in mouse models of HIV-1 infection engrafted with modified resistant cells. 
Promising results led to the first clinical trial of ZFN-mediated gene editing in a phase I study 
involving 12 patients from which autologous CD4+ T cells were transduced ex vivo with an 
adenoviral vector expressing a CCR5-ZFN and re-infused in the patient [358]. Preliminary 
results demonstrated that CCR5-modified autologous CD4+ T cells were safe within this study. 
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Figure 1.24- Targeted nucleases designed to disrupt CCR5. a) Schematic representation of the CCR5 co-
receptor located at the cellular membrane. Dotted boxes indicate the region targeted by engineered nucleases and 
the Δ32 deletion. Three targeted nucleases were design to efficiently knock out CCR5. Corresponding DNA target 
sites are highlighted in green for Cas9 RNA-guide nuclease (RGN), blue for TALEN and orange for ZFN. 
Cleavage sites are pointed out by black triangles. b) Schematic representation of the designed nucleases targeting 
CCR5. RGN cut the CCR5 gene through their nuclease domains within Cas9 protein (RuvC and HNH). TALEN 
and ZFN promote DSB at CCR5 by assembling the modular DNA-binding domain with the FokI nuclease domain 
(light red), which cuts the DNA upon dimerization of the two monomers at the target site. Source: Cornu et al. 
2015 [356]. 
The advancements made with this approach had such potential that completed and 
ongoing gene editing clinical trials are dominated by ZFN-mediated deletion of CCR5 [239] 
(Table 1.1). Two studies however revealed a significant level of genome wide off-target by 
CCR5-ZFN [359,360], raising concerns about the use of this platform for HIV treatment. 
Considering their straightforward modular DNA recognition, TALENs were able to knock out 
CCR5 with similar activity and lower toxicity [272,361], being a valid alternative to generate 
HIV resistant cells. Naturally, further studies to disrupt CCR5 were pursued using RNA-guided 
CRISPR-Cas9, a suitable platform for multiplex targeting [250], also achieving promising 
results [248]. 
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Table 1.1- Representative completed and ongoing gene editing clinical trials.  
Source: Maeder and Gersbach et al. 2016 [239]. 
 
While gene editing of CCR5 enables modified cells to survive and expand in the 
presence of R5-tropic strains, these cells could still be susceptible to CXCR4-strains. Once 
HAART is discontinued, X4-tropic strains could emerge and lead to viral rebound. In order to 
avoid this potential hazard, simultaneous disruption of CCR5 and CXCR4 by ZFN were 
reported to protect CD4+ T cells from both R5 and X4-tropic strains in a mouse model [362]. 
However, opposed to CCR5, CXCR4 seems to have a critical role in immune regulation, 
particularly in B cell development [363]. This limitation narrows the possibilities of CXCR4 
gene editing in HSCs, restricting this application to CD4+T cells only [362,364], that in 
comparison has far less long-term clinical benefit [365].  
Genome engineering to turn cells resistant to HIV also extended to host restriction 
factors by targeting Lens epithelium-derived growth factor (LEGDF/p75) encoded by the 
PSIP1 gene. LEDGF/p75 binds HIV integrase, acting as a tether domain to facilitate integration 
of provirus cDNA into host genome [366,367]. Disruption of PSIP1 by ZFN [368] or TALEN 
[369] reduced HIV inhibited in cell lines. Nevertheless, LEDGF/p75 knockout in mice caused 
prenatal death or development of abnormalities, questioning the viability of LEDGF as a 
potential target for HIV treatment [370]. 
Besides engineering HIV resistant cells, targeted nucleases have also been developed 
to directly target and disrupt the HIV provirus. This strategy implies the direct delivery in vivo 
of designed nucleases to the infected cells, without the need for autologous cell manipulation 
and transplant. Another advantage of this approach is that in most cases only one copy of 
integrated provirus needs to be inactivated, as opposed to the two copies of host genes of the 
diploid genome [371]. ZFN [372], TALEN [373] and CRISPR/Cas9 [374,375] nucleases, most 
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targeting the LTR regions flanking the provirus, have demonstrated to efficiently excise HIV 
genome and reduce viral loads in vitro, both on active and latent infected cells. Similar to its 
natural adaptive immune role in bacteria, CRISPR-Cas9 nucleases can also be harnessed for 
antiviral response in human cells. In addition to target and excise HIV provirus from already 
infected cells, stably expressing CRIPR/Cas9 can also be used as an intracellular defense 
system against HIV-1 by targeting and inactivating pre-intregrated dsDNA, protecting the cells 
from novel infections [376]. Surgical removal of HIV from infected cells using engineered 
nucleases might raise some concerns about the variability introduced into the viral genome by 
NHEJ repair. Recent reports have demonstrated the emergence of treatment resistant HIV 
strains presenting random insertions or deletions [377–381], pointing out that extreme caution 
should be taken when targeting nucleases to disrupt HIV genes.  
Prior to the development of targeted nucleases against HIV, application of evolved 
recombinases also demonstrated exciting results in the excision of HIV genome. In 2007, 
Hauber and colleagues developed a Tre recombinase (HIV LTR-recombinase) by direct 
evolution of wild type Cre recombinase [382] that shifted the natural recognition of loxP site 
to an assymetric sequence within the HIV LTR region [383]. Site-specific recombinases 
catalyze DNA rearrangements, removing genomic sequences while avoiding the NHEJ-
mediated random variability [382]. Tre recombinase efficiently excised the HIV-1 proviral 
genome from infected cells [383]. More recently, these authors further evolved Cre to a broad 
HIV-recombinase (Brec1) that recognizes more conserved regions in the LTR. Brec1 precisely 
and safely removed integrated HIV from various clinical isolates in vitro and in vivo, including 
mice humanized with patient-derived cells [384]. 
Alternatively to gene editing, programmable DNA-binding platforms have been 
associated with effector domains that regulate gene transcription or modulate chromatin 
epigenetic marks [241] (for more details see chapter 1.2.3.3.2.). Instead of using RNA 
interference methods [192], researchers have successfully developed zinc-finger transcription 
repressors KRAB-ZF that directly target LTR promoter and shutdown HIV transcription while 
reducing viral loads [343–346]. While RNAi must inactivate several mRNA copies which may 
difficult complete and sustained repression, this strategy has the advantage to target only one 
copy of the HIV provirus. 
Even in the absence of effector domains, DNA-binding proteins can still inhibit HIV 
replication. One example of this is the development of zinc-fingers that target the formation of 
2-LTR conformation of the pre-integration complex, formed prior to genome integration. The 
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design of 2LTR-zinc-fingers fused to a GFP moiety (2LTRZFP-GFP) could reduce lentiviral 
integration by approximately 50% while causing a 100-fold reduction of HIV replication in 
vitro [385], suggesting that simple binding of 2LTRZFP-GFP to pre-integration complex could 
interfere with HIV integration. 
Overall, genome engineering has led to the development of a wide range of promising 
cutting-edge tools to target HIV-1 infection, and therefore should be considered a valid 
alternative for patient treatment. The continuous development of these technologies targeted to 
critical points of HIV infection will lead to design of more improved and safe therapeutic 
approaches against HIV. 
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2.1. ABSTRACT 
The presence of replication-competent HIV-1 – which resides mainly in resting CD4+ 
T cells – is a major hurdle to its eradication. While pharmacological approaches have been 
useful for inducing the expression of this latent population of virus, they have been unable to 
purge HIV-1 from all its reservoirs. Additionally, many of these strategies have been associated 
with adverse effects, underscoring the need for alternative approaches capable of reactivating 
viral expression. Here we show that engineered transcriptional activators based on customizable 
transcription activator-like effector (TALE) proteins can induce gene expression from the HIV-
1 long terminal repeat promoter, and that combinations of TALE activators can synergistically 
reactivate latent viral expression in cell line models of HIV-1 latency. We further show that 
complementing TALE activators with class-selective histone deacetylase inhibitors enhances 
HIV-1 expression in latency models. In addition, we engineered an HIV-responsive suicide 
lentivector that selectively eliminates HIV latent cells when conjugated with TALE activators. 
Stimulation of HIV latent cells through TALE activators was required to induce gene 
expression from suicidal lentivector, leading to cell death of HIV latent cells with minimal 
hazard to non-infected cells. Collectively, these findings demonstrate that TALE activators are 
a potentially effective alternative to current pharmacological routes for reactivating latent virus 
and that combining synthetic transcriptional activators with histone deacetylase inhibitors or 
suicide lentivectors could lead to the development of improved therapies for latent HIV-1 
infection. 
 
Keywords: HIV latency / TALE / synthetic transcription activators / histone deacetylase 
inhibitors / suicide lentivectors 
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2.2. INTRODUCTION 
Over the past two decades, numerous advances in the treatment of HIV/AIDS have 
significantly increased the lifespan – and quality of life – of individuals infected with HIV type 
1 (HIV-1). Highly active antiretroviral therapy (HAART), in particular, has emerged as a 
powerful treatment option, capable of decreasing plasma viral loads to below the limit of 
detection of many clinical assays [30–32]. Yet despite its effectiveness, HAART does not cure 
patients of HIV-1 infection, due to the existence of residual latent and replication-competent 
virus hidden in cellular reservoirs [37,49,386–388]. This population of cells, which consists 
mainly in resting memory CD4+ T cells, harbors integrated proviral DNA that re-emerges 
shortly after discontinuation of HAART. HIV-1 latency is typically established when activated 
CD4+ T cells become infected with the virus and revert back to a resting memory state [37]. 
These cells are thus non-permissive for viral gene expression and refractory to many treatments, 
including HAART. Although the mechanisms behind latency are complex [37,41], they likely 
involve: (i) the absence of key host transcription factors that drive transcriptional initiation 
[65,66] or elongation [67,68] in resting CD4+ T cells; (ii) low levels of the trans-activator of 
transcription (Tat) regulatory protein [389]; (iii) proviral integration into condensed chromatin 
regions [54,55] or expressed regions that become silenced by promoter occlusion or collision 
[57–60]; and (iv) the induction of epigenetic modifications that can inhibit viral gene 
expression, including DNA methylation [62,63] and histone deacetylation [64]. 
Because the presence of latent HIV-1 represents an enormous barrier toward its 
eradication, numerous strategies have been developed to purge it from its cellular reservoirs. 
Chief among these has been activation of latently infected T cells via treatment with cytokines 
[77] or monoclonal antibodies [74], as well as NF-B stimulation via protein kinase C agonists 
[79,80]. Histone deacetylase (HDAC) inhibitors, such as valproic acid [82] and Vorinostat [83], 
have also proven capable of inducing viral gene expression by disrupting recruitment of HDAC 
proteins to the HIV long terminal repeat (LTR) promoter [87,88]. These approaches, however, 
have been unable to eradicate virus from all latent pools and have even been associated with 
adverse effects, including severe immune reactions [29,52,78,390]. Additionally, the host 
immune response mediated by CD8+ cytotoxic T lymphocytes (CTL) lacks robustness to clear 
the HIV infected cells, requiring supplementary stimulation of anti-HIV immune response [91]. 
As a result, new strategies capable of inducing viral gene expression and enforce infected cell 
elimination are needed to enable the development of next-generation HIV-1 therapeutics. 
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The emergence of customizable DNA-binding platforms, including engineered zinc-
finger [243] and transcription activator-like effector (TALE) [391] proteins, as well as CRISPR-
Cas9 [251], has provided investigators with a set of tools capable of sequence-specific DNA 
recognition [240]. TALE proteins, in particular, have now been utilized to create a broad range 
of tools capable of gene modification and regulation, including transcriptional activators 
[268,269] and repressors [270], nucleases [268,271,272], site-specific recombinases [273] and 
epigenetic effectors [274–276]. The DNA binding domain of a TALE protein consists of a 
series of repeat domains, each ~34 amino acid residues in length, that coordinate to recognize 
a single base pair (bp) via two adjacent amino acid residues, termed repeat variable diresidues 
(RVDs) [244,245]. A variety of approaches have now been developed that enable rapid 
construction of custom TALE arrays capable of recognizing nearly any contiguous sequence 
[265,392]. As a result, TALEs have achieved widespread use throughout biotechnology, with 
the potential to impact future developments in human gene therapy. 
Numerous studies have also demonstrated the utility of genome engineering for 
combating HIV/AIDs. Specifically, zinc-finger based transcriptional repressors [343–346], in 
addition to RNA interference [192,393,394], have proven effective at inhibiting HIV 
replication. Targeted nucleases have also demonstrated the capacity to excise integrated 
proviral DNA from infected cells [372–374] and confer HIV resistance to cells by inducing 
knockout of the primary co-receptors for HIV infection [272,289,358,395]. Targeted gene 
regulation technologies may also prove effective at reversing HIV-1 latency. Specifically, due 
to their versatility and ability to stimulate robust levels of gene expression in a highly specific 
manner [396], TALE activators [268] could be used to stimulate viral gene expression within 
latent HIV-1 reservoirs, providing new means for enabling “shock and kill” therapy. Here we 
demonstrate that TALE activators can be engineered to recognize the HIV-1 LTR promoter and 
induce viral gene expression in cell line models of HIV-1 latency. We show that complementing 
TALE activators with HDAC inhibitors can further enhance TALE-induced activation of latent 
HIV-1 expression. We also provide evidence that engineered suicide lentivectors can be 
associated with TALE activators to enforce clearance of stimulated HIV latent cells. These 
findings indicate that TALE activators and suicide lentivectors are potentially effective tools 
for reactivating and eliminating latent virus and could contribute to the development of next-
generation HIV-1 therapies.
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2.3. MATERIALS AND METHODS  
2.3.1. TALE activator constructs  
Design of HIV-targeted TALEs was performed at TAL Effector-Nucleotide Targeter 
(TALE-NT) 2.0 web server (https://boglab.plp.iastate.edu/) [397]. TALEs were generated as 
previously described [392,398] using the Golden Gate TALEN and TAL Effector Kit 2.0 
(Addgene ID: 1000000024) [265]. Briefly, single RVDs modules were digested with BsaI and 
ligated in predetermined arrays into pFUS-A and pFUS-B to respectively generate pTLT-A 
(containing RVD positions 1-10) and pTLT-B (containing RVD positions 11-14). Next, array 
plasmids pTLT-A and pTLT-B and pLR (last repeat RVD) modules were assembled through 
digestion with BsmBI and ligation into pcDNANT-T-VP64 [267] to generate pTLT-1 through 
10. Correct construction of each plasmid was verified by sequence analysis (Table S2.1).  
2.3.2. Luciferase reporter constructs  
The pTALE activator reporter vectors were constructed through PCR by amplifying the 
luciferase gene from pGL3-Basic (Promega, Madison, WI, USA) using the primers 5’ TALE-
Luc-TLT1 through 10, which contained four direct repeats of each TALE binding site and 3’ 
Luc-Rev. PCR products were digested and cloned into the XhoI and SphI restriction sites of 
pGL3-Basic to generate pGL3-TLT-1 through 10. The HIV-1 LTR reporter plasmid was 
constructed by PCR amplifying the U3-R region of the 5’LTR promoter from pNL4-3 (NIH 
AIDS Reagents) [399] using the primers 5’ LTR-Fwd and 3’ LTR-Rev. PCR product was 
digested and cloned into the MluI and NheI restriction sites of pGL3-Basic to generate pGL3-
LTR. Primer sequences are provided in Table S2.2. 
The mLTR reporter constructs were generated through PCR mutagenesis of U3 region 
of the 5’LTR promoter from pNL-GFP-RRE(SA) [188]: wtLTR was generated by PCR using 
the primers 5’ U3-Fwd and 3’ R-Rev; mLTR1 was generated by PCR using primers 5’ U3-Fwd 
and 3’ -455 U3-Rev; mLTR2 was generated by PCR using primers 5’ U3-Fwd and 3’ -147/-
115 U3-Rev; mLTR3 was generated by PCR using primers 5’ U3-Fwd and 3’ -183/-115 U3-
Rev; mLTR4 was generated by PCR using primers 5’ U3-Fwd and 3’ -183 U3-Rev; mLTR5 
was generated by PCR using primers 5’ U3-Fwd and 3’ -183/-115 TAR U3-Rev. mLTR1-
mLTR5 fragments were assembled by overlap PCR with -115 U3-R region amplified by PCR 
using primers 5’ -115 U3-Fwd and 3’ R-Rev. PCR products were digested and cloned into the 
MluI and NheI restriction sites of pGL3-Basic to generate pGL3-wtLTR through mLTR5. 
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Correct construction of each plasmid was verified by sequence analysis (Table S2.3). Primer 
sequences are provided in Table S2.4. 
2.3.3. Suicidal lentivector constructs 
HIV suicidal lentivector constructs were generated from the Rev-dependent pNL-GFP-
RRE(SA) vector [188] (kindly provided by Dr. Jon W. Marsh, NIMH). pNLR-Fluc was 
generated by PCR amplifying the firefly luciferase gene from pGL3-Basic using the primers 5’ 
Fluc-Fwd and 3’ Fluc-Rev. PCR fragment was digested and cloned into SalI and XbaI 
restriction sites of pNL-GFP-RRE(SA) (GenBank accession no. EF408805.1). pmNLR-Fluc 
was generated by amplifying the U3-R regions of mLTR3 promoter from pGL3-mLTR3 
through PCR using the primers 5’ U3-Fwd and 3’ R-Rev. U3-R region was assembled by 
overlap PCR with U5 region amplified from pNL-GFP-RRE using primers 5’ U5-Fwd and 3’ 
U5-Rev. PCR product was digested and cloned into StuI and SalI restriction sites of pNLR-
Fluc. pNLR-E2C and pmNLR-E2C were generated by PCR amplifying the E2Crimson [400] 
gene from pCMV-E2Crimson (Clontech, Mountain View, CA, USA) using primers 5’ E2C-
Fwd and 3’ E2C-Rev, and cloning into SalI and XbaI restriction sites of pNLR-Fluc and 
pmNLR-Fluc, respectively. pmNLRW-E2C was generated by isolating the WPRE region from 
FugW (Addgene plasmid #14883) through PCR using the primers 5’ WPRE-Fwd and 3’ 
WPRE-Rev and cloning into XbaI restriction site of pmNLR-E2C using the In-Fusion cloning 
kit (Clontech, Mountain View, CA, USA). pmNLRW-DTA (Diptheria toxin A chain), 
pmNLRW-LFN (Anthrax Lethal Factor N-terminal), pmNLRW-RTA (Ricin toxin A chain) 
and pmNLRW-SLO (Streptolysin O) were constructed by cloning the PCR-amplified toxins 
into SalI and XbaI restriction sites of pmNLRW-E2C. Diptheria toxin A chain (GenBank 
accession no. AB602359.1) was amplified from FUW-DTA [401] using primers 5’ DTA-Fwd 
and 3’ DTA-Rev. Anthrax Lethal Factor N-terminal (GenBank accession no.M29081.1) was 
amplified from pet-15b LFN-DTA (Addgene plasmid #11075) using primers 5’ LFN-Fwd and 
3’ LFN-Rev. Ricin toxin A chain (GenBank accession no. AASG02053821.1) was amplified 
from pCAGGS-RTA (kindly provided by Dr. Wendie Cohick, The State University of New 
Jersey), using primers 5’ RTA-Fwd and 3’ RTA-Rev. Streptolysin O (GenBank accession no. 
AB050250.1) was amplified from pBAD-SLO (kindly provided by Dr. Michael Caparon, 
Washington University) using primers 5’ SLO-Fwd and 3’ SLO-Rev. Primer sequences are 
provided in Table S2.5. 
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2.3.4. Cell culture 
Human embryonic kidney 293T (HEK293T) (American Type Culture Collection; 
ATCC) cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Life 
Technologies, Carlsbad, CA, USA) supplemented with 10% (v/v) fetal bovine serum (FBS; 
Gibco, Carlsbad, CA, USA), 2 mM L-glutamine and 1% (v/v) antibiotic-antimycotic (Anti-
Anti; Gibco, Carlsbad, CA, USA). Jurkat E6-1 and J-Lat clones (NIH AIDS Reagents) were 
cultured in RPMI-1640 medium (Life Technologies, Carlsbad, CA) supplemented with 10% 
(v/v) FBS, 2 mM L-glutamine and 1% (v/v) Anti-Anti. Cells were maintained at 37°C in a 
humidified atmosphere of 5% CO2. 
Peripheral blood mononuclear cells (PBMCs) were obtained from healthy anonymous 
donors through the Scripps Research Institute Normal Blood Donor Program as described 
[263]. Briefly, PBMCs were isolated using density gradient centrifugation and Ficoll-Paque 
PLUS (GE Healthcare) according to the manufacturer instructions. Resting CD4+ T cells were 
purified from PBMCs by negative selection using EasySep custom kit for Human Resting CD4+ 
T Cell Enrichment Cocktail (Stem Cell Technologies). Unwanted cells were removed using 
anti-CD8, CD14, CD16, CD19, CD20, CD36, CD123, TCT /, GlyA, CD66b, CD25, HLA-
DR and CD69 magnetic-coated beads. Resting CD4+ T cells were cultured in RPMI-1640 
medium supplemented with 10 % (v/v) FBS, 2 mM L-Glutamine and 1% (v/v) Anti-Anti and 
maintained at 37°C in a humidified atmosphere of 5% CO2. 
2.3.5. Luciferase assays 
Luciferase assays were performed as previously described [398]. Briefly, HEK293T 
cells were seeded onto 96-well plates at a density of 4 x 104 cells per well. At 16-24 h after 
seeding, cells were transfected with 200 ng of plasmid expression construct, 5 ng of pGL3-
luciferase reporter construct and 1 ng of pRL-CMV (Promega, Madison, WI, USA) using 
Lipofectamine 2000 (Life Technologies, Carlsbad, CA, USA) according to the manufacturer’s 
instructions. At 48 h after transfection, cells were washed once with Dulbecco’s PBS (DPBS; 
Life Technologies, Carlsbad, CA, USA) and lysed with Passive Lysis Buffer (Promega, 
Madison, WI, USA). Luciferase expression was measured with the Dual-Luciferase Reporter 
Assay System (Promega, Madison, WI, USA) using a Veritas Microplate Luminometer (Turner 
Biosystems, Sunnyvale, CA, USA) according to the manufacturer’s instructions. Normalized 
luciferase activity was determined by dividing firefly luciferase activity by Renilla luciferase 
activity.  
Chapter II – Construction of TALE activators and suicide lentivectors for targeted elimination 
of latent HIV cells 
60 
 
2.3.6. TALE activator expression 
HEK293T cells were seeded onto a 6-well plate at a density of 5 x 104 cells per well. At 
16-24 h after seeding, cells were transfected with 5 µg of pTLT-1 through pTLT-10 or pcDNA 
backbone vector by the calcium phosphate method [402]. At 48 h after transfection, cells were 
harvested and lysed with RIPA buffer (25 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 1% sodium 
deoxycholate and 0.1 % SDS, pH 7.6) supplemented with EDTA-free Protease Inhibitor 
Cocktail Tablets (Roche, Basel, Switzerland). The Bio-Rad Protein Assay Kit (Bio-Rad, 
Hercules, CA, USA) was used to determine protein concentration according to the 
manufacturer’s instructions. TALE transcription factor expression was analyzed by 4-12% 
SDS-PAGE (National Diagnostics, Atlanta, GA, USA). Samples were transferred onto a 0.2 
m nitrocellulose membrane as described [403] and detected with Immobilon Western 
Chemiluminescent HRP substrate (Millipore, Billerica, MA, USA) and Amersham Hyperfilm 
ECL (GE Healthcare, Little Chalfont, UK) chemiluminescence film. TALE activators were 
detected by horseradish peroxidase-conjugated anti-HA monoclonal antibody (Clone 3F10; 
Roche, Basel, Switzerland). -actin was used as an internal control and detected using a mouse 
anti-β-actin monoclonal antibody (Clone AC-74; Sigma, St. Louis, MO, USA) and horseradish 
peroxidase-conjugated goat anti-mouse IgG antibody (Bio-Rad, Hercules, CA, USA) (kindly 
provided by Dr. Cecília Rodrigues, Universidade de Lisboa).  
2.3.7. HIV-1 reactivation 
J -Lat cells were seeded onto a 10-cm dish at a density of 1 x 105 cells per mL. At 48 h 
after seeding, 2 x 105 cells per transfection were centrifuged at 100 g for 10 min at room 
temperature and resuspended in Nucleofector Solution SE (Lonza, Basel, Switzerland) with 2 
µg of pTLT-1 through pTLT-10 or pTat. Cells were transferred to 16-well Nucleocuvette Strips 
(Lonza, Basel, Switzerland) and electroporated by a 4D-Nucleofector System (Lonza, Basel, 
Switzerland) using the program CL-120, according to the manufacturer’s instructions. J-Lat 
cells were either left untreated or incubated with 10 ng/µL of TNF-α (R&D Systems, 
Minneapolis, MN, Canada). At 48 h after transfection, cells were washed twice with DPBS 
(Life Technologies, Carlsbad, CA, USA) and GFP expression was evaluated by flow cytometry 
(BD LSR II Flow Cytometer System; BD Biosciences, Franklin Lakes, NJ, USA). For each 
sample, 10,000 live events were collected, and data was analyzed using FlowJo (Tree Star, Inc., 
San Carlos, CA, USA). 
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2.3.8. HDAC inhibitor treatments 
HDAC inhibitors were kindly provided by Dr. Richard Barnard and Dr. Daria Hazuda 
(Merck Research Laboratories, Pennsylvania, USA) J-Lat cells were seeded onto a 10-cm dish 
at a density of 2 x 105 cells per mL. At 48 h after seeding, 1 x 106 cells per transfection were 
centrifuged at 100 x g for 10 min at room temperature and resuspended in Nucleofector Solution 
V (Lonza, Basel, Switzerland) with 4 µg of pTLT-5 through pTLT-8. Cells were transferred to 
a Nucleocuvette (Lonza, Basel, Switzerland) and electroporated with an Amaxa Nucleofector 
II Device (Lonza, Basel, Switzerland) using the program X-001 according to the manufacturer’s 
instructions. At 24 h after transfection, J-Lat cells were treated with DMSO 0.1%, SAHA (330 
nM, 660 nM or 1 µM), MRK-1 (660 nM, 1 µM or 2 µM), MRK-11 (3 µM, 5 µM, 20 µM) [84] 
or H-12 (1 µM, 3 µM or 5 µM) for 24 h. After treatment, cells were washed twice with DPBS 
and GFP expression was evaluated by flow cytometry analysis (BD LSR II Flow Cytometer 
System; BD Biosciences, Franklin Lakes, NJ, USA). For each sample, 10,000 live events were 
collected, and data was analyzed using FlowJo (Tree Star, Inc., San Carlos, CA, USA). The 
selective IC50 activity for each HDAC inhibitor is presented in Table S2.5. 
2.3.9. Lentivirus production 
Pseudo-typed HIV NL4-3Δenv-EGFP and second-generation NLR-E2C reporter 
lentivectors were generated HEK293T cells using the Lipofectamine 3000 optimized protocol 
for lentiviral production (Life Technologies, Carlsbad, CA, USA). HEK293T cells were seeded 
in 6-well plates at a density of 1.2 x 106 cells per well for 24 hours. VSVg-pseudotyped NL4-
3ΔenvEGFP was produced by transfection with 3.3 μg of pNL4-3ΔenvEGFP (NIH AIDS 
Reagents) [404] and 0.3 μg of VSVg envelope pMD2.G. VSVg-pseudotyped mNLR-E2C and 
mNLRW-E2C lentivirus were produced by transfection with 1.8 μg of pmNLR-E2C or 
pmNLRW-E2C constructs respectively, 1.5 μg of packaging plasmid psPAX2 (Addgene 
plasmid # 12260; Funcional lentivirus - LV) or psPAX2-D64V (Addgene plasmid # 63586; 
Integrase-deficient lentivirus - IDLV) and 0.3 μg of VSVg envelope pMD2.G (Addgene 
plasmid # 12259). Cell medium was replaced 6 hours after transfection. Lentivirus present in 
the cell supernatant were collected after 24 hours and cleared form cell debris by centrifugation 
at 500 g for 10 min at room temperature and stored at -80 ºC. Viral production was quantified 
by a p24 capture ELISA assay (NCI-Frederick Cancer Research and Development Center – 
AIDS Vaccine Program kit, NIH, USA), according to manufacturer’s instructions. 
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2.3.10. HIV/Suicide lentivector co-transduction 
Jurkat cells were seeded onto 24-well plates with 5 x 105 cells per well. Cells were 
transduced with VSVg-pseudotyped NL4-3Δenv-EGFP at an MOI of 2 (20 ng p24) through 
spinoculation by centrifugation (800 g, 60 min, 32 ºC) in the presence of polybrene (8 µg/mL). 
Plates were incubated at 37 ºC for 4 hours and cell medium was replaced. Twenty-four hours 
after infection, 1 x 105 of non-infected or infected cells were transduced with VSVg-
pseudotyped mNLR-E2C lentivirus (20 ng p24), mNLRW-E2C lentivirus (20 ng p24) or 
integration-deficient lentivirus (50 ng p24) through spinoculation (800 g, 60 min, 32 ºC) in the 
presence of polybrene (8 µg/mL). Plates were incubated at 37 ºC for 4 hours and cell medium 
was replaced. At 48 hours after transduction, cells were washed twice with DPBS (Life 
Technologies, Carlsbad, CA, USA). E2-Crimson and GFP expression was evaluated by flow 
cytometry (BD Accuri C6 Flow Cytometer System; BD Biosciences, Franklin Lakes, NJ, 
USA). For each sample, 10,000 live events were collected, and data was analyzed using FlowJo 
(Tree Star, Inc., San Carlos, CA, USA). 
2.3.11. TALE/Suicide lentivector-mediated cell death analysis 
Jurkat or J-Lat 10.6 cells were seeded onto a 10-cm dish at a density of 1 x 105 cells per 
mL. At 48 h after seeding, 2 x 105 cells per transfection were centrifuged at 100 g for 10 min at 
room temperature and resuspended in Nucleofector Solution SE (Lonza, Basel, Switzerland) 
with 1 µg of pTLT5-7 and 1 µg of suicide lentivector. Cells were transferred to 16-well 
Nucleocuvette Strips (Lonza, Basel, Switzerland) and electroporated by a 4D-Nucleofector 
System (Lonza, Basel, Switzerland) using the program CL-120, according to the 
manufacturer’s instructions. At 48 h after transfection, cells were washed twice with DPBS 
(Life Technologies, Carlsbad, CA, USA) and apoptotic cells were stained with Annexin V (Life 
Technologies, Carlsbad, CA, USA), according to manufacturer instructions. Annexin V 
staining was evaluated by flow cytometry (BD LSR II Flow Cytometer System; BD 
Biosciences, Franklin Lakes, NJ, USA). For each sample, 10,000 events were collected, and 
data was analyzed using FlowJo (Tree Star, Inc., San Carlos, CA, USA). 
2.3.12. Statistical analysis 
Statistical analyses for all experiments were performed from three independent 
experimental replicates (n = 3) unless otherwise indicated. Two-tailed Student’s t-test was used 
for paired and unpaired samples (Prism Software 5.0, GraphPad Software).
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2.4. RESULTS 
2.4.1. Designing TALE activators to target the HIV-1 promoter 
We sought to reverse HIV-1 latency by inducing viral gene expression using engineered 
TALE activators. We constructed ten TALE proteins designed to recognize distinct 16-bp sites 
within the HIV-1 LTR, the region of the virus that serves as its promoter (Fig. 2.1A). TALE 
binding sites were constrained only by the presence of a 5’ thymidine (T0) nucleotide [267]. 
We fused each synthetic TALE array to VP64 [254], a tetrameric repeat of the herpes simplex 
virus VP16 transactivation domain, to generate synthetic transcriptional activators. VP64 is a 
widely used transactivation domain [241] capable of recruiting host cellular transcription 
factors to targeted genomic loci [405,406], but does not activate gene expression alone [254]. 
Each TALE transcription factor contained a C-terminal hemagglutinin (HA) tag and an internal 
nuclear localization signal (NLS) sequence between the DNA binding and transactivation 
domains (Fig. 2.1A). The amino acid sequence of each protein is presented in Table S2.1. 
In order to determine whether each TALE could recognize its intended target site and 
induce gene expression, we adapted a previously described transient reporter assay [398] that 
correlates TALE-induced gene activation with increased luciferase expression. We inserted 
four direct repeats of each LTR binding site upstream of a luciferase reporter gene and co-
transfected human embryonic kidney (HEK) 293T cells with reporter plasmid and expression 
vectors for each TALE activator (Fig. 2.1C and 2.1D). This strategy was undertaken in order 
to increase reporter gene expression and more accurately evaluate TALE activity. Eight of the 
ten TALE activators (all but TLT4 and TLT8) induced a >800-fold increase in luciferase 
expression, with TLT1 (~3,400-fold), TLT3 (~2,900-fold), TLT7 (~2,500-fold) and TLT9 
(~2,200-fold) inducing the highest levels of activation (p < 0.001) (Fig. 2.1D). TLT4 and TLT8 
achieved similarly high levels of absolute luciferase activity, but induced a modest ~100-fold 
increase in activation over mock-transfected cells. Even in the absence of a TALE activator, 
transfection of the TLT4 and TLT8 reporter plasmids led to a significant increase in luciferase 
expression (p < 0.001) (data not shown). Not surprisingly, however, the binding sites for TLT4 
and TLT8 overlap with those recognized by the endogenous transcription factors C/EBP and 
NF-B [407] (Fig. 2.1A), respectively, indicating that native proteins could have been 
contributing to reporter gene activation. Compared to the reporter plasmid alone, increasing 
luciferase expression was evident after co-transfection with the specific TALE activator, 
indicating that TALEs have the potential to outcompete endogenous transcription factors for 
LTR binding sites. 
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Western blot analysis of HEK293T lysates also revealed that each TALE activator was 
well expressed (Fig. 2.1D). Low levels of a non-specific band (~70 KDa), however, were 
detected in several samples, possibly due to translation of a second open-reading frame present 
within the TALE mRNA transcript or recombination within the TALE DNA-binding domain, 
a phenomenon that can occur within a highly repetitive motif [408]. 
 
Figure 2.1- TALE activators designed to target the HIV-1 LTR promoter. (A) Schematic representation of 
the TALE transcription activator (TLT) binding sites within the HIV-1 long terminal repeat (LTR) promoter 
relative to the transcriptional start site (TSS) and main endogenous transcription factor binding sites. (B) (Left) 
Cartoon illustrating the structure of a TALE activator, adapted from [285]. TALE repeats are colored cyan and 
purple, DNA shown as grey sticks. (Right) Schematic representation of the TLT expression construct used in this 
study. CMV indicates the cytomegalovirus promoter, TALE repeats are shown as individual bars (14.5 repeats 
total), VP64 denotes the tetrameric repeat of the herpes simplex virus VP16 transactivation domain, NLS stands 
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for the nuclear localization signal derived from the simian virus (SV40) and HA indicates the hemagglutinin A 
tag. (C) Schematic representation of the luciferase reporter system containing four direct repeats of the TALE 
target sites for each TALE activator. Each TALE target site is shown. (D) (Top) Fold-activation of luciferase 
expression after co-transfection of TALE activators with luciferase reporter plasmid into HEK293T cells. 
Luciferase expression was normalized to cells transfected with reporter plasmid only. Renilla luciferase expression 
was used to normalize for transfection efficiency and cell number. Error bars indicate standard deviation of one 
experiment with three transfection replicates (n = 3; *p < 0.05; **p < 0.01; ***p < 0.001; t-test sample vs control 
(4x TALE binding site vector only; Empty)). (Bottom) Western blot of lysate from HEK293T cells transfected 
with TALE activators. Samples were taken 48 h after transfection and probed with horseradish peroxidase-
conjugated anti-HA and anti-β-actin (loading control) antibodies. Empty indicates lysate from HEK293T cells 
transfected with empty pcDNA vector only.  
 
2.4.2. TALE activators activate gene expression from the HIV LTR  
We next set out to test the ability of each TALE activator to stimulate transcription from 
the full-length U3 and R regions of the HIV-1 LTR using an episomal reporter assay. The U3-
R regions of the LTR contain the core promoter, enhancer and modulatory region, and regulate 
viral expression. Notably, unlike the transient reporter assay described above, which asked 
whether each TALE protein could bind its intended DNA target, this analysis aimed to evaluate 
the ability of each TALE activator to stimulate transcription from the full-length HIV-1 
promoter. 
HEK293T cells were co-transfected with TALE activator and a reporter vector that 
contained the sequence between -455 and +96 from the LTR transcriptional start site (TSS) 
upstream of a luciferase reporter gene (Fig. 2.2). We co-transfected separately an expression 
vector encoding the HIV-1 Tat protein and the reporter vector as positive control. Multiple 
activators, including TLT4, 5, 6, 7 and 8, induced a 7.5- to 14-fold increase in luciferase activity 
(p < 0.01), while Tat yielded only a ~7-fold increase in activation (Fig. 2.2), likely because it 
stimulates transcriptional elongation more efficiently than initiation [409]. 
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Figure 2.2- TALE-mediated gene 
activation from the HIV-1 LTR 
promoter. (Top) Schematic 
representation of the luciferase 
reporter system used to evaluate 
TALE activator activity from the 
HIV-1 LTR promoter. The U3 and R 
regions of the HIV LTR were placed 
upstream of the luciferase reporter. 
(Bottom) Fold-activation of 
luciferase expression in HEK293T 
cells co-transfected with reporter 
plasmid and TALE activator or Tat 
expression vectors. Luciferase expression was normalized to cells transfected with reporter plasmid only. Error 
bars indicate standard deviation of one experiment with three transfection replicates (n = 3; *p < 0.05; **p < 0.01; 
***p < 0.001; t-test sample vs. control (LTR)). 
Previous reports have demonstrated that co-delivery of combinations of TALE 
transcription factors can lead to a synergistic increase in gene expression via cooperative effects 
that could mimic those associated with natural transcriptional processes [302,305]. The most 
potent TALE activators, TLT4, 5, 6, 7 and 8, were designed to recognize a small region of the 
LTR between -170 and -100 bp from the TSS (Fig. 2.1A). We thus co-transfected HEK293T 
cells with LTR reporter plasmid and different combinations of TALE activators to test whether 
these proteins could be used in tandem to further enhance gene expression. Increased gene 
activation was observed for each set tested, most notably with a ~70-fold increase in luciferase 
expression after co-transfection with TLT5, 6, 7 and 8 (hereafter referred to as TLT5-8) (p < 
0.001) (Fig. 2.2). Overall, these data demonstrate that TALE activators designed to target the 
U3 and R regions of the HIV LTR promoter can induce efficient gene activation.  
2.4.3. Reactivation of latent HIV-1 by TALE activators 
We next asked whether TALE activators could reactivate viral expression in a cell line 
model of HIV-1 latency. To explore this, we used the Jurkat-derived J-Lat lymphocytic cell 
lines, which harbor a full-length integrated HIV-1 proviral genome containing a GFP gene that 
serves as a reporter for viral gene expression (HIV1-Env-GFP) (Fig. 2.3A). J-Lat cells poorly 
express the integrated proviruses under normal conditions, but viral gene expression can be 
efficiently induced by stimulation using tumor necrosis factor (TNF)-α [55]. Since each J-Lat 
clone is derived from a unique HIV-1 integration event, they display differential levels of gene 
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and/or chromatin repression, as demonstrated by their distinct gene activation thresholds after 
TNF-α stimulation [410].  
We nucleofected J-Lat 10.6 cells, which display a low viral gene activation threshold, 
with expression vectors encoding TALE activators or Tat and evaluated HIV-1 expression by 
measuring the percentage of GFP-positive cells by flow cytometry (Fig. 2.3A). As expected, 
cells treated with TNF-α or transfected with Tat showed robust reactivation, with upwards of 
55% and 75% of cells producing GFP, respectively. Among all individual TALE activators 
tested, TLT5 and 6 (~40% GFP-positive cells each) and TLT7 and 8 (~30% GFP-positive cells 
each) yielded the highest levels of expression, with cells transfected with TLT5-8 also showing 
upwards of 50% GFP-positive cells (p < 0.05) (Fig. 2.3A). Nucleofection of an empty vector 
(pcDNA) resulted in minor (~5%) reactivation, indicating that stress from the nucleofection 
process can also contribute to reactivation (Fig. 2.3A). Sequence analysis of different strains of 
HIV-1 subtype B (i.e. the most predominant subtype across Europe, America, Australia and 
Japan) revealed that the binding sites for these TALEs are generally well conserved, with 
increasing preservation from TLT5 to TLT8 (Table S2.7). 
The relative potencies of the TALE activators in J-Lat 10.6 cells correlated with their 
ability to stimulate transcription in the reporter assay used in Fig. 2.2. Analysis of mean 
fluorescence intensity (MFI) in transfected J-Lat 10.6 cells further indicated that each TALE 
activator induced approximately a 10 to 15-fold increase in viral gene expression (Fig. S2.1A). 
Interestingly, in contrast to the episomal studies presented in Fig. 2.2, TLT5-8 yielded a similar 
number of GFP positive cells as the combinations TLT6-7 and TLT5-7 (Fig. 2.3A). One 
possible explanation for this is that measuring the number of GFP positive J-Lat 10.6 cells may 
not necessarily afford the amount of sensitivity needed to distinguish between the potencies of 
specific combinations of activators. Indeed, analysis of MFI in J-Lat 10.6 cells revealed that 
TLT5-8 induced higher amounts of viral gene expression (~20-fold compared to the negative 
control) than TLT7 or the combinations TLT6-7 and TLT5-7 (~14-fold compared to the 
negative control) (Fig. S2.1B). 
To test the versatility of the TALE activators, we next evaluated their ability to induce 
HIV-1 transcription in the J-Lat clones 6.3, 8.4 and 9.2, which each possess a higher gene 
activation threshold than J-Lat 10.6 cells [55]. Sequence mapping of these clones previously 
revealed that the HIV-1 provirus is integrated into actively transcribed genes, unfavorable to 
HIV transcription [58,411]. We observed significant reactivation in each cell line tested after 
co-transfection with TLT5-8 (p < 0.05) but at rates much lower than by TNF- stimulation (Fig. 
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2.3B), indicating that the level of repression within latently-infected cells can influence the 
ability of TALEs to mediate activation. 
 
Figure 2.3- Reactivation of latent HIV-1 expression by TALE activators in multiple cell line models of HIV-
1 latency. (A) (Top) Schematic representation of the HIV-1 proviral genome present in J-Lat cells. Full-length 
HIV-1 was derived from the molecular clone pNL4-3-ΔEnv-GFP and expresses a GFP gene from the LTR 
promoter. Structural viral genes are shown in black, auxiliary genes are shown in grey. The nef and env genes were 
inactivated to force a single infection cycle. (Bottom) Percentage of GFP positive J-Lat 10.6 cells after 
nucleofection with TALE-TF and Tat expression plasmids, or treatment with TNF-α (10 ng/L). GFP positive 
cells were measured by flow cytometry 48 h after nucleofection. “J-Lat” indicates non-transfected J-Lat 10.6 cells. 
“Mock” indicates cells transfected with an empty pcDNA backbone. Error bars indicate standard deviation of three 
independent experiments (n = 3). (B) Percentage of GFP positive J-Lat 6.3, 8.4 and 9.2 cells after nucleofection 
with TLT5-8 and Tat expression plasmids, or treatment with TNF-α (10 ng/L). GFP positive cells were measured 
by flow cytometry 48 h after nucleofection. “J-Lat” indicates non-nucleofected cells. Error bars indicate standard 
deviation (n = 3; *p < 0.05; **p < 0.01; ***p < 0.001; t-test sample vs control (J-Lat)). 
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2.4.4. Combining TALE activators with HDAC inhibitors enhances latent HIV 
activation 
We next explored the possibility of enhancing HIV-1 reactivation by combining TALE 
activators with a histone deacetylase (HDAC) inhibitor. Because HIV-1 proviral integration in 
J-Lat clones favors heterochromatic regions, especially those near alphoid DNA repeat 
elements [55], we hypothesized that chromatin remodeling by HDAC inhibition could enhance 
TALE binding to the HIV-1 LTR, thereby increasing viral gene expression. Indeed, previous 
reports have indicated that the LTR promoter is typically hypoacetylated and that treatment 
with HDAC inhibitors can lead to the recruitment of the transcriptional machinery to the HIV-
1 promoter [64], as well as activation of the positive transcription elongation factor b (P-TEFb), 
which can stimulate viral transcriptional elongation [412,413]. Moreover, multiple studies have 
shown that combining HDAC inhibitors with other compounds also capable of reversing HIV 
latency can synergistically increase viral reactivation across a variety of repression states [414–
417].  
We transfected J-Lat 6.3 and 10.6 cells, which each display distinct activation 
thresholds, with TLT5-8 and treated each population with increasing concentrations of HDAC 
inhibitors selective towards specific enzyme types: Vorinostat (i.e., suberoylanilide hydroxamic 
acid or SAHA), strongly inhibits class I HDACs (1, 2, 3) but also has modest activity against 
class II (6, 10, and 11); MRK-1, selectively targets class I (1, 2 and 3) and class II HDAC6; 
MRK-11, selective for class II HDAC6 HDACs (4, 5, 6 and 7) and class I HDAC8; and H-12, 
highly selective for class I HDAC1 and HDAC2 only. SAHA, in particular, is an FDA-approved 
HDAC inhibitor that has been shown to induce viral transcription in latent CD4+ T cells from 
HIV-infected patients [87,88] (though it was unable to increase HIV-1 production [87]).  The 
HDAC inhibitors IC50 activity is presented in Table S2.6. Based on previous studies [418,419], 
we used a specific range of HDAC inhibitor concentrations that would show minimal activity 
without inducing significant cell death. Compared to cells transfected with TLT5-8 alone, we 
observed a significant increase (p < 0.05) in HIV-1 expression upon co-treatment with SAHA, 
MRK-1 and MRK-11 (Fig. 2.4). Specifically, reactivation was evident in up to ~23% and ~75% 
of J-Lat 6.3 and 10.6 cells, respectively, corresponding to a 3.5- and 2-fold increase in HIV-1 
transcription (Fig. 2.4). In contrast, combining TLT5-8 with H-12 inhibitors caused no 
significant increase in HIV expression in all cell lines, indicating that HDAC-1 and -2 
suppression alone is not sufficient to further stimulate latent HIV expression. We also observed 
increased levels of HIV-1 expression in J-Lat 8.4 and 9.2 cells co-treated with TLT5-8 and 
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HDAC inhibitors, but these values were neither significant nor dose-dependent (Fig. S2.2), 
showing that cooperation between TALE activators and HDAC inhibitors was context-
dependent. Analysis of MFI in treated J-Lat 10.6 cells also revealed a significant and dose-
dependent increase in viral gene expression after co-treatment with TLT5-8 and SAHA (Fig. 
S2.3). Cells treated with only SAHA, MRK-1 and MRK-11 yielded a negligible increase in 
reactivation except for MRK-1 in J-Lat 10.6 clone (~30% with 2 µM of MRK-1). Collectively, 
these results demonstrate that complementing TALE activators with HDAC inhibitors can lead 
to enhanced reactivation of latent HIV-1 expression. 
 
Figure 2.4- Enhanced reactivation of latent HIV-1 expression by combining TALE activators with a histone 
deacetylase inhibitor. Percentage of GFP-positive J-Lat 6.3 and 10.6 cells after nucleofection with TLT5-8 
expression plasmids and treatment with increasing concentrations of SAHA (330 nM, 660 nM, 1 µM), MRK-1 
(660 nM, 1 µM, 2 µM), MRK-11 (3 µM, 5 µM, 20 µM), H-12 (1 µM, 3 µM, 5 µM) or DMSO (0.1%) control for 
24 h. GFP-positive cells were measured by flow cytometry 48 h after nucleofection. Error bars indicate standard 
error of the mean of three independent experiments (n = 3; *p < 0.05; **p < 0.01; ***p < 0.001; t-test sample vs 
control (DMSO)). 
 
2.4.5. TALE activators do not activate primary resting CD4+ T cells 
Activation of CD4+ T cells during induction of latent HIV expression has the potential 
to trigger a generalized immune response [52]. To determine whether TALE activators designed 
to bind the HIV LTR can inadvertently trigger T cell activation, we nucleofected primary 
resting CD4+ T cells with TLT5-8 or an empty pcDNA backbone vector and measured the 
percentage of cells CD25 activation marker. As expected, resting CD4+ T cells stimulated with 
a cocktail of anti-CD3/CD28 expressed high levels of CD25 (~75%), while less than 2% of 
cells transfected with TLT5-8 expressed CD25 (Fig. 2.5A). Resting CD4+ T cells treated with 
1 M of SAHA also displayed a negligible increase in CD25 expression (Fig. 2.5A). Forward 
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and side scatter (FSC/SSC) gating of live cells revealed that CD4+ T cells transfected with 
TLT5-8 showed no decrease in cell viability compared to mock transfected cells (Fig. 2.5B). 
Taken together, these results indicate that TALE activators do not dramatically increase the 
expression of CD4+ T cell activator markers or impact cell viability. 
 
Figure 2.5- Cell-activation 
mark expression and cell 
viability analysis of primary 
resting CD4+T cells in the 
presence of TALE activators. 
(A) Percentage of CD25-
positive-resting CD4+ T cells 
after nucleofection with empty 
pcDNA, and TLT5-8 
expression plasmids or 
treatment with SAHA. (B) 
Percentage of viable resting CD4+ T cells measured by forward and side scatter (FSS/SCC) gating after 
nucleofection with empty pcDNA and TLT5-8 expression plasmids or treatment with SAHA. RCD4 indicates 
unstimulated cells; CD3/CD28 indicates cells stimulated with anti-CD3/CD28 beads. Cells were analyzed by 
flow cytometry 72 h after nucleofection. Error bars indicate standard error of the mean (n= 4 independent donors). 
2.4.6. Engineering of suicidal lentivectors to clear latent HIV cells stimulated by TALE 
activators 
Despite the potential of TALE synthetic activators to stimulate latent viral expression, 
it does not guarantee elimination of HIV reservoirs particularly due to lack of efficient CTL-
mediated immune response [91]. For this purpose, we explored a suicidal gene therapy 
approach to selectively kill latent HIV cells reactivated by our TALE activator technology. We 
engineered a previously developed HIV-reporter lentivector (pNL4-3-GFP-RRE) for 
conjugation with our TALE activator technology. This vector incorporates a GFP reporter 
responsive to the presence of Tat and Rev regulatory proteins typically expressed during HIV 
replication cycle [188]. Tat and Rev regulatory function in HIV-1 replication is described in 
section 1.1.2.1. We modified pNL4-3-GFP-RRE to design a suicidal lentivector incorporating 
a toxin (pmNLR-Toxin; Fig. 2.6A) that could be conjugated with HIV-targeted TALE 
activators previously designed in Chapter II and clear reactivated latent cells through a “shock 
and kill” gene-based approach (Fig. 2.6B). 
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Figure 2.6– “Shock and kill” 
gene-therapeutic strategy to 
selectively eliminate HIV-1 
latent cells. (A) Schematic 
illustration of the HIV suicide 
lentivector construct. Lentiviral 
HIV-responsive suicidal vector 
contains a toxin gene under the 
control of Tat-responsive LTR and 
a Rev-responsive element (RRE) 
between donor (DS) and acceptor 
(AS) splicing sites of HIV-1. The 
5’LTR promoter is modified (Δ) to 
prevent TALE activator 
recognition and undesirable gene 
expression in non-infected cells. 
(B) Schematic representation of 
the strategy proposed for cell-
specific elimination of HIV-1 
latently infected cells. Cells are co-transfected with TALE activators (TALE-VP64) and a suicidal lentivector 
(pmNLR-Toxin). TALE activators specifically target the HIV LTR promoter and recruit the transcription 
machinery to induce latent viral expression (1). HIV-responsive suicidal lentivector harbors a suicide gene (Toxin) 
conditioned to the presence of HIV Tat and Rev proteins. In the absence of Tat and Rev, any leaking transcripts 
from the suicidal vector in will be excised due to the presence of HIV-1 splicing sites, eliminating the toxic gene. 
In HIV-1 infected cells, Tat expression will enhance the suicidal vector transcription from the 5´LTR (2), while 
Rev expression will promote the export of the unspliced mRNA to the cytoplasm (3), enabling toxin expression 
and mediated killing of infected cells. 
Both 5’LTR from integrated HIV provirus and suicidal lentivectors vector are identical, 
so it is expected that TALE activators should likewise bind the suicidal vector and lead to 
undesirable gene activation. In addition, transcriptional background from the 5’LTR promoter 
posed a major obstacle to HIV suicidal gene therapy due to unspecific cell death of non-infected 
cells [420–422]. Initial studies characterizing the 5’LTR demonstrated that mutations at the 
modulatory region from -187 to -112 bp relative to TSS reduced background transcription 
without affecting Tat activity [423]. On this principle, we designed luciferase reporter 
constructs under the control of modified 5’LTR promoters (mLTR1-mLTR5) to disrupt binding 
of TALE activators (TLT5, TLT6 and TLT7) (Fig. 2.7A). This strategy was carried to reduce 
basal activity and simultaneously prevent TALE-mediated activation without affecting Tat 
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transactivation. Four of the mLTR constructs (mLTR1, mLTR3, mLTR4 and mLTR5) showed 
far reduction of TALE-mediated activation (~2-fold) compared to native 5’LTR (wtLTR; ~65-
fold). Among these, mLTR3 – for which U3 modulatory region from -183 to -115 bp relative 
to TSS was substituted for an irrelevant segment – showed a slight decrease of background 
transcription and increased Tat-mediated activation in comparison to wtLTR (Fig. 2.7A). 
Consequently, we selected mLTR3 to drive gene expression from our suicidal lentivector 
construct. 
We next evaluated gene expression from the Tat/Rev-dependent suicidal lentivector 
incorporating a firefly luciferase (Fluc) reporter driven by the native wtLTR (pNLR-Fluc) or 
modified mLTR3 (pmNLR-Fluc) in HEK293T cells (Fig. 2.7B; Left). Despite the absence of 
Tat and Rev proteins, TLT5-7 enhanced luciferase activation (~12-fold) in pNLR-Fluc, while 
in pmNLR-Fluc a slight increase (~4-fold) was observed possibly due to unspecific activation 
caused by the presence of VP64. On the other hand, mLTR3-driven pmNLR-Fluc activation 
(~53-fold) in the presence of Tat and Rev was superior to that observed with wtLTR-driven 
pNLR-FLuc (~23-fold) (Fig. 2.7B; Right). These results indicate that incorporation of mLTR3 
turn activation of HIV suicidal lentivector far more specific to the presence of Tat and Rev viral 
proteins. 
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Figure 2.7– Engineering LTR promoter of Tat/Rev-dependent suicide lentivector for conjugation with 
TALE activators. (A) Design of luciferase reporter constructs driven by LTR mutants (mLTR) to disrupt TALE-
mediated activation. TALE activators (TLT5, TLT6 and TLT7) binding sites relative to the transcriptional start 
site (TSS) are illustrated. The U3 and R regions of the HIV LTR were placed upstream of the luciferase reporter:  
wtLTR corresponds to the native full-length U3 and R regions; in mLTR1 the U3 segment upstream of -115 bp 
was entirely deleted; in mLTR2 the U3 segment from -147 to -115 bp was substituted for an irrelevant segment; 
in mLTR3 the U3 segment from -183 to -115 bp was substituted for an irrelevant segment; in mLTR4 the U3 
segment from -183 to -115 bp was entirely deleted; in mLTR5 the U3 segment from -183 to -115 bp was substituted 
for Tat-binding trans-activating response element (TAR). Fold-activation of luciferase expression was evaluated 
in HEK293T cells co-transfected with native (wtLTR) or modified mLTR (mLTR1-mLTR5) luciferase constructs 
and empty pcDNA vector (Background activation), TLT5-7 constructs (TALE-mediated activation) or Tat-
expression plasmids (Tat-mediated activation). Luciferase expression was normalized to cells co-transfected with 
pcDNA control. Renilla luciferase expression was used to normalize for transfection efficiency and cell number. 
(B) (Left) Schematic representation of the suicide lentivectors incorporating a firefly luciferase (Fluc) reporter 
under the control of native wtLTR (pNLR-Fluc) or modified mLTR3 (pmNLR-Fluc) promoter. (Right) Fold-
activation of luciferase expression in HEK293T cells co-transfected with pNLR-Fluc or pmNLR-Fluc and empty 
pcDNA vector (Mock), TALE activator expression constructs (TLT5-7) or Tat and Rev-expression plasmids 
(Tat/Rev). Luciferase expression in each construct was normalized to cells transfected with Mock control. Renilla 
luciferase expression was used to normalize for transfection efficiency and cell number. Error bars indicate 
standard deviation of one experiment with three transfection replicates (n = 3; *p < 0.05; **p < 0.01; ***p < 0.001; 
t-test sample vs control(Mock)). 
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We next determined whether engineered mLTR3 promoter affected lentivirus 
production and maintained expression of suicidal lentivector specific to HIV-1 infected cells. 
Jurkat T lymphocytes were infected with a non-replicative HIV-1 clone harboring EGFP as 
reporter for viral infection (NL4-3Δenv-EGFP). Non-infected and HIV-1 infected cells were 
then transduced with HIV-responsive lentivector (mNLR-E2C) that incorporates a far-red E2-
Crimson reporter [400] driven by modified mLTR3 (Fig. 2.8; Top). Additionally, we 
introduced a WPRE regulatory element [424] downstream of E2C reporter (mNLRW-E2C) to 
further support lentivector expression (Fig. 2.8; Top). We observed that E2C-positive cells 
(~17%) derived from mNLR-E2C activation were detected only in GFP-positive HIV-1 
infected cells. (Fig. 2.8; Bottom). Furthermore, incorporation of WPRE in mNLW-E2C 
enhanced lentivector expression (~38% E2C-positive) without affecting specificity to HIV-1 
infection. To enforce safety of this approach, delivery of these therapeutic plasmids to target 
cells should be mediated by integration-deficient lentivirus (IDLV) that avoid genotoxic effects 
from lentivirus integration into the chromatin however with dramatic reduction of gene 
expression (see chapter 1.2.1. for details). Still, efficient E2C expression (~26% E2C-positive 
cells) was detected in HIV-1 infected cells following IDLV delivery of pmNLRW-E2C (Fig. 
2.8; Bottom). Briefly, we demonstrate that engineered suicidal lentivector is highly responsive 
to the presence of active HIV-1 infected cells.  
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Figure 2.8– Specific gene expression of engineered suicidal lentivector in HIV-1 infected cells. (Top) 
Schematic representation of mLTR3-driven suicide lentivector incorporating E2Crimson (pmNLR-E2C) reporter. 
In pmNLRW-E2C, woodchuck hepatitis post-transcriptional regulatory element (WPRE) was incorporated 
downstream of E2C reporter to further enhance gene expression. (Bottom) Percentage of GFP and E2C gene 
expression of Jurkat cells non-infected or infected at MOI 2 with HIV-1 NL4-3ΔenvEGFP-reporter (HIV-1 
infected) followed by transduction of mNLR-E2C lentivirus (LV), mNLRW-E2C lentivirus (LV) or integration-
deficient lentivirus (IDLV) at the indicated MOI. Cells were analyzed by flow cytometry 48 hours after 
transduction. “Untreated” indicates non-transduced with E2C-suicidal vectors. 
2.4.7. Suicidal lentivectors with TALE activators specifically eliminate latent HIV-1 cells 
To evaluate the selective elimination of HIV latent cells by the proposed strategy, we 
first compared the suicidal lentivector expression in non-infected Jurkat or HIV latent J-Lat 
10.6 cells co-nucleofected with TALE activators (TLT5-7) and pmNLRW-E2C reporter. We 
show that E2C expression (~11% E2C-positive cells) is only observed in J-Lat 10.6 cells highly 
expressing GFP, with approximately 11% of J-Lat cells positive for E2-Crimson reporter (Fig. 
2.9A). Additionally, we do not detect E2C-positive cells in Jurkat population even in the 
presence of TLT5-7, indicating that TALE-mediated activation of latent HIV expression is 
necessary to trigger expression of suicide lentivector. 
To promote the elimination of latent HIV population, we explored the potential of   
toxins derived from pathogenic bacteria, frequently explored for therapeutic applications by 
inducing programmed cell death of target cells [425]. We tested a different set of potent toxins 
that mediate cell apoptosis through distinct modes of action: Diptheria toxin A chain from 
Corynebacterium diphtheria and Ricin toxin A chain from Ricinus communis block protein 
synthesis; Anthrax Lethal factor N-terminal from Bacillus Anthracis lead to programmed cell 
death by blocking cell signaling activity; and Streptolysin O from Streptococcus pyogenes 
disrupts cell membrane integrity. J-Lat cells co-nucleofected with TLT5-7 activators and 
suicide lentivectors incorporating these toxins were analyzed by flow cytometry for by 
Annexin-V staining of apoptotic cells. Only suicide lentivectors incorporating Diphtheria 
(~52%) and Ricin (~43%) could lead to apoptosis of J-Lat 10.6 cells (Fig. 2.9B), pointing out 
that inducible expression of these toxins is sufficient to stimulate cell death. 
Finally, we set out to evaluate selective elimination of HIV latent cells. For this, we 
compared cell death between non-infected Jurkat and HIV latently infected J-Lat 10.6 
populations co-nucleofected with TLT5-7 activators and increasing amounts of suicide 
lentivector driving expression of Diphtheria toxin (pmNLRW-DTA). Significant cell death of 
both Jurkat and J-Lat is observed with equal amounts of TLT5-7 and pmNLRW-DTA (1 µg) 
Results 
 
77 
 
However, while high-level of J-Lat apoptosis (40-50%) is detected at all pmNLRW-DTA 
amounts, cell death in Jurkat decreases with lower dose of transfected suicidal lentivector (Fig. 
2.9C), indicating that unspecific death of non-infected cells might be caused by leaking 
expression from excessive plasmid transfection. At the lower amount of lentivector transfected 
(0.1 µg), we observe a significant difference in cell death between non-infected Jurkat (~10%) 
and HIV latent J-Lat 10.6 (~50%) populations. Overall, these results demonstrate that TALE-
mediated activation of HIV latent cells drive expression of engineered suicidal lentivector and 
conjugation of both can lead to specific elimination of this population. 
 
Figure 2.9– Selective elimination of HIV-1 latent cells through conjugation of TALE activators and suicide 
lentivectors. (A) Percentage of GFP and E2C gene expression of non-infected Jurkat cells or J-Lat 10.6 HIV latent 
cells nucleofected with pcDNA empty vector (Mock), TALE activators (TLT5-7) alone or with E2C-reporter 
suicidal lentivector (pmNLRW-E2C). Cells were analyzed by flow cytometry 48 hours after nucleofection. (B) 
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Percentage of apoptotic cells of J-Lat 10.6 population co-nucleofected with pTLT5-7 and HIV suicidal lentivectors 
incorporating indicated toxin genes (pmNLRW-Toxin). “Mock” indicates cells nucleofected with pcDNA empty 
vector. “E2Crimson” indicates cells nucleofected with pmNLRW-E2C reporter. Apoptotic cells were detected by 
flow cytometry analysis following AnnexinV staining 48 hours after cell nucleofection. Percentage of apoptotic 
cells were normalized to Mock control. (C) Percentage of apoptotic cells of non-infected Jurkat cells or J-Lat 10.6 
HIV latent cells co-nucleofected with TLT5-7 activators (1 µg) and increasing amounts of Diphtheria-incorporated 
suicidal lentivector (pmNLRW-DTA). Cell nucleofection of TLT5-7 and pmNLRW-DTA was supplemented with 
pcDNA to 2 µg of total DNA Apoptotic cells were detected by flow cytometry analysis following AnnexinV 
staining at 48 hours after cell nucleofection. Percentage of apoptotic cells were normalized to cells nucleofected 
with pcDNA vector.
2.5. DISCUSSION 
HIV-1 latency is a substantial obstacle facing its eradication. Many approaches have 
been developed to indirectly activate HIV-1 from persistent cellular reservoirs, typically by 
altering the transcriptional landscape surrounding the integrated provirus 
[74,77,79,80,82,83,87,88]. While promising, these strategies have been unable to completely 
purge all virus from the reservoir and, in some cases, have even been associated with adverse 
effects, including immune reactions [29,52,78,390]. While targeted nucleases and 
recombinases have the capacity to excise integrated proviral DNA from infected cells [372–
374,383], these tools also have the potential to induce unwanted non-specific DNA breaks, and 
thus carry a substantial risk of genotoxicity [240]. Conversely, synthetic transcription factors, 
which can be designed to induce transcription from the native viral promoter, represent a 
potentially safe and effective genetic alternative for reactivating latent virus in cells. 
Here, we designed ten TALE proteins that spanned nearly the entire length of the HIV-
1 LTR promoter in order to create activators capable of stimulating HIV-1 transcription. We 
identified four proteins (TLT5, TLT6, TLT7 and TLT8) that induced viral gene expression in 
cell line models of HIV latency. Interestingly, we observed that the effectiveness of individual 
TALEs correlated with their proximity to the TSS, as they targeted a conserved segment of the 
HIV LTR modulatory region, located upstream of the NF-κB and Sp1 cis-regulatory sites, and 
nearby regulatory elements that contribute to viral transcriptional initiation [407,426]. This data 
indicates that cooperation between endogenous transcription factors and engineered TALE 
activators may be an important factor for efficient reactivation of viral gene expression. These 
TALEs might thus promote transcription in a manner that mimics the natural activity of 
enhancer-like regulatory proteins, potentially serving as “molecular switches” for reactivation. 
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We showed that co-transfection of combinations of TALE activators can further 
increase gene expression, indicating that strategies for mimicking the natural complexity of 
gene regulation [302,305] are also effective for inducing viral gene expression. Specifically, 
co-transfection of J-Lat 10.6 cells with TLT5-8 led to similar amounts of HIV-1 expression as 
those previously reported for compounds such as phytohemagglutinin (PHA), phorbolmyristate 
acetate (PMA) and prostratin [419]. Moreover, the specificity of our TALE activators could be 
improved in the future by incorporating recently described chemical- [398,427] or light-
inducible [275,428] features that enable spatial and temporal control of HIV-1 expression.  
Two reports initially demonstrated that engineered zinc-finger and TALE transcription 
factors can induce latent HIV expression, albeit with relatively modest efficiencies [429,430]. 
More recently, several other studies have shown that TALE [431] and CRISPR-Cas9 [432–
436] activators can induce robust activation of latent viral expression. Our data correlates with 
these most recent reports and further indicates the potential of artificial transcription factor 
technology for eliminating the latent reservoir. 
Although the TALE activators used in our study induced efficient HIV-1 expression in 
J-Lat 10.6 cells, reduced levels of viral gene expression were observed in J-Lat clones 
containing more repressive transcriptional backgrounds. Specifically, integration of the HIV-1 
provirus into condensed regions of heterochromatin can negatively affect viral gene expression 
by hindering DNA accessibility to key host transcription factors [37,41]. Because histone 
deacetylases (HDACs) play a central role in maintaining HIV latency by promoting compact 
chromatin structures around integrated proviral DNA [37], we hypothesized that treating cells 
with HDAC inhibitors could increase binding site accessibility and further enhance HIV-1 
reactivation. We found that combining TALE activators with different classes of HDAC 
inhibitors led to a significant increase in viral gene expression in J-Lat 6.3 and 10.6 cells 
comparable to those previously described for other latency-reversing compounds, including 
PHA and Bryostatin [419]. We also observed that HDAC inhibitor selectivity affects TALE-
mediated stimulation of HIV expression, as H-12 (selective for HDAC-1 and -2 only) had no 
effect on this matter. Our data correlates with previous studies reporting the major contribution 
of class I HDACs, and more specifically HDAC-3 on the epigenetic regulation of HIV 
expression [418,437]. This indicates the broad utility of this concept for HIV-1 reactivation, 
and supports further investigation into the effects of combining HDAC inhibition with TALE-
mediated activation in primary cell models of HIV latency [419]. Combining synthetic 
activators and HDAC inhibition with HAART or nuclease-induced knockout of HIV co-
receptors CCR5 and CXCR4 [356] may also prove effective for combating HIV infection. 
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Additionally, we designed a strategy to enforce elimination of stimulated HIV latent 
cells by conjugating TALE activators with a HIV-responsive suicide lentivector. We 
engineered a Tat/Rev-dependent suicide lentivector with a tailored 5’LTR promoter that 
disrupts TLT5-7 binding and non-specific activation in uninfected cells. This modified vector 
induced gene expression only in the presence of HIV-1 infected cells, even when delivered as 
non-integrative IDLV which provides a safety advantage for gene therapeutic applications 
[138]. We provide evidence that activation of J-Lat HIV latent cells by TLT5-7 is required to 
induce expression of suicidal lentivector. Conjugation of TLT5-7 and a small dose of suicidal 
lentivector incorporating a Diphtheria toxin selectively induced efficient cell death of HIV 
latent cells with minimal damage to healthy uninfected cells, demonstrating the potential of this 
strategy to safely eliminate HIV reservoirs stimulated by our TALE activator technology. 
While TALE activators have the capacity to activate latent HIV-1 transcription, several 
barriers must be overcome for this technology to be implemented for therapeutic purposes. In 
particular, due to their highly repetitive nature, lentiviral vector-mediated delivery of TALEs 
into cells has proven challenging [240,290,438]. Methods for overcoming this limitation are 
rapidly emerging, including those based on adenoviral [291,439], AAV [275], mRNA [440] 
and protein-based delivery systems [285,287]. Additionally, recent work has indicated that 
TALE nucleases could be introduced into cells as mRNA using lentivirus particles containing 
inactivated reverse transcriptase [441]. However, it remains unknown whether such systems 
can support in vivo delivery to latent resting CD4+ T cells. Although our current study indicates 
that a specific combination of four TALE activators is optimal for inducing HIV-1 
transcriptional activation, current evidence demonstrate that the potency of these activators can 
be further enhanced to promote single TALE systems [312]. 
In summary, we demonstrate that TALE activators are effective tools for activating 
latent HIV expression and their use, alone or in combination with HDAC inhibitors or suicide 
lentivectors, could pave the way for improved HIV therapies.
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2.7. SUPPLEMENTARY INFORMATION 
2.7.1. Supplementary Figures 
  
Supplementary Figure S 2.1- Analysis of GFP mean fluorescence intensity in J-Lat 10.6 cells nucleofected 
with TALE activators. Mean fluorescence intensity (MFI) of GFP expression in J-Lat 10.6 cells after 
nucleofection with a (A) single TALE activator (TLT5, TLT6, TLT7, and TLT8) or (B) a combination of TALE 
activators (TLT7, TLT6-7, TLT5-7, and TLT5-8). MFI was measured by flow cytometry 48 h after nucleofection. 
“J-Lat” indicates non-transfected J-Lat 10.6 cells. Histograms are representative of a single experiment from three 
independent replicates. 
  
Chapter II – Construction of TALE activators and suicide lentivectors for targeted elimination 
of latent HIV cells 
84 
 
 
Supplementary Figure S 2.2 – Evaluation of HIV reactivation in J-Lat 8.4 and 9.2 following co-treatment 
with TALE activators with class-selective histone deacetylase inhibitors. Percentage of GFP-positive J-Lat 8.4 
and 9.2 cells after nucleofection with TLT5-8 expression plasmids and treatment with increasing concentrations 
of SAHA (330 nM, 660 nM, 1 µM), MRK-1 (660 nM, 1 µM, 2 µM), MRK-11 (3 µM, 5 µM, 20 µM), H-12 (1 
µM, 3 µM, 5 µM) or DMSO (0.1%) control for 24 h. GFP-positive cells were measured by flow cytometry 48 h 
after nucleofection. Error bars indicate standard error of the mean of three independent experiments (n = 3). 
 
Supplementary Figure S 2.3- SAHA increases mean fluorescence intensity in J-Lat cells nucleofected with 
combinations of TALE activators. Mean fluorescence intensity (MFI) of GFP expression in J-Lat 10.6 cells 
nucleofected with TALE activators (TLT5-8) and co-treated with SAHA.J-Lat 10.6 cells were nucleofected with 
TLT5-8 expression plasmids and treated with increasing concentrations of SAHA or DMSO only for 24 h. MFI 
was measured by flow cytometry 48 h after nucleofection. Histograms are representative of a single experiment 
from three independent replicates. 
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2.7.2. Supplementary Tables 
Supplementary Table S 2.1- TALE proteins sequences used in this study. TALE N-terminal domain is colored 
orange. TALE DNA-binding domain is colored blue. RVD residues are shown in red. Nuclear localization signal 
(NLS) sequence is highlighted grey. VP64 domain is colored green. HA tag is colored purple. 
>TLT1-VP64 
MAQAASGSPRPPRAKPAPRRRAAQPSDASPAAQVDLRTLGYSQQQQEKIKPKVRSTVAQHHEALVGHGFTHAHIVALSQHPA
ALGTVAVTYQHIITALPEATHEDIVGVGKQWSGARALEALLTDAGELRGPPLQLDTGQLVKIAKRGGVTAMEAVHASRNALTG
AP 
LNLTPDQVVAIASNIGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASHDGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASHDGGKQALETVQRLLAVLCQDH 
GLTPDQVVAIASNIGGKQALETVQRLLAVLCQDH 
GLTPDQVVAIASHDGGKQALETVQRLLAVLCQDH 
GLTPDQVVAIASNIGGKQALETVQRLLAVLCQDH 
GLTPDQVVAIASHDGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNIGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASHDGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNIGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNIGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNNGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNNGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASHDGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNGGGKQALESIVAQLSRPDPALAALTNDHLVALACLGGRPAMDAVKKGLPHAPELIRRVNRRIGERTSHRVA
DYAQVVRVLEFFQCHSHPAYAFDEAMTQFGMSGQAGQASPKKKRKVGRADALDDFDLDMLGSDALDDFDLDMLGSDALDD
FDLDMLGSDALDDFDLDMLINYPYDVPDYAS 
 
>TLT2-VP64 
MAQAASGSPRPPRAKPAPRRRAAQPSDASPAAQVDLRTLGYSQQQQEKIKPKVRSTVAQHHEALVGHGFTHAHIVALSQHPA
ALGTVAVTYQHIITALPEATHEDIVGVGKQWSGARALEALLTDAGELRGPPLQLDTGQLVKIAKRGGVTAMEAVHASRNALTG
AP 
LNLTPDQVVAIASNNGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNIGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASHDGGKQALETVQRLLAVLCQDH 
GLTPDQVVAIASHDGGKQALETVQRLLAVLCQDH 
GLTPDQVVAIASNGGGKQALETVQRLLAVLCQDH 
GLTPDQVVAIASNGGGKQALETVQRLLAVLCQDH 
GLTPDQVVAIASNGGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNNGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNNGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNIGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNGGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNNGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNNGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNGGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNNGGKQALESIVAQLSRPDPALAALTNDHLVALACLGGRPAMDAVKKGLPHAPELIRRVNRRIGERTSHRVA
DYAQVVRVLEFFQCHSHPAYAFDEAMTQFGMSGQAGQASPKKKRKVGRADALDDFDLDMLGSDALDDFDLDMLGSDALDD
FDLDMLGSDALDDFDLDMLINYPYDVPDYAS 
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>TLT3-VP64 
MAQAASGSPRPPRAKPAPRRRAAQPSDASPAAQVDLRTLGYSQQQQEKIKPKVRSTVAQHHEALVGHGFTHAHIVALSQHPA
ALGTVAVTYQHIITALPEATHEDIVGVGKQWSGARALEALLTDAGELRGPPLQLDTGQLVKIAKRGGVTAMEAVHASRNALTG
AP 
LNLTPDQVVAIASNGGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNNGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNGGGKQALETVQRLLAVLCQDH 
GLTPDQVVAIASNGGGKQALETVQRLLAVLCQDH 
GLTPDQVVAIASNIGGKQALETVQRLLAVLCQDH 
GLTPDQVVAIASHDGGKQALETVQRLLAVLCQDH 
GLTPDQVVAIASNIGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASHDGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASHDGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASHDGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNGGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNNGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNGGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNNGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNIGGKQALESIVAQLSRPDPALAALTNDHLVALACLGGRPAMDAVKKGLPHAPELIRRVNRRIGERTSHRVA
DYAQVVRVLEFFQCHSHPAYAFDEAMTQFGMSGQAGQASPKKKRKVGRADALDDFDLDMLGSDALDDFDLDMLGSDALDD
FDLDMLGSDALDDFDLDMLINYPYDVPDYAS 
 
>TLT4-VP64 
MAQAASGSPRPPRAKPAPRRRAAQPSDASPAAQVDLRTLGYSQQQQEKIKPKVRSTVAQHHEALVGHGFTHAHIVALSQHPA
ALGTVAVTYQHIITALPEATHEDIVGVGKQWSGARALEALLTDAGELRGPPLQLDTGQLVKIAKRGGVTAMEAVHASRNALTG
AP 
LNLTPDQVVAIASHDGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNIGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASHDGGKQALETVQRLLAVLCQDH 
GLTPDQVVAIASNIGGKQALETVQRLLAVLCQDH 
GLTPDQVVAIASNGGGKQALETVQRLLAVLCQDH 
GLTPDQVVAIASNNGGKQALETVQRLLAVLCQDH 
GLTPDQVVAIASNNGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASHDGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASHDGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASHDGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNNGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNIGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNNGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNIGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNNGGKQALESIVAQLSRPDPALAALTNDHLVALACLGGRPAMDAVKKGLPHAPELIRRVNRRIGERTSHRVA
DYAQVVRVLEFFQCHSHPAYAFDEAMTQFGMSGQAGQASPKKKRKVGRADALDDFDLDMLGSDALDDFDLDMLGSDALDD
FDLDMLGSDALDDFDLDMLINYPYDVPDYAS 
 
>TLT5-VP64 
MAQAASGSPRPPRAKPAPRRRAAQPSDASPAAQVDLRTLGYSQQQQEKIKPKVRSTVAQHHEALVGHGFTHAHIVALSQHPA
ALGTVAVTYQHIITALPEATHEDIVGVGKQWSGARALEALLTDAGELRGPPLQLDTGQLVKIAKRGGVTAMEAVHASRNALTG
AP 
LNLTPDQVVAIASNNGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNNGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASHDGGKQALETVQRLLAVLCQDH 
GLTPDQVVAIASHDGGKQALETVQRLLAVLCQDH 
GLTPDQVVAIASHDGGKQALETVQRLLAVLCQDH 
GLTPDQVVAIASNNGGKQALETVQRLLAVLCQDH 
GLTPDQVVAIASNIGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNNGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNIGGKQALETVQRLLPVLCQDH 
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GLTPDQVVAIASNNGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASHDGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNGGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNNGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASHDGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNIGGKQALESIVAQLSRPDPALAALTNDHLVALACLGGRPAMDAVKKGLPHAPELIRRVNRRIGERTSHRVA
DYAQVVRVLEFFQCHSHPAYAFDEAMTQFGMSGQAGQASPKKKRKVGRADALDDFDLDMLGSDALDDFDLDMLGSDALDD
FDLDMLGSDALDDFDLDMLINYPYDVPDYAS 
 
>TLT6-VP64 
MAQAASGSPRPPRAKPAPRRRAAQPSDASPAAQVDLRTLGYSQQQQEKIKPKVRSTVAQHHEALVGHGFTHAHIVALSQHPA
ALGTVAVTYQHIITALPEATHEDIVGVGKQWSGARALEALLTDAGELRGPPLQLDTGQLVKIAKRGGVTAMEAVHASRNALTG
AP 
LNLTPDQVVAIASNNGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASHDGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNIGGKQALETVQRLLAVLCQDH 
GLTPDQVVAIASNGGGKQALETVQRLLAVLCQDH 
GLTPDQVVAIASHDGGKQALETVQRLLAVLCQDH 
GLTPDQVVAIASHDGGKQALETVQRLLAVLCQDH 
GLTPDQVVAIASNNGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNNGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNIGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNNGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNGGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNIGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASHDGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNGGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNIGGKQALESIVAQLSRPDPALAALTNDHLVALACLGGRPAMDAVKKGLPHAPELIRRVNRRIGERTSHRVA
DYAQVVRVLEFFQCHSHPAYAFDEAMTQFGMSGQAGQASPKKKRKVGRADALDDFDLDMLGSDALDDFDLDMLGSDALDD
FDLDMLGSDALDDFDLDMLINYPYDVPDYAS 
 
>TLT7-VP64 
MAQAASGSPRPPRAKPAPRRRAAQPSDASPAAQVDLRTLGYSQQQQEKIKPKVRSTVAQHHEALVGHGFTHAHIVALSQHPA
ALGTVAVTYQHIITALPEATHEDIVGVGKQWSGARALEALLTDAGELRGPPLQLDTGQLVKIAKRGGVTAMEAVHASRNALTG
AP 
LNLTPDQVVAIASNNGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASHDGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNGGGKQALETVQRLLAVLCQDH 
GLTPDQVVAIASNNGGKQALETVQRLLAVLCQDH 
GLTPDQVVAIASNIGGKQALETVQRLLAVLCQDH 
GLTPDQVVAIASHDGGKQALETVQRLLAVLCQDH 
GLTPDQVVAIASNIGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNGGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASHDGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNNGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNIGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNNGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASHDGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNGGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNGGGKQALESIVAQLSRPDPALAALTNDHLVALACLGGRPAMDAVKKGLPHAPELIRRVNRRIGERTSHRVA
DYAQVVRVLEFFQCHSHPAYAFDEAMTQFGMSGQAGQASPKKKRKVGRADALDDFDLDMLGSDALDDFDLDMLGSDALDD
FDLDMLGSDALDDFDLDMLINYPYDVPDYAS 
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>TLT8-VP64 
MAQAASGSPRPPRAKPAPRRRAAQPSDASPAAQVDLRTLGYSQQQQEKIKPKVRSTVAQHHEALVGHGFTHAHIVALSQHPA
ALGTVAVTYQHIITALPEATHEDIVGVGKQWSGARALEALLTDAGELRGPPLQLDTGQLVKIAKRGGVTAMEAVHASRNALTG
AP 
LNLTPDQVVAIASNGGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNGGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASHDGGKQALETVQRLLAVLCQDH 
GLTPDQVVAIASHDGGKQALETVQRLLAVLCQDH 
GLTPDQVVAIASNNGGKQALETVQRLLAVLCQDH 
GLTPDQVVAIASHDGGKQALETVQRLLAVLCQDH 
GLTPDQVVAIASNGGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNNGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNNGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNNGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNNGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNIGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASHDGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNGGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNGGGKQALESIVAQLSRPDPALAALTNDHLVALACLGGRPAMDAVKKGLPHAPELIRRVNRRIGERTSHRVA
DYAQVVRVLEFFQCHSHPAYAFDEAMTQFGMSGQAGQASPKKKRKVGRADALDDFDLDMLGSDALDDFDLDMLGSDALDD
FDLDMLGSDALDDFDLDMLINYPYDVPDYAS 
 
>TLT9-VP64 
MAQAASGSPRPPRAKPAPRRRAAQPSDASPAAQVDLRTLGYSQQQQEKIKPKVRSTVAQHHEALVGHGFTHAHIVALSQHPA
ALGTVAVTYQHIITALPEATHEDIVGVGKQWSGARALEALLTDAGELRGPPLQLDTGQLVKIAKRGGVTAMEAVHASRNALTG
AP 
LNLTPDQVVAIASNNGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNNGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASHDGGKQALETVQRLLAVLCQDH 
GLTPDQVVAIASNNGGKQALETVQRLLAVLCQDH 
GLTPDQVVAIASNIGGKQALETVQRLLAVLCQDH 
GLTPDQVVAIASNNGGKQALETVQRLLAVLCQDH 
GLTPDQVVAIASHDGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASHDGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASHDGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNGGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASHDGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNIGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNNGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNIGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNGGGKQALESIVAQLSRPDPALAALTNDHLVALACLGGRPAMDAVKKGLPHAPELIRRVNRRIGERTSHRVA
DYAQVVRVLEFFQCHSHPAYAFDEAMTQFGMSGQAGQASPKKKRKVGRADALDDFDLDMLGSDALDDFDLDMLGSDALDD
FDLDMLGSDALDDFDLDMLINYPYDVPDYAS 
 
>TLT10-VP64 
MAQAASGSPRPPRAKPAPRRRAAQPSDASPAAQVDLRTLGYSQQQQEKIKPKVRSTVAQHHEALVGHGFTHAHIVALSQHPA
ALGTVAVTYQHIITALPEATHEDIVGVGKQWSGARALEALLTDAGELRGPPLQLDTGQLVKIAKRGGVTAMEAVHASRNALTG
AP 
LNLTPDQVVAIASNGGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNIGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNGGGKQALETVQRLLAVLCQDH 
GLTPDQVVAIASNGGGKQALETVQRLLAVLCQDH 
GLTPDQVVAIASNNGGKQALETVQRLLAVLCQDH 
GLTPDQVVAIASNIGGKQALETVQRLLAVLCQDH 
GLTPDQVVAIASNNGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNNGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASHDGGKQALETVQRLLPVLCQDH 
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GLTPDQVVAIASNGGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNGGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNIGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNIGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASNNGGKQALETVQRLLPVLCQDH 
GLTPDQVVAIASHDGGKQALESIVAQLSRPDPALAALTNDHLVALACLGGRPAMDAVKKGLPHAPELIRRVNRRIGERTSHRVA
DYAQVVRVLEFFQCHSHPAYAFDEAMTQFGMSGQAGQASPKKKRKVGRADALDDFDLDMLGSDALDDFDLDMLGSDALDD
FDLDMLGSDALDDFDLDMLINYPYDVPDYAS 
 
Supplementary Table S 2.2- Primer sequences for the construction of the luciferase reporter plasmids used 
in this study. TALE binding sites are underlined. Restriction sites are in bold. 
>5’ TALE-Luc-TLT1 
ACTGCTATCTCGAGTACCACACACAAGGCTTAGCGTACCACACACAAGGCTTAGCGTACCACACA
CAAGGCTTAGCGTACCACACACAAGGCTTAGCGATCTGCGATCTAAGTAAGCT 
>5’ TALE-Luc-TLT2 
ACTGCTATCTCGAGTGACCTTTGGATGGTGTAGCGTGACCTTTGGATGGTGTAGCGTGACCTTTGG
ATGGTGTAGCGTGACCTTTGGATGGTGTAGCGATCTGCGATCTAAGTAAGCT 
>5’ TALE-Luc-TLT3 
ACTGCTATCTCGAGTTGTTACACCCTGTGATAGCGTTGTTACACCCTGTGATAGCGTTGTTACACCC
TGTGATAGCGTTGTTACACCCTGTGATAGCGATCTGCGATCTAAGTAAGCT 
>5’ TALE-Luc-TLT4 
ACTGCTATCTCGAGTCACATGGCCCGAGAGTAGCGTCACATGGCCCGAGAGTAGCGTCACATGGC
CCGAGAGTAGCGTCACATGGCCCGAGAGTAGCGATCTGCGATCTAAGTAAGCT 
>5’ TALE-Luc-TLT5 
ACTGCTATCTCGAGTGGCCCGAGAGCTGCATAGCGTGGCCCGAGAGCTGCATAGCGTGGCCCGAG
AGCTGCATAGCGTGGCCCGAGAGCTGCATAGCGATCTGCGATCTAAGTAAGCT 
>5’ TALE-Luc-TLT6 
ACTGCTATCTCGAGTGCATCCGGAGTACTATAGCGTGCATCCGGAGTACTATAGCGTGCATCCGGA
GTACTATAGCGTGCATCCGGAGTACTATAGCGATCTGCGATCTAAGTAAGCT 
>5’ TALE-Luc-TLT7 
ACTGCTATCTCGAGTGCTGACATCGAGCTTTAGCGTGCTGACATCGAGCTTTAGCGTGCTGACATC
GAGCTTTAGCGTGCTGACATCGAGCTTTAGCGATCTGCGATCTAAGTAAGCT 
>5’ TALE-Luc-TLT8 
ACTGCTATCTCGAGTTTCCGCTGGGGACTTTAGCGTTTCCGCTGGGGACTTTAGCGTTTCCGCTGGG
GACTTTAGCGTTTCCGCTGGGGACTTTAGCGATCTGCGATCTAAGTAAGCT 
>5’ TALE-Luc-TLT9 
ACTGCTATCTCGAGTGGCGAGCCCTCAGATTAGCGTGGCGAGCCCTCAGATTAGCGTGGCGAGCC
CTCAGATTAGCGTGGCGAGCCCTCAGATTAGCGATCTGCGATCTAAGTAAGCT 
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>5’ TALE-Luc-TLT10 
ACTGCTATCTCGAGTTATTGAGGCTTAAGCTAGCGTTATTGAGGCTTAAGCTAGCGTTATTGAGGC
TTAAGCTAGCGTTATTGAGGCTTAAGCTAGCGATCTGCGATCTAAGTAAGCT 
>3’ Luc-Rev 
CGTTTTCCCGGTACCAGAT 
 
>5’ LTR-Fwd 
CGACGCGTTGGAAGGGCTAATTTGGTCCCA 
>3’ LTR-Rev 
CTAGCTAGCTTGAGCACTCAAGGCAAGCTTTATTG 
 
Supplementary Table S 2.3- Modified 5’LTR (mLTR) sequences tested in this study. TALE binding sites are 
underlined. LTR substituted sequence are highlighted in yellow. 
>wtLTR 
TGGAAGGGCTAATTTGGTCCCAAAAAAGACAAGAGATCCTTGATCTGTGGATCTACCACACACAAGGCTACTTCCCTGATT
GGCAGAACTACACACCAGGGCCAGGGATCAGATATCCACTGACCTTTGGATGGTGCTTCAAGTTAGTACCAGTTGAACCA
GAGCAAGTAGAAGAGGCCAATGAAGGAGAGAACAACAGCTTGTTACACCCTATGAGCCAGCATGGGATGGAGGACCCG
GAGGGAGAAGTATTAGTGTGGAAGTTTGACAGCCTCCTAGCATTTCGTCACATGGCCCGAGAGCTGCATCCGGAGTACTA
CAAAGACTGCTGACATCGAGCTTTCTACAAGGGACTTTCCGCTGGGGACTTTCCAGGGAGGTGTGGCCTGGGCGGGACTG
GGGAGTGGCGAGCCCTCAGATGCTACATATAAGCAGCTGCTTTTTGCCTGTACTGGGTCTCTCTGGTTAGACCAGATCTGA
GCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGTGCTCAA 
>mLTR1 
CTTTCTACAAGGGACTTTCCGCTGGGGACTTTCCAGGGAGGTGTGGCCTGGGCGGGACTGGGGAGTGGCGAGCCCTCAG
ATGCTACATATAAGCAGCTGCTTTTTGCCTGTACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTA
ACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGTGCTCAA 
>mLTR2 
TGGAAGGGCTAATTTGTCCCAAAAAAGACAAGAGATCCTTGATCTGTGGATCTACCACACACAAGGCTACTTCCTGATTGG
CAGAACTACACACCAGGGCCAGGGATCAGATATCCACTGACCTTTGGATGGTGCTTCAAGTTAGTACCAGTTGAACCAGA
GCAAGTAGAAGAGGCCAATGAAGGAGAGAACAACAGCTTGTTACACCCTATGAGCCAGCATGGGATGGAGGACCCGGA
GGGAGAAGTATTAGTGTGGAAGTTTGACAGCCTCCTAGCATTTCGTCACATGGCCCGAGAGCTGCATGCATATGGCATGC
CTCGAGAAGCTTACCGGTATTTCTACAAGGGACTTTCCGCTGGGGACTTTCCAGGGAGGTGTGGCCTGGGCGGGACTGGG
GAGTGGCGAGCCCTCAGATGCTGCATATAAGCAGCTGCTTTTTGCCTGTACTGGGTCTCTCTGGTTAGACCAGATCTGAGC
CTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGTGCTCAA 
>mLTR3 
TGGAAGGGCTAATTTGGTCCCAAAAAAGACAAGAGATCCTTGATCTGTGGATCTACCACACACAAGGCTACTTCCCTGATT
GGCAGAACTACACACCAGGGCCAGGGATCAGATATCCACTGACCTTTGGATGGTGCTTCAAGTTAGTACCAGTTGAACCA
GAGCAAGTAGAAGAGGCCAATGAAGGAGAGAACAACAGCTTGTTACACCCTATGAGCCAGCATGGGATGGAGGACCCG
GAGGGAGAAGTATTAGTGTGGAAGTTTGACAGCGCCATATGGCATGCCTCGAGAAGCTTACCGGTATGCCATATGGCATG
CCTCGAGAAGCTTACCGGTATTTTCTACAAGGGACTTTCCGCTGGGGACTTTCCAGGGAGGCGTGGCCTGGGCGGGACTG
GGGAGTGGCGAGCCCTCAGATGCTACATATAAGCAGCTGCTTTTTGCCTGTACTGGGTCTCTCTGGTTAGACCAGATCTGA
GCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGTGCTCAA 
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>mLTR4 
TGGAAGGGCTAATTTGGTCCCAAAAAAGACAAGAGATCCTTGATCTGTGGATCTACCACACACAAGGCTACTTCCCTGATT
GGCAGAACTACACACCAGGGCCAGGGATCAGATATCCACTGACCTTTGGATGGTGCTTCAAGTTAGTACCAGTTGAACCA
GAGCAAGTAGAAGAGGCCAATGAAGGAGAGAACAACAGCTTGTTACACCCTATGAGCCAGCATGGGATGGAGGACCCG
GAGGGAGAAGTATTAGTGTGGAAGTTTGACAGCTTTCTACAAGGGACTTTCCGCTGGGGACTTTCCAGGGAGGCGTGGCC
TGGGCGGGACTGGGGAGTGGCGAGCCCTCAGATGCTACATATAAGCAGCTGCTTTTTGCCTGTACTGGGTCTCTCTGGTT
AGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGTGCT
CAA 
>mLTR5 
TGGAAGGGCTAATTTGGTCCCAAAAAAGACAAGAGATCCTTGATCTGTGGATCTACCACACACAAGGCTACTTCCCTGATT
GGCAGAACTACACACCAGGGTCAGGGATCAGATATCCACTGACCTTTGGATGGTGCTTCAAGTTAGTACCAGTTGAACCA
GAGCAAGTAGAAGAGGCCAATGAAGGAGAGAACAACAGCTTGTTACACCCTATGAGCCAGCATGGGATGGAGGACCCG
GAGGGAGAAGTATTAGTGTGGAAGTTTGACAGCGCATGTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCTCTC
TGGCTAACTAGGGAACCCAGCTTTCTACAAGGGACTTTCCGCTGGGGACTTTCCAGGGAGGTGTGGCCTGGGCGGGACTG
GGGAGTGGCGAGCCCTCAGATGCTACATATAAGCAGCTGCTTTTTGCCTGTACTGGGTCTCTCTGGTTAGACCAGATCTGA
GCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGTGCTCAA 
 
Supplementary Table S 2.4- Primer sequences for the construction of the modified luciferase reporter 
plasmids used in this study. Restriction sites are in bold. 
>5’ U3-Fwd 
CGACGCGTAGGCCTCCACCTGGGTC 
>3’ R-Rev 
CTAGCTAGCTTGAGCACTCAAGGCAAGCTTTATTG 
>5’ -115 U3-Fwd 
TTTCTACAAGGGACTTTCCGCTGG 
 
>3’ -455 U3-Rev 
CCAGCGGAAAGTCCCTTGTAGAAAGCCTTTCCTGGTGTAAGTAGAACTGG 
 
>3’ -147/-115 U3-Rev 
CCAGCGGAAAGTCCCTTGTAGAAATACCGGTAAGCTTCTCGAGGCATGCCATATGCATGCAGCTCT
CGGGCCAT 
 
>3’ -183/-115 U3-Rev 
CCAGCGGAAAGTCCCTTGTAGAAAATACCGGTAAGCTTCTCGAGGCATGCCATATGGCATACCGGT
AAGCTTCTCGAGGCATGCCATATGGCGCTGTCAAACTTCCACACTAATACTTCTCC 
 
>3’ -183 U3-Rev 
CCAGCGGAAAGTCCCTTGTAGAAAGCTGTCAAACTTCCACACTAATACTTCTCC 
 
>3’ -183/-115 TAR U3-Rev 
CCAGCGGAAAGTCCCTTGTAGAAAGCTGGGTTCCCTAGTTAGCCAGAGAGCTCCCAGGCTCAGATC
TGGTCTAACCAGAGAGACCCACATGCGCTGTCAAACTTCCACACTAATACTTCTCC 
 
>5’ U5-Fwd 
CAATAAAGCTTGCCTTGAGTGCTCAAAGTAGTGTGTGCCCGTCTGTT 
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>3’ U5-Rev 
TTCCGCGGCCGCTATGGCCGACGTCGACGGATCCGCCCGGGTGCTACTACTAATGC 
Supplementary Table S 2.5- Primer sequences for the construction of the HIV suicidal lentivectors used in 
this study. Restriction sites are in bold. 
>5’ FLuc-Fwd  
ACGCGTCGACATGGAAGACGCCAAAAACATAAAGAAAGG 
>3’ FLuc-Rev  
CTAGTCTAGATTACACGGCGATCTTTCCGCC 
>5’ E2C-Fwd  
CGCGGATCCGTCGACGTCGCCACCATGGATAGCACT 
>3’ E2C-Rev  
CTAGTCTAGAGCTAGCGCTACTGGAACAGGTGGTGGC 
>5’ WPRE-Fwd  
TCCAGTAGCGCTAGCTCTAGAATTCGATATCAAGCTTATCGATAATCAACCTCT 
>3’ WPRE-Rev  
GGGTACACTTACCTGGTACCTGCGGGGAGGCGGC 
>5’ DTA-Fwd  
ACGCGTCGACATGGGCGCTGATGATGTTGTTG 
>3’ DTA-Rev  
CTAGTCTAGATTAGAGCTTTAAATCTCTGTAGGTAGTTTGTCC 
>5’ LFN-Fwd  
ACGCGTCGACATGGCGGGCGGTCATGG 
>3’ LFN-Rev  
CTAGTCTAGATCAGGATAGATTTATTTCTTGTTCGTTAAATTTATCCATGTAATTAAAAG 
>5’ RTA-Fwd  
ACGCGTCGACATGATCTTCCCCAAGCAGTACCCTATC 
>3’ RTA-Rev  
CTAGTCTAGATCAAAACTGGCTAGAGGGGGG 
>5’ SLO-Fwd  
ACGCGTCGACATGCATCATCATCATCATCATGAATCGAACAAACA 
>3’ SLO-Rev  
CTAGTCTAGACTACTTATAAGTAATCGAACCATATGGGCTCA 
Supplementary Table S 2.6- IC50 values for HDAC inhibitors used in this study. Values are presented relative 
to HDACs 1-3, 6 and 8. Data provided by Merck Research Laboratories.  
 HDAC IC50 (µM) 
 HDAC1 HDAC2 HDAC3 HDAC6 HDAC8 
SAHA 0.004 0.011 0.003 0.002 1 
MRK-1 0.0129 0.0965 0.0449 5.4 0.030 
MRK-11 0.0789 0.4597 0.1546 0.0057 0.0045 
H1/2 0.0083 0.0465 4.8 >50* >50* 
 
*Highest concentration tested
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Supplementary Table S2.7. Sequence conservation of the TALE transcription factor binding sites across HIV-1 subtype B strains. Data based on 2014 edition of the 
HIV Sequence Database (http://hiv-web.lanl.gov). Dashes indicate sequence identity between subtype strains. Dots indicate gaps in the HIV genome sequence. 
 
 TLT5 TLT6 TLT7 TLT8 
HIV strain TGGCCCGAGAGCTGCA TGCATCCGGAGTACTA TGCTGACATCGAGCTT TTTCCGCTGGGGACTT 
B.FR.83.HXB2_LAI_IIIB_BRU.K03455 ---------------- ---------------T ---------------- ---------------- 
B.AU.86.MBC200.AF042100 ---------------- ---------------- --A----C-------- ---------------- 
B.AU.87.MBC925.AF042101 ---------------- ---------------- --------G------- ---------------- 
B.AU.95.C24.AF538304 -----AA--------- ---------------- ---------T------ ---------------- 
B.BR.02.02BR011.DQ358809 -----------AAA-- AA-------------- --------G----T-- ---------------- 
B.CN.02.02HNsc11.DQ007903 -----A---------- ---------------- -------------T-- ------T--------- 
B.CN.05.05CNHB_hp3.DQ990880 -----------AAA-- AA-----T----T--- --------CT-----A ---------------- 
B.ES.89.U61.DQ854716 A------------A-- -A-------------- ---------------- ---------------- 
B.GB.83.CAM1.D10112 -----------AA--- A-----------T--- ---------------- ---------------- 
B.GB.86.GB8_46R.AJ271445 -------C--A-C--- C-----------TT-- -----------GAG-- ---------------- 
B.GB.x.MANC.U23487 ---------------- ---------------- --------GGC----- --------A------- 
B.JP.00.DR2508.AB289588 -----A---------- ----------T----- -----------.AG-- ---------------- 
B.JP.04.DR5913.AB480696 -------C-----A-- -A----------TT-- ---------------- ---------------- 
B.JP.05.DR6538.AB287363 A-----------AA-- AA----------TT-- -------------T-- ---------------- 
B.JP.98.DR1120.AB480698 -----------AAA-- AA----------TT-- -------------A-- ---------------- 
B.KR.03.03KGS5.JQ316132 -----------AAA-- AA-------------- -------------AAC ---------------- 
B.KR.04.04LHS6.AY839827 .....----------- ---------------- --------C------- ---------------- 
B.KR.05.05YJN2.JQ316134 -A---------AAA-- AA-------------- --------CT------ ---------------- 
B.NL.96.H434_42_A1.AY970948 ---------------- ---------------- ---------------- ---------------- 
B.TW.94.TWCYS_LM49.AF086817 GA-----------A-- -A-------------- --------Y------- -------.T------- 
B.US.00.ES1_20.EF363123 ---------------- ---------------T ---------------- ---------------- 
B.US.01.REJO_TF1.JN944911 -----------AA--- A--------------T --------C------- --------.------- 
B.US.04.ES4_24.EF363124 ---------------- ---------------- ---------------- ---------------- 
B.US.06.CH106_TF1.JN944897 -A---------AAA-- AA----------T--- ---------------- ---------------- 
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B.US.09.C1P.GU733713 -A---------AAA-- AA-------------T --------C--CT--C ---------------- 
B.US.10.VC1.JN397364 -A---------AAA-- AA-------------- ---------------- ---------------- 
B.US.11.CP10_3A.KF384798 ---------------- ----------T----- --------G------- ---------------- 
B.US.83.5018_83.AY835777 ---------------- ---------------- ---------------- ---------------- 
B.US.84.5019_84.AY835779 ---------------- ---------------- ---------------- ---------------- 
B.US.85.5077_85.AY835769 ---------------- ---------------- ---------------- ---------------- 
B.US.86.5084_86.AY835775 ---------------- ---------------- ---------------- ---------------- 
B.US.87.5113_87.AY835758 ---------------- ---------------- ---------------- ---------------- 
B.US.88.5160_88.AY835763 ---------------- ---------------- ---------------- ---------------- 
B.US.89.P896_89_6.U39362 ---------------- ---------------T --------CT-----A ---------------- 
B.US.90.WEAU160_GHOSH.U21135 -A-------------- ---------------T -------------T-- -----A---------- 
B.US.91.5048_91.AY835761 ---------------- ---------------- ---------------- ---------------- 
B.US.94.5082_94.AY835773 ---------------- ---------------- ---------------- ---------------- 
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3.1. ABSTRACT 
Despite all efforts to develop an effective treatment capable of eradicating HIV-1 from 
the infected patient, a cure has not been achieved up to this day. While highly active anti-
retroviral therapy (HAART) targets viral replication, latent non-replicative HIV-1 is able to 
escape this treatment. Strategies that could reactivate HIV-1 latent cells and expose cellular 
reservoirs to combined HAART and host immune system have been proposed for HIV-1 
eradication. Pharmacological approaches tested so far were unsuccessful and led to severe side-
effects in the patients mainly due to systemic immune activation. Here, we present an alternative 
approach through protein delivery of cell-penetrating zinc-finger activators (CPP-ZFA) for 
direct translocation and stimulation of HIV latent cells. CysHis2 zinc-fingers in fusion with 
VP64 activation domain were engineered to specifically target the HIV 5’LTR promoter and 
induce viral transcription. A single zinc-finger activator (PBS1-VP64) was capable of 
reactivating viral expression from a cell model of HIV latency. Following protein delivery, this 
CPP-ZFA was able to efficiently transfect and stimulate HIV latent expression. When fused 
with multiple positively charged nuclear localization signal (NLS) repeats, the entry capability 
and reactivation potency of this artificial transcription factor were dramatically increased. On 
the other hand, we show that short-term protein delivery of a single CPP-ZFA is able to 
efficiently induce sustained gene expression in HIV-1 latent cells. Our work demonstrates that 
protein delivery of zinc-finger activators is a potential and safer alternative to promote 
reactivation of HIV-1 latent cells  
 
Keywords: HIV latency / Zinc-finger activators / Cell-penetrating peptides / Protein delivery 
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3.2. INTRODUCTION 
The HIV-1 infection global pandemic is still one of the major concerns in public 
health. Development of antiretroviral drugs targeting key steps of HIV-1 replication 
dramatically inhibited progression of infection while extending lifespan of infected patients 
[30–32]. However, antiretroviral therapy does not provide a cure to patients, requiring 
continuous administration throughout their life course and often associated with toxic side 
effects [29]. Inability of antiretroviral therapy to eradicate HIV infection is generally due to 
existence of transcriptionally silent HIV reservoirs that persist in patients but re-emerge once 
the treatment is interrupted [36]. HIV latent reservoirs can be found mostly in resting CD4+T 
cells that harbor integrated provirus but suppress viral expression due to its non-permissive 
transcriptional environment [37]. The absence of viral replication allows these latent reservoirs 
to escape antiretroviral action or host immune response, representing the major barrier towards 
a cure for HIV infection.  
Considering the mechanisms behind HIV latency, a “shock and kill” strategy has been 
proposed to eradicate latent reservoirs. This approach attempts to activate latent HIV expression 
and expose reservoirs to the immune response or cytopathic effects caused by viral replication 
to clear the infected cells [72]. Initial attempts were based on pharmacological drugs that 
manipulated the transcriptional landscape surrounding latent integrated provirus by engaging 
cell signaling pathways, using monoclonal antibodies, [74] cytokines [76,77] or agonists of 
protein kinase C (PCK) activation [79–81]; or altering epigenetic landmarks through inhibitors 
of histone deacetylases (HDACs) [82,83] or DNA methyltransferases [62,63]. Despite evidence 
that these drugs can induce latent viral expression, none of these strategies were able to 
significantly reduce HIV reservoirs, and some of them were associated with undesirable and 
toxic generalized immune activation [42,52], highlighting the need for alternative strategies to 
induce latent HIV expression. 
Despite their silent nature that limits development of targeted strategies, HIV latent 
cells share a trait marker resultant from the provirus integration, that although silenced leaves 
a scar in the cell genome. Emergence of DNA-binding domains, including zinc-fingers [243], 
transcription activator-like effector (TALE) [391] proteins, or more recently the CRISPR-Cas9 
system [251] have enabled the generation of genome engineering tools that can directly target 
specific sites in the human genome and modify its sequence or modulate the transcriptional 
environment [278]. Engineered zinc-finger domains were the first to be successfully 
implemented for genome engineering applications [242]. The best characterized Cys2His2 
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motif is composed of approximately 30 amino acids arranged in a ββα conformation, with 
residues within α-helix at position -1, 3 and 6 making contact with three base-pairs (triplets) 
[253]. Due to their versatility, zinc-fingers were assembled to effector domains and repurposed 
for generation of targeted transcriptional activators or repressors [260,442], epigenetic 
modulators  [326,443], and site-directed nucleases [444,445] or recombinases [446,447]. 
Zinc-finger engineering studies have also gained relevance to develop antiviral 
strategies targeting HIV infection. Development of site-directed zinc-finger nucleases have 
proven effective at inhibiting viral infection by directly removing integrated provirus from 
infected cells [372–374] or turning autologous cells resistant to HIV entry through knockout of 
major HIV co-receptors [289,357,362,364], the latter culminating in clinical studies [358]. 
Inhibition of HIV transcription through zinc-finger based transcriptional repressors [343–346] 
have also proven effective at shutting down HIV replication.  
Given the nature of silent HIV reservoirs, targeted transcription activators have a 
particular interest to reverse HIV-1 latency. We [448] and others [429–432,434–436,449] have 
demonstrated the potential of site-directed artificial transcription factors to recognize the HIV 
promoter and stimulate latent HIV expression, providing a targeted strategy for the “shock and 
kill” approach. Interestingly, zinc-fingers were found to possess a natural ability to cross the 
anionic cellular membrane, owing to the positive net charge involving these DNA-binding 
domains [243]. This cell penetrating capacity grants zinc-fingers a great potential for direct 
protein delivery that could be useful to transport protein cargo [450] but also make precise 
genome modifications [263,264]. 
Herein, we describe a novel approach to target HIV latent cells by direct protein 
delivery of cell-penetrating zinc-finger activators (CPP-ZFA). We show proof-of-concept of an 
engineered CPP-ZFA that can directly penetrate HIV latent cells without the need of any carrier, 
and target the 5’LTR promoter to induce viral expression. Our work demonstrate that 
engineered zinc-finger activators are a promising tool to target HIV latency and its innate cell-
penetrating ability could overcome some of the limitations associated with delivery of these 
artificial transcription factors to target cells. 
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3.3. MATERIALS AND METHODS 
3.3.1. Zinc-finger activator constructs 
Design of HIV-targeted polydactyl zinc-fingers activators (ZFA) was performed at 
Zinc-finger Tools web server (http://www.zincfingertools.org) [451]. Zinc-finger arrays were 
generated by modular assembly [452]. ANN [256], GNN [254,255] or CNN [257] binding zinc-
finger modules were isolated through XmaI/SpeI digestion and cloned into AgeI/SpeI 
restriction sites of pSCV [452] vector until generation of 4-finger or 6-finger arrays. ZFAs were 
generated by cloning of the zinc-finger arrays into XhoI/SpeI restriction sites of pAart-VP64 
(pAart6) [453] to generate ZFA constructs pZLT4A through pZLT6B and pAart4. Previously 
designed HIV-targeted zinc-fingers repressors [344,346] were digested and cloned into 
XhoI/SpeI restriction sites of pAart6 to generate ZFA expression constructs pHLTR1 through 
pPBS3.Correct construction of each plasmid was verified by sequence analysis (Table S3.1). 
pET28b-PBS1-VP64 was generated by PCR amplifying PBS1-VP64 from pPBS1 using 
primers 5’ ZF-Fwd 3’ VP64-Rev and cloning into NdeI/SacI restriction sites of pET28b-
CCR5R-1NLS [264]. pET28b-3NLS-PBS1-VP64 and pET28b-3NLS-Aart6-VP64 were 
generated by respectively PCR amplifying PBS1-VP64 from pPBS1 and Aart6-VP64 from 
pAart6 using primers 5’ 3NLS-ZF-Fwd and 3’ VP64-Rev. PCR products were digested with 
SalI and SacI and cloned into XhoI/SacI restriction sites of pET28b-CCR5R-1NLS. Correct 
construction of each plasmid was verified by sequence analysis (Table S3.2). Primer sequences 
are provided in Table S3.3. 
3.3.2. Luciferase reporter constructs 
The pZFA luciferase reporter vectors were constructed through PCR by amplifying the 
luciferase gene from pGL3-Basic (Promega, Madison, WI, USA) using the primers 5’ ZF-Luc-
ZLT4A through PBS3, which contained four direct repeats of each zinc-finger binding site and 
3’ Luc-Rev. PCR products were digested and cloned into the XhoI/SphI restriction sites of 
pGL3-Basic to generate pGL3-ZF-ZLT4A through PBS3. The HIV-1 LTR-PBS reporter 
plasmid was constructed by PCR amplifying the 5’LTR (U3-R-U5) promoter and PBS region 
from pNL4-3 (NIH AIDS Reagents) [399] using the primers 5’ LTR-PBS-Fwd and 3’ LTR-
PBS-Rev. PCR product was digested and cloned into the MluI/NheI restriction sites of pGL3-
Basic to generate pGL3-LTR-PBS. Primer sequences are provided in Table S3.3. 
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3.3.3. Cell culture 
Human embryonic kidney 293T (HEK293T) (American Type Culture Collection; 
ATCC) cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Life 
Technologies, Carlsbad, CA, USA) supplemented with 10% (v/v) fetal bovine serum (FBS; 
Gibco, Carlsbad, CA, USA), 2 mM L-glutamine and 1% (v/v) antibiotic-antimycotic (Anti-
Anti; Gibco, Carlsbad, CA, USA). Jurkat E6-1 and J-Lat clones (NIH AIDS Reagents) were 
cultured in RPMI-1640 medium (Life Technologies, Carlsbad, CA, USA) supplemented with 
10% (v/v) FBS, 2 mM L-glutamine and 1% (v/v) Anti-Anti. Cells were maintained at 37 °C in 
a humidified atmosphere of 5% CO2. 
3.3.4. Luciferase assays 
Luciferase assays were performed as previously described [448]. Briefly, HEK293T 
cells were seeded onto 96-well plates at a density of 4 x 104 cells per well. At 16-24 h after 
seeding, cells were transfected with 200 ng of pZFA constructs, 5 ng of pGL3-ZFA binding site 
reporters and 1 ng of pRL-CMV (Promega, Madison, WI, USA) using Lipofectamine 2000 
(Life Technologies, Carlsbad, CA, USA) according to the manufacturer’s instructions. At 48 h 
after transfection, cells were washed once with Dulbecco’s PBS (DPBS; Life Technologies, 
Carlsbad, CA, USA) and lysed with Passive Lysis Buffer (Promega, Madison, WI, USA). 
Luciferase expression was measured with the Dual-Luciferase Reporter Assay System 
(Promega, Madison, WI, USA) using a Veritas Microplate Luminometer (Turner Biosystems, 
Sunnyvale, CA, USA) according to the manufacturer’s instructions. Normalized luciferase 
activity was determined by dividing firefly luciferase activity by Renilla luciferase activity.  
3.3.5. ZFA expression analysis 
For expression analysis of designed zinc-finger activators, we seeded HEK293T cells 
onto a 24-well plate at a density of 2 x 104 cells per well. Twenty-four hours after seeding, cells 
were transfected with 500 ng of indicated ZFA expression constructs or pcDNA3.1 (Life 
Technologies, Carlsbad, CA, USA) backbone vector by Lipofectamine 3000 (Life 
Technologies, Carlsbad, USA), according to manufacturer instructions. At 48 h after 
transfection, cells were harvested and lysed with RIPA buffer (25 mM Tris-HCl pH 7.6, 150 
mM NaCl, 1% NP-40, 1% sodium deoxycholate and 0.1% SDS) supplemented with EDTA-
free Protease Inhibitor Cocktail Tablets (Roche, Basel, Switzerland). The Bio-Rad Protein 
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Assay Kit (Bio-Rad, Hercules, CA, USA) was used to determine protein concentration 
according to the manufacturer’s instructions. Zinc-finger activator expression was analyzed by 
4-12% SDS-PAGE (National Diagnostics, Atlanta, GA, USA). Samples were transferred onto 
a 0.2 m nitrocellulose membrane as described [403] and detected with SuperSignal West 
Femto (Thermo Fischer, Waltham, MA, USA) and Amersham Hyperfilm ECL (GE Healthcare, 
Little Chalfont, UK) chemiluminescence film. Zinc-finger activators were detected by 
horseradish peroxidase-conjugated anti-HA monoclonal antibody (Clone 3F10; Roche, Basel, 
Switzerland). Vinculin was used as an internal control and detected using a mouse anti-Vinculin 
monoclonal antibody (Clone 7F9; Santa Cruz Biotechnology, Dallas, TX, USA) and 
horseradish peroxidase-conjugated goat anti-mouse IgG antibody (Bio-Rad, Hercules, CA, 
USA). 
3.3.6. J-Lat ZFA nucleofection 
Episomal transfection of zinc-finger activators in J-Lat cells was performed by plasmid 
nucleofection as previously described [448]. Briefly, we seeded J-Lat cells onto a 10-cm dish 
at a density of 1 x 105 cells per mL. After 48 hours, 2 x 105 cells per transfection were 
centrifuged at 100 g for 10 min at room temperature and resuspended in Nucleofector Solution 
SE (Lonza, Basel, Switzerland) with 2 µg of indicated pcDNA ZF activator construct. Cells 
were transferred to 16-well Nucleocuvette (Lonza, Basel, Switzerland) and electroporated with 
by a 4D-Nucleofector System (Lonza, Basel, Switzerland) selecting the program CL-120. At 
48 h after transfection, cells were washed twice with DPBS (Life Technologies, Carlsbad, CA, 
USA) and GFP expression was evaluated by flow cytometry (BD LSR II Flow Cytometer 
System; BD Biosciences, Franklin Lakes, NJ, USA). For each sample, 10,000 live events were 
collected, and data was analyzed using FlowJo (Tree Star, Inc., San Carlos, CA, USA). 
3.3.7. CPP-ZFA protein expression and purification 
Expression and purification of cell-penetrating zinc-finger activators was adapted from 
a previously optimized protocol [264]. Zinc-finger pET28b expression constructs were 
transformed into chemically competent E. Coli BL21(DE3) strain (Merck KGaA, Darmstadt, 
Germany). Overnight culture from a single colony was inoculated into 500 mL of LB media 
supplemented with 200 mM NaCl, 50 µg/ml kanamycin, 100 µM ZnCl2 and 0.2% glucose. Cell 
culture was grown at 37 °C until OD600 reached 0.5 and then at room temperature until OD600 
reached 0.8. Protein expression was induced with 1 mM isopropyl-β-D-thiogalactopyranoside 
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(IPTG; Thermo Fischer, Waltham, MA, USA) for 4 hours at room temperature. Cells were 
pelleted by centrifugation at 12,000 g for 5 min and stored at -20 °C until purification protocol.  
Purification of Zinc-finger activators was carried by resuspending cell pellet in 20 mL 
of ZF binding buffer (20 mM HEPES pH 8.0, 2 M NaCl, 1 mM MgCl2, 100 µM ZnCl2 and 10% 
glycerol). This solution was supplemented with 1 mM β-mercaptoethanol, protease inhibitors 
(Roche, Basel, Switzerland) and 0.1% Triton X-100. Cells were lysed by sonication (10 min, 
50% output, pulse on) and centrifuged at 12,000 g for 60 min at 4 °C. The supernatant was 
cleared by running through a 0.45 µM low protein binding filter. Cell lysate was transferred to 
a His GraviTrap flow gravity column (GE Healthcare, Little Chalfont, United Kingdom).  
Column was washed with 10 mL of 5 mM imidazole (Merck KGaA, Darmstadt, Germany) and 
with 5 mL of 35 mM imidazole in ZF binding buffer. ZF protein elution was performed with 
300 mM imidazole in ZF binding buffer. Ten fractions of 0.5 mL eluted proteins were collected 
and supplemented with 100 mM L-Arginine. Fractions containing majority of eluted protein 
were selected, combined and buffer-exchanged to ZF storage buffer (20 mM HEPES pH 8.0, 
500 mM NaCl, 1 mM MgCl2, 100 µM ZnCl2 and 10% glycerol and 100 mM L-Arg) using PD-
10 desalting columns (GE Healthcare, Little Chalfont, United Kingdom). ZF proteins were then 
concentrated using an Amicon Ultra-15 Centrifugal Filter Unit (Merck KGaA, Darmstadt, 
Germany) and stored at -80 °C. Purified CPP-ZFA batches were analyzed by 4-12% SDS-
PAGE (National Diagnostics, Atlanta, GA, USA) and stained using BlueSafe (NzyTech, 
Lisboa, Portugal). 
3.3.8. CPP-ZFA binding analysis 
 Assessment of zinc-finger activator proteins binding to target sites was performed by 
enzyme-linked immunosorbent assay (ELISA). Briefly, ELISA plates were coated with 400 ng 
streptavidin per well overnight at 4 ºC. After rinsing with ddH2O, wells were incubated with 25 
ng biotin-marked oligonucleotides containing ZFA target site for one hour at 37 ºC. Plates were 
rinsed with ddH2O and blocked with 3% BSA in ZNBA buffer (20 mM Tris-HCl pH 7.4, 90 
mM KCl, 1 mM MgCl2, 100 µM ZnCl2) for one hour at 37 ºC. Serial dilutions of CPP-ZFA 
protein were prepared starting from 125 nM in ZF storage buffer supplemented with 1% BSA 
and 3 µg herring sperm DNA. Plates were incubated with protein dilutions for 2 hours at room 
temperature. Following washing with DPBS-Tween20 0.1%, wells were probed with anti-HA 
monoclonal antibody (Clone 3F10; Roche, Basel, Switzerland) in 1% BSA/ZF storage buffer 
for 30 min at room temperature. Following washing with ddH2O, plates were developed with 
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ABTS (Calbiochem Merck KGaA, Darmstadt, Germany) conjugated with H2O2  for 15 minutes 
and analyzed by measuring Abs (405/492 nm) on Tecan Infinite M-200 plate reader. 
3.3.9. J-Lat CPP-ZFA protein treatment 
J-Lat cells were seeded 24 hours before protein treatment in 24-well plates with 2 x 105 
cells per well. After 24 hours, cells were centrifuged at 300 g for 5 min at room temperature. 
Zinc-finger activators were diluted in supplemented RPMI medium at final concentration 
indicated. J-Lat cells were resuspended in zinc-finger protein solution and incubated at 37ºC 
and 5% CO2 atmosphere for 90 minutes, unless otherwise indicated. After protein treatment, 
cells were washed twice with supplemented RPMI media and then moved to 37ºC and 5% CO2 
atmosphere. For each experiment, cells were also incubated with ZF storage buffer as mock 
control.  
For analysis of HIV activation, cells were collected 48 hours after protein treatment, 
washed twice with DPBS (Life Technologies, Carlsbad, CA, USA) and GFP expression was 
evaluated by flow cytometry (BD LSR II Flow Cytometer System; BD Biosciences, Franklin 
Lakes, NJ, USA). For each sample, 10,000 live events were collected, and data was analyzed 
using FlowJo (Tree Star, Inc., San Carlos, CA, USA). 
3.3.10. CPP-ZFA cell transduction analysis 
Evaluation of CPP-ZFA cell entry by flow cytometry was performed through protein 
treatment of Jurkat cells with FITC-conjugated CPP-ZFA for 90 minutes. PBS1-VP64 and 
3NLS-PBS1-VP64 were stained using the FluoReporter FITC Protein Labeling Kit (Thermo 
Fischer, Waltham, MA, USA), according to manufacturer’s instructions. Jurkat cells were 
treated with increasing concentrations of PBS1-VP64 and 3NLS-PBS1-VP64 following the J-
Lat CPP-ZFA protein treatment protocol described above in section 3.3.8. Cells were collected 
and washed twice with Trypsin 0.25%-EDTA (GE Healthcare, Little Chalfont, UK) and 
resuspended in DPBS (Life Technologies, Carlsbad, CA, USA). FITC positive cells were 
evaluated by flow cytometry (BD LSR II Flow Cytometer System; BD Biosciences, Franklin 
Lakes, NJ, USA). For each sample, 10,000 live events were collected, and data was analyzed 
using FlowJo (Tree Star, Inc., San Carlos, CA, USA). 
Evaluation of 3NLS-PBS1-VP64 cell entry kinetics was assessed by western blot 
following protein treatment of J-Lat cells with 2 µM of purified protein, as described in section 
3.3.8. Cells were collected at indicated timepoints, washed twice with Trypsin/EDTA (GE 
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Healthcare, Little Chalfont, UK) and lysed with RIPA buffer (25 mM Tris-HCl, 150 mM NaCl, 
1% NP-40, 1% sodium deoxycholate and 0.1 % SDS, pH 7.6) supplemented with EDTA-free 
Protease Inhibitor Cocktail Tablets (Roche, Basel, Switzerland). Protein quantification and 
3NLS-PBS1-VP64 detection by western blot was performed as described above in section 
3.3.4. 
3.3.11. Statistical analysis 
Statistical analyses for all experiments were performed from three independent 
experimental replicates (n = 3) unless otherwise indicated. Two-tailed Student’s t-test was used 
for paired and unpaired samples (Prism Software 5.0, GraphPad Software). 
3.4. RESULTS 
3.4.1. Design of zinc-finger transcription factors targeting HIV-1 promoter 
To reactivate latent HIV expression from viral reservoirs, we designed zinc-finger 
activators (ZFA) targeting the 5’ long terminal repeat (5’LTR) promoter. Based on our previous 
experience with TALE activators [448], we concentrated on the “hot spot” region of the HIV 
promoter located from -200 bp from the transcription start site (TSS). We submitted this region 
to Zinc-finger Tools web server, an automated design tool to obtain the best zinc-finger domains 
from any given target sequence, based on a experimentally characterized zinc-finger database 
[451]. To enforce binding specificity, we selected zinc-finger matches mainly composed of 
GNN and ANN triplets, restricted at most to one CNN triplet (Table 3.1) [454]. We designed 
4-finger (ZLT4A through ZLT4D) and 6-finger (ZLT6A and ZLT6B) domains to target HIV 
promoter (Fig. 3.1A). While shorter 4-finger (12-bp targets) domains may improve binding 
activity [455], 6-finger (18-bp targets) domains confer genome-wide specificity of target [259].  
Table 3.1 - Representation of zinc-fingers designed in this study to target HIV promoter. 
ZF  Positiona 
Predicted target 
sequence (5'-3') 
ZF α-Helix sequenceb 
   F6 F5 F4 F3 F2 F1 
ZLT4A -163 GGC CCG AGA GCT   DPGHLVR RNDTLTE QLAHLRA TSGELVR 
ZLT4B -134 AAG ACT GCT GAC   RKDNLKN THLDLIR TSGELVR DPGNLVR 
ZLT4C -52 GTG GCG AGC CCT   RSDELVR RSDDLVR ERSHLRE TKNSLTE 
ZLT4D -31 CAT ATA AGC AGC   TSGNLTE QKSSLIA ERSHLRE ERSHLRE 
ZLT6A -146 CGG AGT ACT ACA AAG ACT RSDKLTE HRTTLTN THLDLIR SPADLTR RKDNLKN THLDLIR 
ZLT6B -140 ACT ACA AAG ACT GCT GAC THLDLIR SPADLTR RKDNLKN THLDLIR TSGELVR DPGNLVR 
aPosition relative to transcription start site of HIV-1 promoter. 
bAminoacids from position -1 to +6 relative to zinc-finger α-Helix are shown.  
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In addition, we explored previously designed zinc-fingers against HIV 5’LTR promoter 
(HLTR1, HLTR3 and HLTR6) or primer binding site (PBS) region (PBS1, PBS1a and PBS3) 
(Fig. 3.1A; Table 3.2). These zinc-fingers demonstrated proof-of-principle of HIV inhibition 
when fused to a transcription repressor domain [344,346].  
Table 3.2 - Representation of previously designed zinc-finger to target HIV promoter.  
Zinc-fingers reported in  [344,346]. 
ZF  Positiona 
Predicted target 
sequence (5'-3') 
ZF α-Helix sequenceb 
   F6 F5 F4 F3 F2 F1 
HLTR1 +23 TGG GTG ACG AAT TCG GAG RSDNLVR TSGELVR QSSNLAS QSGDLRR RSDVLVR TSGHLVR 
HLTR3 -80 GGA GGC GTG GCC TGG GCG QSSHLVR DPGHLVR RSDVLVR DCRDLAR RSDHLTT RSDDLVR 
HLTR6 +118 ACA CTG AGA CCA TTG ATC QRHSLTE TSGSLVR DKKDLTR QLAHLRA DPGALVR SPADLTR 
PBS1 +167 AAA TCT CTA GCA GTG GCG QRANLRA RGGWLQA QRHSLTE QSGDLRR RSDVLVR RSDDLVR 
PBS1a
c
 +160 
GTG TGG AAA atctcta 
GCA GTG GCG 
RSDVLVR RSDHLTT QRANLRA QSGDLRR RSDVLVR RSDDLVR 
PBS3 +180 TGG CGC CCG AAC AGG GAC RSDHLTT HTGHLLE RNDTLTE DSGNLRV RSDHLAE DPGNLVR 
         
aPosition relative to transcription start site of HIV-1 promoter. 
bAminoacids from position -1 to +6 relative to zinc-finger DNA-recognition sequence are shown. 
cPBS1a consists in two three-finger modules separated by a long flexible linker (Gly3SerGly4). The F6 to F4 
modules bind the first half site (GTG TGG AAA) and the F3 to F1 modules bind the second half site (GCA GTG 
GCG). Nonbound DNA sequence is indicated by lowercase letters. 
Each zinc-finger protein was fused to VP64 transactivation domain [254] that recruits 
the transcription machinery to induce gene expression [405,406]. ZFA constructs incorporate a 
C-terminal hemagglutinin (HA) tag for protein detection, and an internal nuclear localization 
signal (NLS) sequence between the DNA binding and transactivation domains (Fig. 3.1B; 
Top). Western blot analysis of ZFA expression in HEK293T cells shows expression of all 4-
finger and 6-finger ZFAs designed although with remarkable variance in protein levels among 
some constructs, possibly due to differences in protein conformational stability (Fig. 3.1B; 
Bottom). The amino acid sequence of each protein is presented in Table S1. 
We initially evaluated the potential of each ZFA to specifically induce gene expression, 
using a luciferase reporter assay previously described with TALE activators [398] that correlate 
luciferase expression with the ability of ZFA to recognize its target and stimulate gene 
activation. We constructed luciferase reporter plasmids for each ZFA that contained four direct 
repeats of each binding site to drive firefly luciferase expression (Fig. 3.1C; Top). HEK293T 
cells were transfected with each ZFA construct and its corresponding reporter. We observed 
increased luciferase activation for all ZFA constructs compared to its reporter alone (Fig. 3.1C; 
Bottom). From all designed ZFA, ZLT4D (~1,300-fold), HLTR6 (~1,600-fold), PBS1 (~400-
fold) and PBS1a (~200-fold) expressively enhanced gene activation from their target sites. The 
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remaining ZFA constructs designed induced a modest ~3 to 30-fold gene activation over 
reporter background. Moderate levels of gene activation could only be explained partially by 
low levels of protein expression, as was the case of ZLT6B and HLTR1 activators. This result 
indicates that ZFA binding affinity towards its target site should play a major role in its potential 
for gene activation although we cannot exclude the contribution of the ZFA stability in the 
intracellular environment. 
 
Figure 3.1– Zinc-finger activators (ZFA) designed to target HIV-1 promoter. (A) Schematic illustration of 
zinc-fingers target sites within 5’ long terminal repeat (LTR) promoter and tRNA primer binding site of HIV-1. 
Most relevant endogenous transcription factor binding sites (NF-κB and SP1) are referenced. (B) (Top) Schematic 
representation of ZFA activator expression constructs. ZFA coding sequences are incorporated into a pcDNA 
backbone vector driven by the cytomegalovirus (CMV) promoter. VP64 denotes the tetrameric repeat of the herpes 
simplex virus VP16 transactivation domain, NLS stands for the nuclear localization signal derived from the simian 
virus (SV40) and HA indicates the hemagglutinin A tag. (Bottom) Western blot of 20 µg lysate of HEK293T 
transfected with indicated ZFA constructs. Samples were taken 48 h after transfection and probed with horseradish 
peroxidase-conjugated anti-HA and anti-Vinculin (loading control) antibodies. Mock indicates lysate from 
HEK293T cells transfected with empty pcDNA vector only. (C) (Top) Schematic representation of the luciferase 
reporter system containing four direct repeats of the zinc-finger target sites for each ZFA construct. (Bottom) 
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Fold-activation of luciferase expression after co-transfection of indicated ZFA with luciferase reporter plasmid 
into HEK293T cells. Luciferase expression was normalized to cells transfected with reporter plasmid only 
(Empty). Renilla luciferase expression vector was also co-transfected to normalize for transfection efficiency and 
cell number. Error bars indicate standard deviation of one experiment with three transfection replicates (n = 3; *p 
< 0.05; **p < 0.01; ***p < 0.001; t-test sample vs control (Empty)). 
3.4.2. Zinc-finger activators specifically stimulate latent HIV-1 expression 
In addition to its binding efficacy, the ability of a zinc-finger activator to induce gene 
expression is also connected to the location of its target sequence relative to the transcription 
start site. To evaluate the potential of ZFA to induce HIV transcription from the native 
promoter, we constructed a luciferase reporter driven by the full-length LTR and PBS regions, 
from -455 to +198 relative to TSS. This segment of HIV-1 contains all the essential elements 
that regulate viral gene expression and include all ZFA target sites. We co-transfected 
HEK293T cells with ZFA constructs and the LTR-PBS reporter (Fig. 3.2A). As controls for 
specific target activation of 4-finger and 6-finger ZFA, respective non-targeting Aart4 
(predicted target site: 5’-AGA AAA ACC AGG-3’)  and Aart6 (predicted target site: 5’-ATG 
TAG AGA AAA ACC AGG-3’) ZFA were designed from the previously designed Aart zinc-
finger [256], that in principle should not bind any sequence within the HIV provirus. 
From 4-finger ZFA constructs, none could induce gene activation beyond non-targeting 
Aart4-VP64 control, which induces a 2-fold background luciferase activity, possibly due to 
non-specific activation caused by the presence of VP64 domain. The same effect was observed 
with 6-finger control Aart6-VP64. Within 6-finger ZFA constructs, HLTR6-VP64 (~3-fold) 
and PBS1-VP64 (~4-fold) were able to substantially increase LTR activation over the Aart6 
control (Fig. 3.2A), indicating these as the most potential zinc-finger activators to induce HIV-
1 transcription. Efficient activation of LTR promoter by these ZFA also correlates with their 
ability to stimulate transcription from their target site observed in Fig. 3.1C. However, despite 
their strong ability to induce gene expression, ZLT4D and PBS1a activators were unable to 
induce LTR activation. Interestingly, HLTR3-VP64 activator repressed LTR background 
activity obtained from cells transfected with LTR-PBS reporter alone. This effect is due to 
HTLR3 target overlap with SP1 binding site, that outcompetes this endogenous factor and 
blocks LTR activation, highlighting the importance of zinc-finger location within the HIV 
promoter [344]. Combining different sets of ZFA did not caused a synergistic effect on LTR 
activation (data not shown), as previously demonstrated for TALE activators [448]. 
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We set out to evaluate the potential of ZFA constructs to reactivate latent HIV-1 
expression. For this purpose, latency reactivation was evaluated using the lymphocytic Jurkat-
derived HIV latent cell line (J-Lat). This latency model harbors a full-length integrated HIV-1 
proviral genome containing a GFP gene that serves as a reporter for viral gene expression 
(HIV1-Env-GFP) (Fig. 3.2B). These latent cells do not express integrated provirus unless 
reactivated by a strong stimulus, such as one caused by tumor necrosis factor (TNF)-α [55]. J-
Lat 10.6 clone, which is more sensitive to reactivating stimulus, was nucleofected with 
indicated HLTR6-VP64 or PBS1-VP64 constructs to evaluate HIV-1 expression after detection 
of GFP-positive cells by flow cytometry.  
 
Figure 3.2– Zinc-finger activators target LTR promoter and activate latent HIV-1 expression. (A) (Top) 
Schematic representation of luciferase reporter used to evaluate ZFA activity from the HIV-1 LTR promoter. Full-
length 5’LTR (U3-R-U5) and primer binding site (PBS) regions were placed upstream of firefly luciferase reporter. 
(Bottom) Fold-activation of luciferase expression in HEK293T cells co-transfected with indicated ZFA expression 
constructs and LTR-PBS luciferase reporter. Luciferase expression was normalized to that obtained with 
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transfection of reporter plasmid alone (LTR-PBS). Renilla luciferase expression vector was also co-transfected to 
normalize for transfection efficiency and cell number. Error bars indicate standard deviation of one experiment 
with three transfection replicates (n=3; **p < 0.01; ***p < 0.001; t-test sample vs. control (Aart6)). (B) Percent of 
GFP-positive cells of J-Lat 10.6 cells nucleofected with LTR-targeted HLTR6-VP64 or PBS1-VP64, or non-
specific Aart6-VP64 zinc-finger activators. “J-Lat” indicates non-transfected J-Lat 10.6 cells. GFP-positive cells 
were measured by flow cytometry at 48 hours after nucleofection. Dot plots are representative of a single 
experiment from three independent replicates. 
Contrary to what observed with luciferase episomal assays in HEK293T, HLTR6-VP64 
nucleofection lead to minor (~5% GFP-positive cells) reactivation of latent J-Lat 10.6 
population, even lower to that observed with non-specific Aart6-VP64 control (~10%). 
However, PBS1-VP64 was able to significantly reactivate (~30% GFP-positive cells) latent 
population (Fig. 3.2B), consistent with its ability to stimulate LTR transcription observed when 
co-transfected with luciferase reporter driven by HIV promoter (Fig. 3.2A). Overall, these 
results indicate that PBS1-VP64 activator can specifically activate latent HIV expression from 
the LTR promoter. This zinc-finger targets the tRNA primer binding site region, being 
extremely conserved across distinct HIV subtypes, with full conservation in 80-90% of HIV-1 
strains among subtypes of major (M) group (Fig. S3.1), including the most dominant subtype 
B (prevalent in the Americas, Western Europe, Japan and Australia) and subtype C (prevalent 
in Southern and Eastern Africa, China and India). PBS1 zinc-finger activator was selected for 
subsequent studies on ZFA protein delivery to activate latent HIV infected populations. 
3.4.3. Protein delivery of cell-penetrating zinc-finger activators reactivate latent HIV-1 
expression 
As a mean to explore their potential for direct protein delivery, we evaluated if zinc-
finger activators could act as cell-penetrating peptides (CPP-ZFA) and activate latent HIV 
expression. We incorporated PBS1-VP64 activator into a pET28b vector for expression and 
purification of CPP-ZFA protein from E. Coli (Fig. 3.3A). To enhance ZFA protein delivery, 
we fused three nuclear localization signal (NLS) repeats to the N-terminal region of PBS-VP64 
activator. Incorporation of positively charged NLS sequences have previously shown to 
improve cell permeability of zinc-finger nucleases and enhance its gene editing activity [264]. 
SDS-PAGE analysis of purified CPP-ZFA (Fig. 3.3B) demonstrates the purity of these proteins. 
To confirm that purified CPP-ZFA proteins retained their functionality, we performed 
an ELISA analysis to evaluate protein binding to DNA target site (Fig. 3.3C). Both PBS1-VP64 
and 3NLS-PBS1-VP64 activators similarly recognized PBS1 binding site in a concentration 
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dependent manner, indicating that addition of NLS repeats does not influence CPP-ZFA 
efficacy to bind DNA. 
 
 Figure 3.3– Expression and 
purification of cell-penetrating 
zinc-finger activators (CPP-
ZFA) for protein delivery to 
HIV latent cells. (A) Schematic 
representation of CPP-ZFA 
protein expression vector for 
purification in Escherichia Coli. 
PBS1-VP64 was genetically 
fused to pET28b expression 
vector driven by IPTG-inducible 
T7 promoter. PBS1-VP64 
contains a nuclear localization 
signal (NLS) between PBS1 zinc-
finger and VP64 activation domains. 3NLS-PBS1-VP64 contains three additional NLS repeats at N-terminal of 
DNA-binding domain to enhance cell permeability. 6xHis indicates six histidine tag for protein purification. HA 
indicates the hemagglutinin A tag for protein detection. (B) SDS-PAGE of 0.1 nmol of CPP-ZFA proteins 
produced in E. Coli BL21(DE3). CPP-ZFA were detected using BlueSafe protein staining. (C) ELISA analysis of 
PBS1-VP64 and 3NLS-PBS1-VP64 target binding.  
We next determined whether CPP-ZFA could penetrate HIV latent cells and activate 
viral expression. PBS1-VP64 and 3NLS-PBS1-VP64 proteins were incubated with the J-Lat 
10.6 latency model described above. Strong reactivation of J-Lat 10.6 cells was observed 
following treatment with 3NLS-PBS1-VP64 in a concentration-dependent manner, reaching a 
maximum of ~40% GFP-positive cells after treatment with 8 µM (Fig. 3.4A). Opposed to 
3NLS-PBS1-VP64, we only detected significant reactivation of J-Lat cells treated with PBS1-
VP64 (~15% GFP-positive cells) at maximum protein concentration (8 µM), indicating the 
importance of NLS repeats to promote CPP-ZFA protein delivery and activation of latent HIV 
cells. Comparison of cell-entry between PBS1-VP64 and 3NLS-PBS1-VP64 through detection 
of FITC-conjugated CPP-ZFA in Jurkat T lymphocytes confirms that incorporation of 3NLS 
sequence is necessary to promote efficient cell entry (Fig. 3.4B; Left), reaching approximately 
70% cell transfection with 2 µM protein treatment (Fig. 3.4B; Right). Analysis of live J-Lat 
10.6 population following treatment with 3NLS-PBS1-VP64 indicated that cell viability is 
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drastically reduced after treatment with more than 2 µM of CPP-ZFA (Fig. 3.4C). Therefore, 
subsequent studies were performed with 2 µM protein treatment.  
Defining optimized parameters for protein delivery could be crucial to further enhance 
activation of latent HIV by CPP-ZFA. Increasing CPP-ZFA time of incubation with J-Lat cells 
clearly improved activation of latent population, reaching a maximum of ~40% HIV activation 
with 3NLS-PBS1-VP64 treatment for 6 hours (Fig. 3.3D). Supplementing cell medium with 
ZnCl2 or L-arginine, as previously reported for cell-penetrating zinc-finger nucleases [264], did 
not enhanced CPP-ZFA activity (data not shown). To further observe CPP-ZFA entry and 
function kinetics within J-Lat 10.6 cells, we incubated these cells with 3NLS-PBS1-VP64 for 
6 hours and monitored CPP-ZFA cell entry by western blot and stimulation of latent HIV 
expression through flow cytometry, over a period of 5 days (Fig. 3.3E). We observed that 
efficient entry 3NLS-PBS1-VP64 is only detected after 3 hours, reaching a maximum between 
9 and 18 hours, following degradation to almost complete extinction by 72 hours. In turn, HIV 
stimulation occurs at 12 hours and persists for up to 72 hours at which CPP-ZFA is already 
degraded, after it declines possibly due to the superior fitness of HIV latent over HIV expressing 
cells. This data indicates that protein delivery of CPP-ZFA remains in the latent cells for a short 
period but sufficient to sustain HIV activation.  
Multiple short-term treatments with CPP-ZFA further increased the fraction of 
reactivated population (Fig. 3.3F), considerably improving HIV activation over extending CPP-
ZFA incubation to 6 hours (Fig. 3.3C). For all conditions tested, we did not observe any 
significant changes in J-Lat 10.6 reactivation when treated with non-specific 3NLS-Aart6-
VP64, clearly indicating that viral gene expression is specifically induced by HIV-targeting 
PBS1 activator. In conclusion, these results indicate that short-term CPP-ZFA protein delivery 
is able to penetrate latent cells and specifically activate HIV expression from the LTR promoter. 
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Figure 3.4- Protein delivery of CPP-ZFA induce latent HIV expression. (A) Percentage of HIV activation in 
J-Lat 10.6 population following treatment with 0.25 µM to 8 µM of PBS1-VP64 (filled circles) or 3NLS-PBS1-
VP64 (open squares) proteins for 90 minutes. HIV activation of J-Lat 10.6 population was evaluated through 
detection of GFP-positive cells by flow cytometry at 48 hours after protein incubation. (B) (Left) Mean 
fluorescence intensity analysis determined by flow cytometry of Jurkat cells treated with increasing concentrations 
(from 0.25 µM to 2 µM) of FITC-stained PBS1-VP64 or 3NLS-PBS1-VP64 for 90 minutes. (Right) Percentage 
of FITC-positive cells of Jurkat cells untreated or treated with 2 µM of FITC-stained PBS1-VP64 or 3NLS-PBS1-
VP64 for 90 minutes. (C) Percentage of live cells of J-Lat 10.6 cells treated with increasing concentrations (from 
0.25 µM to 8 µM) of 3NLS-PBS1-VP64 for 90 minutes. Cell viability were assessed through flow cytometry at 
48 hours after protein treatment by gating the forward-scatter/side-scatter (FSC/SSC) live population. Percentage 
of live cells is normalized for untreated J-Lat cells. (D) Percentage of HIV activation in J-Lat 10.6 population 
treated with 2 µM of PBS1-VP64 (white columns) or 3NLS-PBS1-VP64 (black columns) for different periods of 
protein incubation. HIV activation of J-Lat 10.6 population was evaluated through detection of GFP-positive cells 
by flow cytometry at 48 hours after protein incubation. (E) Flow cytometry analysis of HIV activation (Top) and 
western blot (20 µg lysate) analysis of CPP-ZFA entry (Bottom) of J-Lat 10.6 cells treated with  2 µM of 3NLS-
PBS1 for 6 hours. Samples were collected for analysis at the indicated timepoints. (F) Percentage of HIV activation 
in J-Lat 10.6 population following multiple treatments with 2 µM of 3NLS-Aart6-VP64 (white columns) or 3NLS-
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PBS1-VP64 (black columns) proteins. Cells were incubated with CPP-ZFA protein for 1.5h per treatment. HIV 
activation of J-Lat 10.6 population was evaluated through detection of GFP-positive cells by flow cytometry at 48 
hours after protein incubation. Error bars indicate standard deviation of three independent experiments (n=3; *p < 
0.05). 
3.5. DISCUSSION  
The “shock and kill” strategy has gained consensus as the most promising approach to 
eliminate HIV reservoirs. However, non-targeted therapeutics developed to activate viral 
expression were unable to reduce the reservoir size and associated with toxic effects generally 
caused by uncontrollable host immune response [29,52,78,390]. The emergence of genome 
engineering tools have greatly expanded the possibilities to target the HIV genome and promote 
an antiviral effect [456]. Site-directed nucleases and recombinases are able to recognize and 
excise the integrated HIV proviral genome from infected cells [372–374,383], nevertheless 
genotoxicity caused by unwanted cuts at the human genome [240] or emergence of resistant 
HIV strains generated by double-strand breaks at the viral genome [377–381] raise concerns 
about the safety of this approach.  
Opposite to nucleases, engineered activators have been shown to modulate gene 
expression [254,269,303] without causing disruptive DNA breaks and generally with absence 
of off-target effects [396]. The elevated number of recent studies [429–432,434–436,448,449] 
reporting the design of synthetic activators to induce latent HIV expression clearly demonstrate 
the potential of this approach to target HIV reservoirs. However, drawbacks associated with 
standard delivery methods, including toxicity, integration-derived mutagenesis or low 
efficiency in some cell-types, have limited application of these cutting-edge tools into patients 
[457]. Zinc-fingers possess the innate ability to penetrate the anionic cell membrane, owing to 
the presence of positively charged residues within its backbone [450,458], retaining both cell-
transduction and DNA-binding functions in the same molecule. Accordingly, we explored its 
potential to open new perspectives for protein delivery of engineered activators to target HIV 
reservoirs.  
In this study, we report the construction of a cell-penetrating zinc-finger activator (CPP-
ZFA) for direct protein delivery and activation of latent HIV infected cells. We designed zinc-
finger activators (ZFA) to target the HIV 5’LTR promoter and induce viral gene expression. 
Contrary to that observed with TALE activators [448], ZFA are less consistent in activating 
gene expression. PBS1-VP64 was identified as the single ZFA to strongly activate latent HIV 
expression, reaching levels comparable to those reported in our study using TALE activators 
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[448]. Despite HLTR6-VP64 ability to activate gene expression from the LTR promoter, this 
zinc-finger might not access its target site within chromatin [344], as evidenced by its inability 
to stimulate latent HIV expression in J-Lat 10.6 model. PBS1 target site overlaps tRNA primer 
binding site and flanking sequences [346] located at the 3’ end of the LTR promoter unbound 
to nucleosome, therefore accessible to binding of engineered activators [459]. More 
importantly, this region is described as the most conserved segment of HIV-1 genome 
[346,460], being required for initiation of viral retro-transcription following binding of human 
tRNALys [461]. Although gene activation is generally stronger when engineered transcription 
factors are targeted upstream of TSS, these can be also efficient from downstream regions [241], 
as demonstrated by PBS1-VP64 capacity to stimulate HIV transcription.  
We further demonstrated that PBS1-VP64 activator can be directly delivered to latent 
cells as cell-penetrating peptide. Significant stimulation of latent HIV expression was only 
obtained with the inclusion of multiple nuclear localization sequences (NLS) at the N-terminal 
region of PBS1-VP64. Despite efficient gene knockout previously demonstrated through cell-
penetrating zinc-finger nucleases [263,264], transactivation domains such as VP64 are 
characterized by the presence of acidic and negatively charged residues [462], which might 
challenge its translocation through the anionic cell membrane. In fact, PBS1-VP64 activator 
alone presents neutral charge at physiological pH (estimation includes the presence of 
polyhistidine-tag, which further increase net charge). Incorporation of 3NLS repeats confer 
high positive charge to this CPP-ZFA (+15.2), demonstrated by its superior cell transduction 
and activity.  This result correlates with previous report by Liu et al. that demonstrates the 
potential of NLS peptides to increase overall positive net charge and enhance protein delivery 
of zinc-finger nucleases [264].  
Protein delivery of CPP-ZFA improves temporal control of engineered activators 
function over gene delivery methods. These “hit and run” strategies are suitable for latent HIV 
activation, for which engineered activators remain in the cell shortly enough to stimulate HIV 
transcription but without causing potentially harmful off-target gene modulation from 
prolonged exposure. In fact, we observed that short-term presence of CPP-ZFA within latent 
HIV cells is able to sustain viral expression. Controlling the protein amount, time of incubation 
or multiple protein injections can better adjust the optimal conditions to enhance gene 
activation.  
Despite TALE or CRISPR/Cas9 exponential growth for therapeutic applications [240], 
these technologies do not match zinc-fingers protein delivery potential due to its supercharged 
surface and relative small size [287]. In addition, the human origin of zinc-finger domains might 
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potentially reduce risks of immunogenicity. Other studies have shown efficient cell-penetration 
of ZFA by conjugating other protein-transduction domains [463,464], leaving room to further 
optimize cell-penetrating capacity of zinc-finger activators. One of these studies went as far as 
to demonstrate in vivo localization of CPP-ZFA in the brain, demonstrating its capacity to cross 
blood-brain barrier and modulate gene expression [464], a desirable feature to target potential 
HIV reservoirs in the central nervous system [465]. Still, translation of this technology into 
infected patients might require conjugation of engineered activators with ligands that target 
these into the relevant cell populations, particularly resting CD4 T lymphocytes. Targeted 
delivery of zinc-finger nucleases have shown to enhance cell transduction efficacy [466], 
further supporting the potential of zinc-finger protein delivery for in vivo applications. 
In conclusion, we provide evidence that cell-penetrating zinc-finger activators can be 
directly delivered to latent HIV cells without any carrier and strongly stimulate viral expression. 
This study is an important step to approach novel “shock and kill” strategies to eradicate latent 
HIV reservoirs. 
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3.7. SUPPLEMENTARY INFORMATION 
3.7.1. Supplementary Figures 
 
Supplementary Figure S 3.1- Sequence conservation of the PBS1 zinc-finger binding site. Percentage of HIV 
Major group (M) subtype strains with complete homology to PBS1 target site. Data based on 2016 edition of the 
HIV Sequence Database (http://hiv-web.lanl.gov).  
3.7.2. Supplementary Tables 
Supplementary Table S 3.1- Zinc-finger activator protein sequences used in this study. ZF α-Helix DNA-
binding domain is colored orange. Nuclear localization signal (NLS) sequence is highlighted grey. VP64 domain 
is colored green. HA tag is colored purple. 
>ZLT4A-VP64 
MAQAALEPGEKP 
YKCPECGKSFSTSGELVRHQRTHTGEKP 
YKCPECGKSFSQLAHLRAHQRTHTGEKP 
YKCPECGKSFSRNDTLTEHQRTHTGEKP 
YKCPECGKSFSDPGHLVRHQRTHTGKKTSGQAGQASPKKKRKVGRADALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLD
MLGSDALDDFDLDMLINYPYDVPDYAS 
 
 
>ZLT4B-VP64 
MAQAALEPGEKP 
YKCPECGKSFSDPGNLVRHQRTHTGEKP 
YKCPECGKSFSTSGELVRHQRTHTGEKP 
YKCPECGKSFSTHLDLIRHQRTHTGEKP 
YKCPECGKSFSRKDNLKNHQRTHTGKKTSGQAGQASPKKKRKVGRADALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLD
MLGSDALDDFDLDMLINYPYDVPDYAS 
 
>ZLT4C-VP64 
MAQAALEPGEKP 
YKCPECGKSFSTKNSLTEHQRTHTGEKP 
YKCPECGKSFSERSHLREHQRTHTGEKP 
YKCPECGKSFSRSDDLVRHQRTHTGEKP 
YKCPECGKSFSRSDELVRHQRTHTGKKTSGQAGQASPKKKRKVGRADALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLD
MLGSDALDDFDLDMLINYPYDVPDYAS 
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>ZLT4D-VP64 
MAQAALEPGEKP 
YKCPECGKSFSERSHLREHQRTHTGEKP 
YKCPECGKSFSERSHLREHQRTHTGEKP 
YKCPECGKSFSQKSSLIAHQRTHTGEKP 
YKCPECGKSFSTSGNLTEHQRTHTGKKTSGQAGQASPKKKRKVGRADALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLD
MLGSDALDDFDLDMLINYPYDVPDYAS 
 
>ZLT6A-VP64 
MAQAALEPGEKP 
YKCPECGKSFSTHLDLIRHQRTHTGEKP 
YKCPECGKSFSRKDNLKNHQRTHTGEKP 
YKCPECGKSFSSPADLTRHQRTHTGEKP 
YKCPECGKSFSTHLDLIRHQRTHTGEKP 
YKCPECGKSFSHRTTLTNHQRTHTGEKP 
YKCPECGKSFSRSDKLTEHQRTHTGKKTSGQAGQASPKKKRKVGRADALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDM
LGSDALDDFDLDMLINYPYDVPDYAS 
 
>ZLT6B-VP64 
MAQAALEPGEKP 
YKCPECGKSFSDPGNLVRHQRTHTGEKP 
YKCPECGKSFSTSGELVRHQRTHTGEKP 
YKCPECGKSFSTHLDLIRHQRTHTGEKP 
YKCPECGKSFSRKDNLKNHQRTHTGEKP 
YKCPECGKSFSSPADLTRHQRTHTGEKP 
YKCPECGKSFSTHLDLIRHQRTHTGKKTSGQAGQASPKKKRKVGRADALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDM
LGSDALDDFDLDMLINYPYDVPDYAS 
 
>HLTR1-VP64 
MAQAALEPGEKP 
YACPECGKSFSTSGHLVRHQRTHTGEKP 
YKCPECGKSFSRSDVLVRHQRTHTGEKP 
YKCPECGKSFSQSGDLRRHQRTHTGEKP 
YACPECGKSFSQSSNLASHQRTHTGEKP 
YKCPECGKSFSTSGELVRHQRTHTGEKP 
YKCPECGKSFSRSDNLVRHQRTHTGKKTSGQAGQASPKKKRKVGRADALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLD
MLGSDALDDFDLDMLINYPYDVPDYAS 
 
>HLTR3-VP64 
MAQAALEPGEKP 
YACPECGKSFSRSDDLVRHQRTHTGEKP 
YKCPECGKSFSRSDHLTTHQRTHTGEKP 
YKCPECGKSFSDCRDLARHQRTHTGEKP 
YACPECGKSFSRSDVLVRHQRTHTGEKP 
YKCPECGKSFSDPGHLVRHQRTHTGEKP 
YKCPECGKSFSQSSHLVRHQRTHTGKKTSGQAGQASPKKKRKVGRADALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLD
MLGSDALDDFDLDMLINYPYDVPDYAS 
 
>HLTR6-VP64 
MAQAALEPGEKP 
YACPECGKSFSSPADLTRHQRTHTGEKP 
YKCPECGKSFSDPGALVRHQRTHTGEKP 
YKCPECGKSFSQLAHLRAHQRTHTGEKP 
YACPECGKSFSDKKDLTRHQRTHTGEKP 
YKCPECGKSFSTSGSLVRHQRTHTGEKP 
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YKCPECGKSFSQRHSLTEHQRTHTGKKTSGQAGQASPKKKRKVGRADALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLD
MLGSDALDDFDLDMLINYPYDVPDYAS 
 
>PBS1-VP64 
MAQAALEPGEKP 
YACPECGKSFSRSDDLVRHQRTHTGEKP 
YKCPECGKSFSRSDVLVRHQRTHTGEKP 
YKCPECGKSFSQSGDLRRHQRTHTGEKP 
YACPECGKSFSQRHSLTEHQRTHTGEKP 
YKCPECGKSFSRGGWLQAHQCTHTGEKP 
YKCPECGKSFSQRANLRAHQRTHTGKKTSGQAGQASPKKKRKVGRADALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLD
MLGSDALDDFDLDMLINYPYDVPDYAS 
 
>PBS1a-VP64 
MAQAALEPGEKP 
YACPECGKSFSRSDDLVRHQRTHTGEKP 
YKCPECGKSFSRSDVLVRHQRTHTGEKP 
YKCPECGKSFSQSGDLRRHQRTHTG 
GGGSGGGGTGEKP 
YACPECGKSFSQRANLRAHQRTHTGEKP 
YKCPECGKSFSRSDHLTTHQRTHTGEKP 
YKCPECGKSFSRSDVLVRHQRTHTGKKTSGQAGQASPKKKRKVGRADALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLD
MLGSDALDDFDLDMLINYPYDVPDYAS 
 
 
>PBS3-VP64 
MAQAALEPGEKP 
YACPECGKSFSDPGNLVRHQRTHTGEKP 
YKCPECGKSFSRSDHLAEHQRTHTGEKP 
YKCPECGKSFSDSGNLRVHQRTHTGEKP 
YACPECGKSFSRNDTLTEHQRTHTGEKP 
YKCPECGKSFSHTGHLLEHQRTHTGEKP 
YKCPECGKSFSRSDHLTTHQRTHTGKKTSGQAGQASPKKKRKVGRADALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLD
MLGSDALDDFDLDMLINYPYDVPDYAS 
 
>Aart4-VP64 
MAQAALEPGEKP 
YKCPECGKSFSRSDHLTNHQRTHTGEKP 
YKCPECGKSFSDKKDLTRHQRTHTGEKP 
YKCPECGKSFSQRANLRAHQRTHTGEKP 
YKCPECGKSFSQLAHLRAHQRTHTGKKTSGQAGQASPKKKRKVGRADALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLD
MLGSDALDDFDLDMLINYPYDVPDYAS 
 
>Aart6-VP64 
MAQAALEPGEKP 
YACPECGKSFSRSDHLAEHQRTHTGEKP 
YKCPECGKSFSDKKDLTRHQRTHTGEKP 
YKCPECGKSFSQRANLRAHQRTHTGEKP 
YACPECGKSFSQLAHLRAHQRTHTGEKP 
YKCPECGKSFSREDNLHTHQRTHTGEKP 
YKCPECGKSFSRRDALNVHQRTHTGKKTSGQAGQASPKKKRKVGRADALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLD
MLGSDALDDFDLDMLINYPYDVPDYAS 
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Supplementary Table S 3.2- Cell-penetrating zinc-finger activator protein sequences used in this study. 
Histidine tag is colored orange. ZF DNA-binding domain is colored blue. Nuclear localization signal (NLS) 
sequence is highlighted grey. VP64 domain is colored green. HA tag is colored purple. 
>PBS1-VP64 
MGSSHHHHHHSSGLVPRGSHMLEAALEPGEKPYACPECGKSFSRSDDLVRHQRTHTGEKPYKCPECGKSFSRSDVLVRHQRTH
TGEKPYKCPECGKSFSQSGDLRRHQRTHTGEKPYACPECGKSFSQRHSLTEHQRTHTGEKPYKCPECGKSFSRGGWLQAHQCT
HTGEKPYKCPECGKSFSQRANLRAHQRTHTGKKTSGQAGQASPKKKRKVGRADALDDFDLDMLGSDALDDFDLDMLGSDAL
DDFDLDMLGSDALDDFDLDMLINYPYDVPDYAS 
>3NLS-PBS1-VP64 
MGSSHHHHHHSSGLVPRGSHMPKKKRKVLDPKKKRKVPGMAPKKKRKVGIHGVPAALEPGEKPYACPECGKSFSRSDDLVRH
QRTHTGEKPYKCPECGKSFSRSDVLVRHQRTHTGEKPYKCPECGKSFSQSGDLRRHQRTHTGEKPYACPECGKSFSQRHSLTEH
QRTHTGEKPYKCPECGKSFSRGGWLQAHQCTHTGEKPYKCPECGKSFSQRANLRAHQRTHTGKKTSGQAGQASPKKKRKVGR
ADALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLINYPYDVPDYAS 
>3NLS-Aart6-VP64 
MGSSHHHHHHSSGLVPRGSHMPKKKRKVLDPKKKRKVPGMAPKKKRKVGIHGVPAALEPGEKPYACPECGKSFSRSDHLAEH
QRTHTGEKPYKCPECGKSFSDKKDLTRHQRTHTGEKPYKCPECGKSFSQRANLRAHQRTHTGEKPYACPECGKSFSQLAHLRAH
QRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSRRDALNVHQRTHTGKKTSGQAGQASPKKKRKVGRA
DALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLINYPYDVPDYAS 
 
Supplementary Table S 3.3- Primer sequences for the construction of the luciferase reporter plasmids used 
in this study. Zinc-finger binding sites are underlined. Restriction sites are in bold. 
>5’ ZF-Fwd  
GGGAATTCCATATGCTCGAGGCCGCCATGGCCCAGGCGGCC 
>5’ 3NLS-ZF-Fwd  
ACGCGTCGACCCAAAGAAGAAACGGAAAGTACCCGGGATGGCCCCCAAGAAAAAGCGGAAAGTG
GGCATCCACGGCGTGCCTGCCGCCCTCGAGCCCGGGGAGAAG 
>3’ VP64-Rev  
CGAGCTCTCAAGAAGCGTAGTCCGGAACG 
>5’ ZF-Luc-ZLT4A  
ACTGCTATCTCGAGGGCCCGAGAGCTTAGCGGGCCCGAGAGCTTAGCGGGCCCGAGAGCTTAGCG
GGCCCGAGAGCTTAGCGATCTGCGATCTAAGTAAGCT 
 
>5’ ZF-Luc-ZLT4B  
ACTGCTATCTCGAGAAGACTGCTGACTAGCGAAGACTGCTGACTAGCGAAGACTGCTGACTAGCG
AAGACTGCTGACTAGCGATCTGCGATCTAAGTAAGCT 
>5’ ZF-Luc-ZLT4C  
ACTGCTATCTCGAGGTGGCGAGCCCTTAGCGGTGGCGAGCCCTTAGCGGTGGCGAGCCCTTAGCG
GTGGCGAGCCCTTAGCGATCTGCGATCTAAGTAAGCT 
>5’ ZF-Luc-ZLT4D  
ACTGCTATCTCGAGCATATAAGCAGCTAGCGCATATAAGCAGCTAGCGCATATAAGCAGCTAGCG
CATATAAGCAGCTAGCGATCTGCGATCTAAGTAAGCT 
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>5’ ZF-Luc-ZLT6A  
ACTGCTATCTCGAGCGGAGTACTACAAAGACTTAGCGCGGAGTACTACAAAGACTTAGCGCGGAG
TACTACAAAGACTTAGCGCGGAGTACTACAAAGACTTAGCGATCTGCGATCTAAGTAAGCT 
>5’ ZF-Luc-ZLT6B  
ACTGCTATCTCGAGACTACAAAGACTGCTGACTAGCGACTACAAAGACTGCTGACTAGCGACTAC
AAAGACTGCTGACTAGCGACTACAAAGACTGCTGACTAGCGATCTGCGATCTAAGTAAGCT 
>5’ ZF-Luc-HLTR1  
ACTGCTATCTCGAGTGGGTGACGAATTCGGAGTAGCGTGGGTGACGAATTCGGAGTAGCGTGGGT
GACGAATTCGGAGTAGCGTGGGTGACGAATTCGGAGTAGCGATCTGCGATCTAAGTAAGCT 
>5’ TALE-Luc-HLTR3  
ACTGCTATCTCGAGGGAGGCGTGGCCTGGGCGTAGCGGGAGGCGTGGCCTGGGCGTAGCGGGAGG
CGTGGCCTGGGCGTAGCGGGAGGCGTGGCCTGGGCGTAGCGATCTGCGATCTAAGTAAGCT 
>5’ ZF-Luc-HLTR6  
ACTGCTATCTCGAGACACTGAGACCATTGATCTAGCGACACTGAGACCATTGATCTAGCGACACTG
AGACCATTGATCTAGCGACACTGAGACCATTGATCTAGCGATCTGCGATCTAAGTAAGCT 
>5’ ZF-Luc-PBS1  
ACTGCTATCTCGAGAAATCTCTAGCAGTGGCGTAGCGAAATCTCTAGCAGTGGCGTAGCGAAATCT
CTAGCAGTGGCGTAGCGAAATCTCTAGCAGTGGCGTAGCGATCTGCGATCTAAGTAAGCT 
>5’ ZF-Luc-PBS1a  
ACTGCTATCTCGAGGTGTGGAAAatctctaGCAGTGGCGTAGCGGTGTGGAAAatctctaGCAGTGGCGTA
GCGGTGTGGAAAatctctaGCAGTGGCGTAGCGGTGTGGAAAatctctaGCAGTGGCGTAGCGATCTGCGA
TCTAAGTAAGCT 
>5’ TALE-Luc-PBS3  
ACTGCTATCTCGAGTGGCGCCCGAACAGGGACTAGCGTGGCGCCCGAACAGGGACTAGCGTGGCG
CCCGAACAGGGACTAGCGTGGCGCCCGAACAGGGACTAGCGATCTGCGATCTAAGTAAGCT 
>3’ Luc-Rev 
CGTTTTCCCGGTACCAGAT 
>5’ LTR-PBS-Fwd 
CGACGCGTTGGAAGGGCTAATTTGGTCCCA 
>3’ LTR-PBS-Rev 
CTAGCTAGCGTCCCTGTTCGGGCGCC 
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Latent non-replicative HIV reservoirs evade retroviral inhibitors but continue to source 
novel infection events, being considered one of the main obstacles to complete eradication. For 
this reason, reactivating the latent expression is considered critical to expose these cells to 
elimination through virus-mediated cytopathic effects or host immune response, providing a 
“shock and kill” effect on HIV reservoirs [467]. Pharmacological strategies that aim to stimulate 
HIV-1 latent cells by modulating cell signaling or epigenetic marks associated with the HIV 
provirus were unsuccessful so far. HDAC inhibitors remain the single latency reversal agent to 
be tested in clinical studies to disrupt HIV reservoirs. Vorinostat [87,88], panobinostat [468] 
and romidepsin [469] induced HIV-1 RNA transcription from aviremic ART-treated patients, 
however these failed to reduce the HIV reservoir size. Such decrease is vital to control the HIV 
infection by the host immune system in the absence of ART and attain a “functional cure”. Low 
levels of HIV stimulation and the heterogeneity of processes or cell subsets associated with 
latent HIV are major hurdles that might limit the effect of these agents [467].  More importantly, 
the non-selective mode of action of pharmacological drugs may raise severe side effects by 
triggering an uncontrolled immune response [29]. The emergence of gene therapy field has 
provided novel targets and expanded possible ways to counter HIV infection [160]. Still, most 
strategies are unable to target HIV reservoirs, masked due to the absence of viral expression or 
cellular markers. In fact, the presence of an integrated silenced provirus within the cell 
chromatin represents the only consistent trait that can distinguish an HIV latently infected from 
a healthy cell. 
In this dissertation, we presented novel gene-targeted strategies to specifically stimulate 
HIV latent expression and induce elimination of viral reservoirs. We set out to explore the 
potential of genome engineering tools to generate synthetic activators that could specifically 
stimulate latent HIV expression without compromising the normal cell function. This approach 
also proposes to generate a broad effect by stimulating HIV reservoirs in a context independent 
manner, regardless of the provirus integrated position [470] or availability of endogenous 
transcription factors [471]. To complement this approach, we also engineered an HIV-
responsive suicidal lentivector to drive expression of a toxic gene and enforce elimination of 
stimulated HIV reservoirs.  
In Chapter I, we presented a general introduction to the HIV pathogenesis, describing 
the establishment of latent infections and its critical importance to obstruct HIV eradication by 
current antiretroviral treatment. State-of-the-art of gene therapy methods with focus on genome 
engineering approaches to target and modulate gene expression are depicted as a promising 
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alternative to pharmacological treatments. We present gene therapeutic and genome 
engineering strategies to target HIV infection with focus on unmet needs and drawbacks of 
available treatment scheme. 
In Chapter II, we describe the design of synthetic activators based on TALE domains to 
target conserved regions of HIV 5’LTR promoter and stimulate transcription of latently infected 
cells [448]. In the pursuit for antiviral strategies, the versatility of programmable DNA-binding 
platforms confers a considerable advantage over available pharmacological or peptide-
mediated inhibitors that are directed to viral proteins. Their straightforward DNA recognition 
mode facilitates the generation of site-directed genome engineering effectors that target 
conserved regions within integrated HIV provirus. Additionally, these proteins can be 
engineered and virtually re-directed to any HIV subtype or potentially emergent resistant strain, 
simply required by knowledge of the viral genomic sequence. Related to this, TALE proteins 
possess unique attributes particularly valuable for targeted anti-HIV strategies. TALEs are 
highly flexible proteins that adapt to target sequence variations commonly associated with the 
diversity of circulating HIV strains. More specifically, the existence of degenerated RVD 
domains that recognize multiple or every bp [244,245] facilitates adjustment to a specific target 
prone for single nucleotide polymorphism at a specific position. In addition, TALEs can be 
engineered to tolerate frameshift deletions mutations through conformational arrangements 
[472]. In comparison to other programmable DNA-binding proteins, TALEs are frequently 
associated with increased specificity and less off-target events [473]. Comparison between 
these platforms for gene activation is limited, regardless TALE activators have shown to 
outperform ZF or CRISPR in most circumstances [306,308,396,474]. 
We generated TALE activators that mapped the HIV 5’LTR promoter to track the region 
more prone for activation of viral transcription. Four TALE activators (TLT5, TLT6, TLT7 and 
TLT8) caused strong activation of the LTR promoter, targeting a small region identified as a 
“hotspot” to stimulate viral transcription due to the presence of endogenous cis-regulatory sites 
that should cooperate with synthetic TALE activators. This finding also correlates with other 
studies reporting synthetic activators to reactivate HIV latency [430,434,436,449,475]. We 
demonstrate that combination of selected TALE activators (TLT5-8) positioned in proximity 
can promote a synergistic upregulation of HIV transcription in a similar manner to what occurs 
with natural gene regulators. TLT5-8 strongly reactivated latent HIV population in the widely-
used J-Lat 10.6 cell line model, still its activity was limited in more suppressed latent clones, 
indicating that the level of repression can affect their performance. Nevertheless, we could 
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alleviate suppression of latent HIV provirus within such unfavorable contexts by combining 
these artificial transcription factors with chromatin-remodeling HDAC inhibitors.  
Class-selective HDAC inhibitors, particularly those targeting HDAC isotype 3  [476], 
cooperated with TLT5-8 and enhanced stimulation of repressive J-Lat clones. Further studies 
are required to investigate if the influence of HDAC inhibitors is to facilitate TALE activators 
access to the HIV promoter [459], increase TALE transgene expression [477] and/or release 
additional blocks to viral transcription by indirectly stimulating productive elongation 
[412,413]. The complex epigenetic regulation involving HDAC enzymes inevitably determine 
that the broad effect of HDAC inhibitor drugs affects expression of numerous host genes [478]. 
To further reduce potential off-target gene regulation caused by HDAC inhibitors, conjugating 
TALE activators with HIV site-directed epigenetic modulators [241] could represent an 
attractive concept to further potentiate the specificity of this approach. Programmable 
acetyltransferases [276] directed to HIV provirus have already shown to modulate a positive 
effect on latent expression [434]. Furthermore, testing novel activation domains [312,314] that 
recruit complementary transcription factors should increase potency of synthetic activators. 
Nonetheless, given the multifactorial nature of HIV-1 latency [27], this study further supports 
that combinatorial strategies [479] are more likely to expand the range of biologically diverse 
reservoirs that can be addressed. 
Future studies should address the delivery method of these programmable synthetic 
activators with potential for in vivo application. Transient delivery through IDLV is highly 
desirable given the lentivirus efficacy to transduce both active and resting T lymphocytes [140]. 
Nevertheless, undesirable recombination owing to the presence of repetitive elements within 
TALE backbone poses an obstacle to implement this system [290]. Codon-optimized TALEs 
[277,480] to minimize repetitive domains and RT-inactive lentivirus for direct mRNA delivery 
[441] are alternative options to overcome this bottleneck. Other alternative viral delivery 
systems should also be considered for this approach. Opposed to TALEN-mediated gene editing 
that requires dimerization of site-directed nucleases, gene modulation can be performed by 
single TALE transcription factor which enable packaging into small AAV vectors [275]. On 
the other hand, the large packaging capacity of adenoviral vectors would enable gene delivery 
of multiple TALEs from a single viral particle [291]. TALE-mediated reactivation of HIV 
latency through such delivery platforms would then be more relevant to evaluate its potential 
in cells extracted from aviremic ART-treated patients [481], or primary cell [419,482] and 
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animal [483] models of HIV latency that recapitulate the biological properties of HIV reservoirs 
that occur in vivo. 
Recent reports have raised concerns that stimulating HIV reservoirs is not sufficient to 
lead their elimination. The ineffective CTL-mediated immune response of HIV patients [91], 
along with the emergence of CTL-resistant strains [92] indicate that supplementary approaches 
might be required to clear the reactivated population. Additionally, the elimination of 
stimulated HIV reservoirs must be swift enough to prevent viral spread to surrounding tissues. 
Conjugating ART with latency reversal agents does not guarantee prevention dissemination, as 
low levels of replication in tissues under suboptimal ART drug concentration contributes to the 
residual viremia observed in treated patients [484,485]. Here we also presented a suicide gene 
therapy approach to directly clear latent HIV cells through conjugation of designed TALE 
activators with an HIV-responsive suicide lentivector. Lentiviral vectors previously developed 
to express suicide genes (e.g. toxins) conditioned to the presence of Tat and Rev showed 
promising results to specifically eliminate HIV infected cells [189,190,486]. Despite its 
specificity, these therapeutic vectors are unable to tackle transcriptionally silent HIV reservoirs 
that do not express these regulatory viral proteins.  
We aimed to expand this approach for targeting HIV reservoirs by taking advantage of 
the gene-targeted modulation of designed TALE activators. We engineered a Tat/Rev-
dependent lentiviral vector [188] with a modified 5’LTR promoter that does not contain binding 
sites for these synthetic activators. By doing so, we could conjugate both technologies and 
generate a “shock and kill” effect on HIV reservoirs without depending on the host immune 
response. In association with TALE activators, a low dose of HIV-responsive suicidal 
lentivector driving expression of Diphtheria toxin specifically induced moderate cell death of 
HIV latent cells with minimal effect on uninfected cells. Despite the potential of HIV suicide 
gene therapy, this approach faces safety issues that might impair its applicability in infected 
patients and requires further improvements. Leaking of suicide gene expression from excessive 
transcription activity may trigger death of healthy cells, requiring moderate HIV-dependent 
expression levels but sufficient to induce cell apoptosis in HIV infected cells. Consequently, 
the choice of suicidal gene for our lentivector is critical to maximize its efficacy and safety. The 
high potency of pathogenic bacterial toxins circumvents the requirement of high levels of 
expression to mediate cell apoptosis [425]. For instance, one molecule of diphtheria toxin is 
sufficient to trigger cell death [487], therefore representing a suitable option for this system. 
Moreover, the generation of resistant cells [488] allows production of viral particles 
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incorporating this suicide gene. Other alternative candidates such as human pro-apoptotic 
[486,489,490] or prodrug-activating [421,491] suicide genes can be tested for increased safety. 
Further engineering of lentiviral vector through incorporation of HIV cis-inhibitory sequences 
from the gag gene [486] could also help to minimize HIV-independent leaky expression. 
Additionally, transient delivery of this system as non-integrative lentivirus [190] should further 
enhance its safety. Future studies might be addressed to incorporate an HIV-independent TALE 
activator cassette into the suicide lentivector and generate a “all-in-one” therapeutic vector that 
could maximize efficacy of this “shock and kill” strategy. 
Although this study provides gene-targeted methods designed to eliminate HIV latent 
cells, significant challenges will exist in clinical translation of these approaches. Gene-delivery 
systems to HIV infected cells have limited efficacy and specificity. However, advances in 
targeted viral delivery promises to overcome this bottleneck [159]. Recent reports showed that 
lentivirus and AAV can be designed with CD4 [492,493] or CCR5 [494] targeting specificity, 
enabling efficient transduction of HIV-susceptible CD4+ T lymphocytes or macrophages both 
in vitro and in vivo. The great potential of AAV for in vivo genome engineering [495] has 
already shown promising results to remove the HIV provirus within infected tissues of animal 
models [496,497] Targeting HIV reservoirs however face problematic obstacles due to their 
presence in hardly accessible niche organs and most importantly the absence of cellular markers 
[29]. Identification of potential biomarkers associated with HIV latent infections in CD4 T cells 
[498] may open new perspectives for delivery of gene therapeutic drugs directly to the HIV 
reservoir. 
In Chapter III, we described a “gene-free” approach to stimulate HIV latent expression 
through direct protein delivery of cell-penetrating zinc-finger activators (CPP-ZFA). For this 
purpose, we took advantage of the high cell-transduction potential of Cys2-His2 zinc-finger 
domains, owed to the high frequency of positively charged lysine and arginine residues present 
within its backbone [450]. This approach combines the cell-penetrating ability with site-specific 
targeting into a single molecule, which may overcome limitations associated with viral or non-
viral gene delivery methods [499], i.e. immunogenicity/toxicity and efficiency. In addition, 
direct protein delivery enables short-term exposure of genome engineering platforms, 
previously correlated with reduction of off-target effects in comparison with long-term 
expression from nucleic acids [287]. Recent findings of in vivo gene modulation by cell-
penetrating zinc-fingers [464] further demonstrate the relevance of this platform to target HIV 
reservoirs in infected patients. 
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We designed and screened zinc-finger activators (ZFA) that could target the 5’LTR 
promoter and stimulate HIV transcription. Opposed to TALE activators described in Chapter 
II, ZFA are far less consistent in activating gene expression, potentially explained by the 
context-dependent variance in protein affinity and specificity between the selected target site 
and corresponding zinc-finger module [243,500]. We narrowed all potential ZFA to PBS1-
VP64, a zinc-finger that targets the HIV primer binding site, one of the most conserved regions 
among HIV subtypes [460]. PBS1-VP64 strongly activated latent HIV expression from the J-
Lat 10.6 model, albeit it binds downstream of TSS.  
The potential of PBS1 as CPP-ZFA was evidenced by its strong efficacy to stimulate 
latent HIV expression through protein delivery, even surpassing in some conditions (longer 
protein exposure, multiple treatments) the efficiency observed from transgene expression. The 
activation mediated by short-term protein delivery could be sufficient to trigger elimination of 
HIV reservoirs while avoiding off-target gene modulation from prolonged exposure to 
engineered zinc-fingers [263]. The presence of multiple positively charge NLS was required to 
promote entry of sufficient CPP-ZFA amounts to activate HIV expression. The cationic 
properties of CPP is of critical importance for interaction and internalization through the anionic 
lipid bilayer [501]. Despite the positive charge involving PBS1, coupling of this zinc-finger to 
VP64 acidic domain decreased overall net charge. However, incorporation of 3NLS repeats 
conferred high positive charge to this CPP-ZFA at physiological pH, demonstrated by its 
superior cell transduction and activity. Still, the elevated concentration required to efficiently 
stimulate latent HIV reactivation notes the necessity for further improvements of CPP-ZFA cell 
transduction efficiency and/or gene activation potency to translate this approach in vivo. The 
former might be attained by further increasing net charge by addition of extra NLS repeats, or 
other positively charged CPP [501]. Multiple protein treatments should also reduce the required 
dosage, facilitated by the human origin of zinc-fingers that reduce possibility of humoral 
immune responses. Gene activation enhancement could be attained by testing novel and more 
potent activation or epigenetic effectors that were reported to outperform VP64 in many 
applications [241]. More importantly, CPP-ZFA must be targeted to HIV latent cells, mostly 
composed of resting CD4 T lymphocytes [42]. Cell-penetrating peptides lacks cell-type 
specificity but can be directed at target populations through varied assembly strategies to 
targeting domains [502]. This approach was already reported to enhance protein delivery of 
zinc-finger nucleases [466], and therefore should be translated to CPP-ZFA targeted activation 
of HIV reservoirs.
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In conclusion, the present thesis provides novel gene-targeted methods to mediate 
elimination of HIV latently infected cells. We demonstrate the potential of TALE-based 
engineered activators to recognize the HIV promoter and specifically stimulate latent 
expression. Furthermore, the epigenetic modulation caused by small-molecule HDAC 
inhibitors can synergistically potentiate TALE-mediated stimulation of HIV latency, providing 
a novel insight for combinatorial strategies to eradicate HIV reservoirs. On the other hand, we 
explored an engineered suicidal lentivector to mediate cell death of HIV latent cells in 
association with TALE activators, enforcing direct elimination of HIV reservoirs while 
preventing spreading of novel viral infections. Finally, we show that cell-penetrating zinc-
finger activators can be directly delivered to HIV latent cells and induce viral expression, 
providing the basis for a novel delivery method to target these reservoirs. Overall, our study 
demonstrates the potential of programmable synthetic activators and suicide lentivectors to 
tackle HIV reservoirs, paving the way for the next generation of therapeutic molecules for 
improved treatment of HIV/AIDS pandemic. 
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